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Thesis Summary 
 
PAWS1/FAM83G, a member of the poorly characterised FAM83 family of 
proteins that share the conserved domain of unknown function DUF1669, was identified 
as an interactor of the SMAD1 transcription factor. Because BMP signalling plays a 
fundamental role during embryogenesis, collaboration with Jim Smith (The Francis Crick 
Institute, London) led to the discovery that ectopic expression of PAWS1 mRNA in 
Xenopus embryos leads to a complete duplication of body axis. In similar assays, such a 
phenotype is associated with either the inhibition of canonical (SMAD4-dependent) BMP 
signalling or the activation of canonical Wnt/β-catenin signalling. PAWS1 has been 
reported to modulate only non-canonical BMP signalling and not influence canonical 
BMP signalling, findings which were also validated in Xenopus embryos and 
PAWS1-knockout U2OS cells in this thesis. Therefore, focus turned to investigating 
potential roles of PAWS1 in the regulation of the canonical Wnt/β-catenin signalling 
pathway. 
The canonical Wnt/β-catenin signalling pathway plays critical roles during 
embryogenesis, stem cell self-renewal and in adult tissue homeostasis and is often 
misregulated in developmental defects, including skin and hair abnormalities, and cancer. 
In the absence of Wnt signals, sequential phosphorylation of the transcriptional co-factor 
β-catenin by CK1 and GSK3 results in the ubiquitylation of β-catenin, priming it for 
degradation via the proteasome. Upon Wnt-activation, β-catenin is stabilised and 
translocates to the nucleus, where it associates with TCF and LEF and regulates the 
expression of Wnt-target genes. Although the fundamental steps in Wnt signalling are 
established, many gaps remain in our understanding of the precise regulation of the 
pathway. It is demonstrated in this thesis that PAWS1 activates Wnt signalling in both 
Xenopus embryos and human cells. Furthermore, in PAWS1-knockout U2OS cells Wnt 
signalling is attenuated. Collectively, these data uncover a role for PAWS1 as a novel 
regulator of canonical Wnt/β-catenin signalling.  
In search of molecular mechanisms through which PAWS1 regulates 
Wnt/β-catenin signalling, a proteomic approach on endogenous PAWS1 revealed the 
Ser/Thr protein kinase CK1α as a robust PAWS1 interactor. PAWS1 interacts and 
colocalises with endogenous CK1α. CK1 isoforms are key regulators of Wnt signalling 
and they phosphorylate many components of the pathway, however their precise 
regulation in cells, despite being critically important, is poorly understood. After mapping 
XII 
 
CK1-interaction sites to key residues within the conserved DUF1669 domain of PAWS1, 
it was possible to demonstrate that the interaction between PAWS1 and CK1α is critical 
for PAWS1 to activate Wnt signalling in both Xenopus embryos and U2OS cells. 
Although the phosphorylation of β-catenin on Ser45, which is reported to be 
phosphorylated by CK1 isoforms, appears to be unaltered by PAWS1-deficiency, the 
Wnt3A-induced nuclear translocation of β-catenin is slightly inhibited in PAWS1 
knockout U2OS cells. It is likely that PAWS1 controls Wnt signalling by directing CK1α 
to key subcellular locations and substrates upon Wnt stimulation to regulate the nuclear 
translocation of β-catenin. Consistent with this hypothesis, a global phosphoproteomics 
analysis of wild type and PAWS1-/- U2OS cells has revealed differential phosphorylation 
of proteins that may be regulated by the PAWS1:CK1α interaction. 
Interestingly, PAWS1 appears to control levels of endogenous CK1α protein and 
vice versa, although the mechanisms by which each achieves this are still unclear. The 
findings that the DUF1669 domain of PAWS1 interacts with CK1α led to the discovery 
that all FAM83 members bind to different CK1 isoforms through an identical mechanism. 
This has led to the hypothesis that FAM83 members serve as anchoring proteins for CK1 
isoforms, and in doing so, they regulate CK1 subcellular localisation and substrate 
accessibility in cells. 
 Regulation of PAWS1 by post-translational modifications remains poorly 
defined. A proteomic approach identified calcium and calmodulin-dependent kinase 
isoforms D and G (CaMK2D and CaMK2G) as two novel interactors of PAWS1. CaMK2 
enzymes are activated in response to calcium signals to control cytoskeletal 
rearrangements and cell movement. PAWS1 has been implicated in actin cytoskeletal 
dynamics and cell migration, through its dynamic interaction with the adapter protein 
CD2AP at the cell periphery. Here, PAWS1 has been shown to be phosphorylated at 
Ser356 by CaMK2D in cells and this phosphorylation event is demonstrated to be 
important for PAWS1-dependent cell migration. 
 Lastly, several PAWS1 mutations have been recently linked with the pathogenesis 
of skin diseases in dogs and humans. However, how these mutations relate to PAWS1 
function in cells and potentially cause the disease phenotypes remain elusive. In this 
thesis, initial steps have been taken to address the potential impact of these pathogenic 
mutants on PAWS1 function. 
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TAE Tris-acetate-EDTA 
TBS tris-buffered saline 
TBST tris-buffered saline with Tween 20 
TCF T cell factor 
TFA trifluoracetic acid 
TEMED tetramethylethylenediamine 
TGFBI transforming growth factor beta induced  
TGFβ transforming growth factor β 
TKI tyrosine kinase inhibitor 
TMT tandem mass tag 
tris tris(hydroxymethyl)methylamine 
Triton X-100 t-octylphenoxypolyethoxyethanol-X-100  
TTBK tau tubulin kinase 
Tween 20 polyethylene glycol sorbitan monolaurate 
Ub ubiquitin 
URP unfolded protein response 
UV ultraviolet 
V volts 
v/v volume to volume 
VRK vaccinia related kinase 
w/v weight to volume 
WASF3 Wiskott-Aldrich syndrome protein family member 3 
Wls Wntless 
wly  wooly 
WRE Wnt-responsive element 
WT wild type 
x Xenopus 
XIRP1 Xin actin-binding repeat-containing protein 1 
XNLA Xenopus laevis 
Xnr Xenopus nodal-related factor 
β-TrCP β-transducin repeat-containing protein 
μ micro 
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amino acid three letter code one letter symbol 
Alanine Ala A 
Arginine Arg R 
Asparagine Asn N 
Aspartic acid Asp D 
Cysteine Cys C 
Glutamic acid Glu E 
Glutamine Gln Q 
Glycine Gly G 
Histidine His H 
Isoleucine Ile I 
Leucine Leu L 
Lysine Lys K 
Methionine Met M 
Phenylalanine Phe F 
Proline Pro P 
Serine Ser S 
Threonine Thr  T 
Tryptophan Trp W 
Tyrosine Tyr Y 
Valine Val V 
any amino acid Xaa X 
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1. Introduction 
 
1.1 Overview of FAM83G/PAWS1 
The human FAM83G protein is a 91 kDa protein composed of 823 amino acids. 
It is encoded by the FAM83G gene, located on Chromosome 17p11.2. FAM83G belongs 
to the poorly characterized FAM83 family (Family with sequence similarity 83) of genes, 
which are conserved in vertebrates. The FAM83 family consists of eight members 
(FAM83A-H), which share the conserved domain of unknown function (DUF1669) at 
their N-terminus (Fig 1-1). To date, very little is known about the biological roles of the 
FAM83 proteins and much less about the DUF1669.  
 
 
Figure 1- 1 Schematic overview of the human FAM83 proteins. 
The relative size and the location of the conserved DUF1669 domain is highlighted in 
blue. The PLDc-like motif which lies within the DUF1669 is highlighted in pink. The 
phylogenetic tree was constructed in Jalview based on the conserved DUF1669 domain. 
 
The Sapkota lab identified FAM83G as an interacting partner of the transcription 
factor SMAD1 and thus it was renamed as PAWS1 (Protein Associated With SMAD1) 
(Vogt, Dingwell et al. 2014). SMAD1 is an intracellular mediator of the bone 
morphogenetic protein (BMP) signalling pathway. BMP signalling regulates many 
cellular processes, such as differentiation, proliferation, motility and apoptosis, during 
embryonic development and in adult tissues (Shi and Massague 2003) During 
embryogenesis, BMP signalling is first seen during gastrulation, when the cell fate 
patterning happens(Little and Mullins 2006). In vertebrates, BMPs pattern ventral cell 
fates, whereas repression of BMP signalling is required for dorsal cell fates (Holley, 
Jackson et al. 1995). Expression of BMPs in the ventral animal pole, in combination with 
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expression of BMP antagonists in the dorsal side, create a gradient of BMP signalling 
along the dorsal-ventral axis, to ensure proper embryonic development (De Robertis and 
Kuroda 2004). Abnormal BMP signalling is associated not only with developmental 
abnormalities but also with many human diseases, including bone defects and cancer 
(Massague, Blain et al. 2000, Shi and Massague 2003). 
 BMPs bind to BMP receptor complexes, leading to the phosphorylation of the 
transcription factors SMAD1, 5 and 8. These SMADs are then associated with SMAD4 
and they translocate into the nucleus (canonical BMP signalling pathway), where they 
modulate the transcription of target genes, such as ID1 and SMAD6 (Ishida, Hamamoto 
et al. 2000, Lopez-Rovira, Chalaux et al. 2002). Alternatively, it has been shown that in 
cells that lack SMAD4 expression, BMPs can signal independently of SMAD4 and can 
regulate the transcription of about a hundred genes involved in the suppression of cell 
proliferation and chemotaxis, including NEDD9, ASNS and PTEN (Beck and Carethers 
2007, Perron and Dodd 2009). This is often referred to as non-canonical BMP signalling 
pathway and to date it remains poorly characterised.  
PAWS1 was shown to form a macromolecular complex with SMAD1 
independent of SMAD4 or BMP stimulation (Vogt, Dingwell et al. 2014). It was further 
shown that the manipulation of PAWS1 levels by over-expression and siRNA knock-
down approaches, did not affect the BMP-induced phosphorylation of SMAD1, nor the 
expression of canonical BMP-target genes (Vogt, Dingwell et al. 2014). PAWS1 is the 
first non-SMAD BMP type I receptor substrate, as it was found to be phosphorylated by 
BMPR1A (ALK3) at Ser610, Ser614 and Ser616 in vitro. BMP stimulation was also 
found to induce PAWS1 phosphorylation at Ser610 in HaCaT cells (human 
keratinocytes). Mutation of Ser610 to Ala did not affect the PAWS1 interaction with 
SMAD1 but did impact the transcription of the PAWS1-target genes NEDD9 and ASNS 
upon BMP stimulation (Vogt, Dingwell et al. 2014). 
Preliminary work, using RNA-sequencing, showed that introduction of PAWS1 in 
PC3 prostate cancer cells, which lack endogenous PAWS1 expression due to 
hypermethylation of its promotor, was found to regulate the transcription of over 800 
genes, in a SMAD4-independent manner [Table 1-1; (Vogt 2013) PhD thesis, 
http://discovery.dundee.ac.uk].  However, most of these genes were regulated by PAWS1 
independent of BMP stimulation, suggesting that PAWS1 also acts in pathways other than 
BMP signalling. It is presently unknown how PAWS1 regulates transcription of so many 
target genes, and whether the association with SMAD1 is required for this. Although there 
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are no apparent or predicted DNA-binding motifs on PAWS1, it is still unclear whether 
PAWS1 can potentially act as a transcription factor or transcription co-factor. 
 
PAWS1 up-regulated PAWS1 down-regulated 
CAMK2B CHRM3 AFF2 ADCY1 
GJB2 HPGD ALDH2 AR 
KCNK13 LGR5 BEX1 CCNA1 
MMP1 MMP13 CNTN1 CXorf57 
MPZL2 MUC3A FREM2 GABRA3 
NPY1R PCDHB8 GABRG3 MAGEA3 
PCDHGB2 PPP2R2C MAGEA6 NEO1 
PROKR1 REG4 NEURL PDGFRA 
SH2D1B TSPAN8 PDZRN3 TUB 
TGFBI ZNF100 WASF3 RFXAP 
Table 1- 1 Top 40 PAWS1-regulated genes in PC3 cells 
PAWS1-dependenent genes were identified by RNA-sequencing and validated by RT-
PCR. (Red: >10fold, black: >5fold, blue: >4fold) (By Vogt PhD thesis, 
http://discovery.dundee.ac.uk).  
 
Remarkably, bioinformatic analysis of the 800 genes that showed transcriptional 
regulation by PAWS1 revealed that these genes could not be assigned to any single, 
known signalling pathway, suggesting that PAWS1 might be involved in multiple 
pathways in cells. The majority of the genes whose expression was significantly altered 
by PAWS1 are reported as mis-expressed or functionally compromised in cancer. 
Moreover, PAWS1 protein expression was shown to be absent from over 60% of the 
cancer cell lines in the National Cancer Institute (NCI) panel (Vogt PhD thesis, 
http://discovery.dundee.ac.uk). In line with this, hundreds of  PAWS1 mutations have 
been identified in various human cancers. According to the online COSMIC database by 
the Sanger Institute, over half of PAWS1 mutations are missense substitutions with the 
majority of them found in skin tissue (http://cancer.sanger.ac.uk/cosmic/gene/analysis? 
ln=FAM83G#overview).  
Another study in the literature reporting on PAWS1 function describes a recessive 
missense mutation (R52P) on PAWS1 in dogs that suffer from hereditary footpad 
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hyperkeratosis (HFH). HFH is characterised by epidermal hyperplasia and hair follicular 
abnormalities (Drogemuller, Jagannathan et al. 2014, Sayyab, Viluma et al. 2016) The 
affected dogs develop hard and cracked footpads, which become severely debilitating 
over time. Hyperkeratosis is a serious condition in humans and it is associated with 
defects in the genes encoding keratins (Cheng, Syder et al. 1992).  Through 
communication with Prof. I. McLean (University of Dundee), who works on skin 
diseases, a novel putative mutation (G640R) in human PAWS1 was identified in patients 
with benign trichilemmal cysts, which originate from hair follicles. More recently, 
another recessive mutation on PAWS1 (A34E) was published and it was associated with 
palmoplantar keratoderma, a condition characterised by abnormal thickening of the palms 
and soles, and exuberant scalp hair (Maruthappu, McGinty et al. 2017) (Fig 1-2). 
 
 
Figure 1- 2 Schematic representation of the PAWS1 protein with the locations of the 
reported mutated residues. 
Missence mutations are shown in green, truncating in black and in-frame in brown. The 
stars highlight the residues that are found to be mutated in skin disease. Figure was 
adapted from www.cbioportal.org. 
 
Finally, Radden et al. (2013) reported a 955 bp deletion of the genomic DNA that 
transcribes the PAWS1 gene in mice with the wooly mutation (wly) (Radden, Child et al. 
2013). The phenotypic characterisation of the affected mice was limited to observations 
of matted and rough coat in 3-4-week-old pups and giant hair follicles during the first 
stage of the hair growth cycle in 5-week-old pups (The Jackson Laboratory; 
https://www.jax.org/strain/004774)  but this was not followed up by any further 
investigation into PAWS1 protein expression or function.  
Taken together, it appears that all the pathological conditions associated with 
PAWS1 affect the skin or the hair. Therefore, one can hypothesise that PAWS1 plays an 
important role in the development or homeostasis of the skin and the hair follicles. Hence, 
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it would be pertinent to investigate potential implications of PAWS1 in the molecular 
pathways that are known to govern these processes. During skin development, Wnt 
signalling is critical for the determination of epidermal cell fate of the ectoderm (Wilson 
and Hemmati-Brivanlou 1995). Activation of Wnt signalling in ectodermal cells leads to 
FGF inhibition followed by the induction of BMPs expression, which were shown to be 
epidermal inducers (Wilson and Hemmati-Brivanlou 1995). In the postnatal skin, active 
Wnt signalling is required for the development of the hair follicle (Andl, Reddy et al. 
2002). Notably, the hair follicles, in addition to their role in hair production, also have 
self-renewal properties due to the presence of pluripotent stem cells and this process is 
also regulated by the Wnt signalling pathway (Lim and Nusse 2013). Hyperactivation of 
Wnt signalling has been linked to skin tumours (Malanchi, Peinado et al. 2008, Yang, 
Andl et al. 2008). Furthermore, patients with mutations in the Wnt genes were reported 
to display palmoplantar hyperkeratosis and hair growth abnormalities (Adaimy, Chouery 
et al. 2007, Petrof, Fong et al. 2011). Collectively, the evidence above raises the 
tantalising possibility that PAWS1 might function in the Wnt signalling pathway. 
Thus far, the main limitation of assigning a biochemical role to PAWS1 is the lack 
of any obvious functional domains within its protein sequence. Therefore, it is important 
to discuss the functional insights gleaned from other FAM83 members and try to 
understand the potential role of the conserved DUF1669 domain that unites all FAM83 
family members. 
1.2 The Fam83 family of proteins 
The FAM83 (FAMily with sequence similarity 83) family of proteins consists of 
8 members (A to H), which were clustered together based on sequence similarity of a 
conserved DUF1669 domain (Pfam PF07894) of unknown function. Often, sequence 
similarity implies similar biological and biochemical functions (Joshi and Xu 2007). The 
conserved globular DUF1669 domain lies at the very N-termini of the FAM83 members. 
Outside the DUF1669 domain there is no detectable sequence similarity among the family 
members and the most of C-terminal section of every FAM83 member is predicted to 
consist of non-globular, disordered regions (Fig 1-3; Appendix Fig A-1). Domains are 
defined as functional and/or structural units of a protein (Sheehan 2011). Thus, grouping 
together proteins based on the presence of a domain can provide a useful starting point to 
form testable hypotheses, especially when there is a lack of any functional information. 
Therefore, identifying the role(s) of the DUF1669 domain, its structure and function in 
cells, is critical for the biological characterisation of the FAM83 family.  
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Figure 1- 3 Multiple sequence alignment of the human FAM83 proteins.  
Alignment was performed with ClustalO in Jalview 2.10.3 and colouring indicates the % 
of sequence identity. 
 
 Often, domains of unknown function (DUFs), by definition are understudied. 
However, many DUFs are present in essential proteins and they are highly conserved, 
implying critical roles in biology (Luo, Gamage et al. 2016, Tong, Chen et al. 2016) .The 
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limited three-dimensional protein structure, phenotypic and protein-protein interaction 
data, has hampered the reliable assignment of a functional annotation of these predicted 
but uncharacterised protein DUF domains. This is the reason why there is not much 
information available regarding the biological and the biochemical properties of the 
FAM83 family. 
 The FAM83 genes are conserved in vertebrates but are absent in more primitive 
organisms. The observations that FAM83 genes are mutated in various cancers (Lee, Hu 
et al. 2008, Cipriano, Graham et al. 2012, Wang, Liu et al. 2013, Cipriano, Miskimen et 
al. 2014, Mao, Liu et al. 2016, Walian, Hang et al. 2016, Wang, Hu et al. 2016, Kim, Park 
et al. 2017, Perez-Pena, Alcaraz-Sanabria et al. 2017, Snijders, Lee et al. 2017) have made 
this novel family of genes an interesting topic for pursuing further biological research, 
aimed at identifying their functions in health and disease. 
1.2.1 Are FAM83 proteins pseudo-PLDs? 
 According to annotation databases (UniProt, SMART), the DUF1669 domain 
displays a short sequence of amino acids that resembles the phospholipase D catalytic 
motif (PLDc). Phospholipase D (PLD) is an enzyme which hydrolyses the most abundant 
membrane lipid, phosphatidylcholine, to choline and phosphatidic acid.  Phosphatidic 
acid is rapidly converted into diacylglycerol by phosphatidic phosphatase, which then 
activates protein kinase C isoforms. PLDs are involved in phospholipid metabolism, 
intracellular signal transduction and vesicle trafficking (Jenkins and Frohman 2005). 
There are six PLD isoforms in humans: PLD1 and PLD2 which share about 50% sequence 
similarity, the endoplasmic reticulum transmembrane PLD3 and PLD4, PLD5, which so 
far is considered inactive enzyme, and PLD6, which is also called mitoPLD (Nelson and 
Frohman 2015). The conventional phospholipase catalytic motif comprises the conserved 
consensus sequence motif His-x-Lys-x-x-x-x-Asp (also referred to as HKD), where x 
denotes any amino acid (Sung, Roper et al. 1997). Human PLD1 and PLD2 have two 
HKD motifs, which are critical for their enzymatic activity (Sung, Roper et al. 1997), 
whereas the rest of the human PLD isoforms have only one HKD motif. It was suggested 
that one His of the HKD motif acts as the nucleophile that attacks a phosphate group of a 
lipid substrate while the second His protonates the remaining group, allowing a water 
molecule or primary alcohol to complete the hydrolysis reaction (Leiros, Secundo et al. 
2000, Xie, Ho et al. 2000). Often, the histidine of the HKD motif is mutated to Ala for 
neutralizing the catalytic activity (Yang and Roberts 2002). Notably, PLD6 is 
phylogenetically closer to the bacterial endonuclease Nuc, which also contains a single 
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HKD motif (Choi, Huang et al. 2006). The resolved crystal structure of Nuc showed that 
it forms a dimer to assemble into a functional complex (Stuckey and Dixon 1999). 
  To date no PLD catalytic activity has been attributed to FAM83 proteins. This is 
supported by the fact that unlike the PLD enzymes, all FAM83 proteins except FAM83D 
have a pseudo HKD motif in which the first His residue is replaced by another amino acid 
(Fig 1-4). Moreover, unlike PLDs, in all FAM83 proteins there is only one HKD motif. 
It is therefore unlikely that FAM83 proteins retain any PLD enzymatic activity. However, 
based on the presence of an inactive PLD motif, FAM83 proteins could be classified as 
pseudo PLDs. Their sequence similarity with the PLD catalytic motif might still imply 
that they have retained related direct or indirect signalling function. Pseudoenzymes 
usually arise from gene duplication events and during evolution they lose the key catalytic 
sites, thereby gaining new functions (Adrain and Freeman 2012). As the signalling events 
become more complex in the higher eukaryotes, it is possible that the pseudoenzymes still 
function in the same signalling pathways as the active enzyme counterparts, as regulators 
of allosteric activation or suppression (Murphy, Farhan et al. 2017). Currently, the only 
example that FAM83 proteins assume such a role was reported by Cipriano et al (2014) 
who showed that overexpression of FAM83B leads to increased PLD activity in human 
mammary epithelial cells, through hyperactivation of the epidermal growth factor 
receptor (EGFR) (Cipriano, Bryson et al. 2014). 
Another piece of evidence to support a putative pseudo-PLD role for the FAM83 
family of proteins comes from the crystal structures of the DUF1669 domains of 
FAM83A and FAM83B. During the course of my PhD, a collaboration with Dr A. 
Bullock (University of Oxford) was set up to resolve the crystal structures of the FAM83 
proteins. The Bullock lab crystallised the human FAM83A and FAM83B DUF1669 
domains (PDB 4URJ and 5LZK, unpublished). Both structures displayed dimerization, 
with the architecture of the pseudo HKD motif almost identical to that of the HKD motifs 
from the crystal structures of Streptomyces sp. PLD, and the Salmonella typhimurium Nuc 
endonuclease (Fig 1-5). However, there were many unique features noted. For example, 
the DUF1669 cleft was found to be more open and funnel-like compared to the cylindrical 
cleft of the PLD catalytic core, suggesting that FAM83 DUF1669 domain could 
accommodate larger ligands than a phospholipid (Fig 1-5). Furthermore, unique structural 
motifs that were observed in FAM83 proteins that were absent from PLD, including beta-
hairpins (Fig 1-4, 1-5). It is yet to be determined if these structural motifs are involved in 
protein folding or if they are important for mediating interactions with other proteins, or 
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DNA (Leon, Tecklenburg et al. 2008). Other than the similarities in the position of the 
catalytic cleft residues, the overall structures of DUF1669 and PLDs were significantly 
different. These findings also suggest that FAM83 proteins might form homo- or hetero- 
dimers, which despite the absence of catalytic residues, might be both necessary and 
important for proper biological function in response to different biological signals.  
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Figure 1- 4 Sequence alignment of the DUf1669 domain of the FAM83 proteins, 
covering the region of FAM83A that was used for crystallography. 
Multiple alignment was performed with T-Coffee software. The secondary structure 
elements on top of the sequences were obtained with the ESPript program based on the 
PDB entry 4URJ (squiggle: α-helix, arrow: b-strand, TT: strict β-turn). Identical and 
similar residues are boxed in red and yellow, respectively (Robert and Gouet 2014). The 
asterisks indicate the HKD motif. 
  
11 
 
 
Figure 1- 5 Crystal structure of the DUF1669 domain.  
A. Structure of the FAM83A DUF1669 domain that was resolved in collaboration by 
Dr A. Bullock (Oxford). The structure reveals a unique dimer with a PLD-like 
fold which brings the putative PLD catalytic motif together at the catalytic cleft 
(green).  
B. PLD1 structure (from PDB entry1FO1). 
C. Ribbon diagram depicting the folding of the FAM83A DUF1669 domain into a 
dimer with two helices perpendicular to those in the PLD1 which form the 
catalytic cleft (green).  
D. Ribbon diagram depicting the folding of the PLD1 (adopted from Leiros et al. 
2000). 
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1.2.2 The biological niche of FAM83 proteins 
Having reviewed the literature on FAM83G (1.1), I will now focus on the rest of 
the FAM83 proteins. 
1.2.2.1 FAM83A and FAM83B 
FAM83A and FAM83B have both been reported to be oncogenes as their 
expression was found to be significantly elevated in various human tumours compared to 
normal tissue (Snijders, Lee et al. 2017). Cancer cells with elevated FAM83A and 
FAM83B expression were shown to display resistance to tyrosine kinase inhibitors (TKI) 
(Lee, Meier et al. 2012, Cipriano, Bryson et al. 2014). Tyrosine kinases, such as EGFR 
and FGFR, are frequently activated in human cancers and they promote cell proliferation, 
growth and survival through activation of the RAS/RAF/MEK/ERK and PI3K/AKT 
pathways (Fig 1-6). Ablation of either FAM83A or FAM83B showed decreased growth 
and proliferation of cancer cells compared to healthy non-cancer controls (Lee, Meier et 
al. 2012). It was suggested that FAM83A interacts with c-RAF and the p85 subunit of 
PI3K upon EGF-stimulation, leading to its oncogenic transduction (Lee, Meier et al. 
2012). However, the above data have not yet been validated in a non-over-expression 
system. FAM83B was shown to substitute for RAS in activating both MAPK and 
PI3K/AKT signalling pathways. In FAM83B over-expressing cells, c-RAF was found to 
interact with FAM83B, an event that then prevented the c-RAF interaction with 14-3-3 
proteins, which negatively regulates the pathway, thereby resulting in increased c-RAF 
localisation at the plasma membrane and sustained MAPK signalling (Cipriano, Graham 
et al. 2012, Cipriano, Miskimen et al. 2013) (Fig 1-6).  
 On the grounds that both FAM83A and B were suggested to play a role in EGFR-
TKI resistance and cancer progression, it was proposed that FAM83 members could 
comprise a novel family of oncogenes that could be promising targets for drug discovery 
(Cipriano, Graham et al. 2012, Lee, Meier et al. 2012, Cipriano, Miskimen et al. 2013). 
Although the above studies highlighted the biological significance and pathogenic roles 
of FAM83A/B, none of them illuminated their biochemical roles, nor the mechanisms 
through which they act. Ideally, the above observations would be strengthened with 
studies performed under physiological conditions, in which the endogenous protein levels 
are kept in homeostatic balance and not affected by over-expression and with genetic 
evidence from FAM83A/B-null cells obtained from genome editing techniques.   
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Figure 1- 6 Proposed model by which FAM83A and FAM83B may modulate 
Tyrosine Kinase signalling. 
Growth factors such as EGF and FGF bind to their tyrosine kinase receptors (TKs) 
resulting in receptor dimerization, autophosphorylation and activation.  In a simplified 
model, the signal is then transduced via the RAS/RAF/MEK/ERK pathway or 
PI3K/AKT/mTOR pathway resulting in cell transformation. Lee et al., 2012 suggested 
that FAM83A binds PI3K p85 subunit and RAF, sustaining the activation of the pathway. 
Cipriano et al., 2013 suggested that FAM83B interacts with RAF, preventing the RAF 
interaction with 14-3-3 proteins that negatively regulate the pathway, and thus sustaining 
downstream ERK signaling. Like FAM83A, FAM83B was also shown to interact with 
p85 sustaining PI3K signaling. By acting downstream of the receptor activation, 
FAM83A and FAM83B might alter the cellular responses to TKIs as they could bypass 
the inhibition of growth signaling caused by TKIs (Modified from Cipriano et al., 2013; 
Lee et al., 2012). 
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1.2.2.2 FAM83D 
 FAM83D or CHICA was identified in a proteomic study of the human spindle 
apparatus and shown to be involved in mitosis (Sauer, Korner et al. 2005). It was then 
found to be required for the proper organisation of the metaphase plate via its association 
with the chromokinesin KID (Santamaria, Nagel et al. 2008), the dynein light chain 1 
motor pretein and microtubule-binding protein HMMR (Dunsch, Hammond et al. 2012). 
It was shown to be cell cycle regulated and phosphorylated in mitosis (Santamaria, Nagel 
et al. 2008). Depletion of FAM83D from cells resulted in shorter spindles and 
chromosome alignment defects (Santamaria, Nagel et al. 2008). 
 Like the other FAM83 genes, FAM83D has been reported to have prognostic 
significance in different human cancers, suggesting that higher FAM83D mRNA could 
correlate with lower survival (Walian, Hang et al. 2016, Perez-Pena, Alcaraz-Sanabria et 
al. 2017). It has also been reported that FAM83D promotes cell proliferation in 
hepatocellular carcinoma through activating cell cycle progression by activating the 
MEK/ERK signalling pathway (Wang, Han et al. 2015), and by downregulating the 
tumour suppressor gene FBXW7 in various cancer types (Wang, Liu et al. 2013). 
1.2.2.3 FAM83H 
 FAM83H is the largest protein of the FAM83 family and it has been reported to 
be mutated in amelogenesis imperfecta (AI) (Kim, Lee et al. 2008, Lee, Hu et al. 2008, 
Ding, Estrella et al. 2009, Hart, Becerik et al. 2009, Hyun, Lee et al. 2009, Lee, Lee et al. 
2009, Wright, Frazier-Bowers et al. 2009, Kweon, Lee et al. 2013, Xin, Wenjun et al. 
2017). Amelogenesis imperfecta (AI) is a group of diverse inherited disorders that cause 
dental enamel defects (Lee, Hu et al. 2008). Although several reports have shown the 
relationship between AI and mutations in FAM83H, there is still a complete lack of 
insight into the biochemical properties by which FAM83H is involved in amelogenesis. 
Studies by Kuga et al. (Kuga, Kume et al. 2013, Kuga, Kume et al. 2016, Kuga, Sasaki 
et al. 2016) proposed a possible mechanism by which FAM83H mutations impact AI 
showing that human ameloblastoma cells transfected with FAM83H mutant DNAs 
resulting in truncated FAM83H protein, displayed aberrant desmosome formation and a 
disorganized keratin cytoskeleton. This was shown to be mediated through interaction 
with and inhibition of Casein Kinase 1 (CK1) (Kuga, Sasaki et al. 2016). They had earlier 
identified CK1 as an interacting protein of FAM83H, and suggested that this association 
regulated the keratin cytoskeleton in colorectal cancer cells (Kuga, Kume et al. 2013). In 
agreement with this, it was then proposed that in metastatic cancer cells with 
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compromised keratin cytoskeleton, FAM83H and CK1 translocated to nuclear speckles 
together with the scaffold protein SON where they potentially regulate invasion 
phenotypes of cancer cells (Kuga, Kume et al. 2016).  
 More recently, FAM83H expression was linked to tumorigenesis as it was shown 
to be under the transcriptional regulation of the MYC oncogene, in liver cancer, and 
knock-down of FAM83H down-regulated proliferation and survival of cancer cells (Kim, 
Park et al. 2017).  
1.2.2.4 FAM83C, E and F 
 The functions of the rest of the FAM83 members remain to be characterised and 
there is currently no literature on the functions of FAM83C and E. FAM83F was found 
to be up-regulated both at the protein and mRNA levels in patients with oesophageal 
squamous cell carcinoma (Mao, Liu et al. 2016). However, there is no biochemical 
function attributed to FAM83F protein so far. 
Overall, as described above, there is emerging evidence indicating that FAM83 
proteins are involved in diverse cellular processes, which could possibly be attributed to 
their diverse C-termini. Of note, most FAM83 protein functions are implicated in 
promoting cancer and tumorigenesis (Snijders, Lee et al. 2017). Various signalling 
pathways that are activated during tumour formation are critical during early embryonic 
development (Yang and Weinberg 2008). Among those pathways are the Wnt, BMP, 
Hedgehog and Notch signalling (Kelleher, Fennelly et al. 2006). Thus, a collaboration 
was initiated between our laboratory and the developmental biologists in Prof J. Smith’s 
lab (The Francis Crick Institute, previously NIMR London), to investigate the role of 
PAWS1 in the molecular pathways during development. Work from J. Vogt (Vogt PhD 
thesis, http://discovery.dundee.ac.uk) and Dr K. Dingwell (Smith lab, The Francis Crick 
Institute, London), provided the first insights into the physiological activity of FAM83 
proteins in vivo, starting with PAWS1 as discussed below.  
1.3 The first physiological indications of PAWS1 function 
In light of the fact that PAWS1 interacts with SMAD1 and is involved in BMP 
signalling, it was speculated that PAWS1 might act during early embryogenesis. To test 
this hypothesis, the Xenopus laevis embryogenesis model, which is an established 
experimental model to study vertebrate embryogenesis, was employed. Xenopus is a 
genus of African clawed frogs and it is a genetically similar vertebrate experimental 
model to humans. It was observed that microinjection of PAWS1 mRNA at the ventral 
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marginal zones of 4-cell stage X. laevis embryos, resulted in the formation of a complete 
secondary body axis at the tadpole stage. Such dorsalised phenotypes, characterised by a 
secondary axis formation, are often caused by either BMP inhibitors such as Chordin, 
(Sasai, Lu et al. 1994) or canonical Wnt signalling activators such as Wnt8 (Du, Purcell 
et al. 1995, Larabell, Torres et al. 1997).  
1.4 Wnt and BMP signalling control early embryogenesis of Xenopus 
laevis 
 Following the sperm entrance at the animal pole of the egg, a rapid movement of 
the egg content is initiated. This internal re-organisation of the yolk characterises the 
specification of the dorso-ventral (D-V) axis (Rowning, Wells et al. 1997) (Fig 1-7A).  
The cytoplasmic content that moves towards the opposite site of sperm entry, has dorsal 
determinants such as Dishevelled and GSK3-binding protein that together with maternal 
Wnt signalling lead to the stabilization and nuclear translocation of β-catenin, activating 
its transcription activity and defining the dorsal side of the embryo (Larabell, Torres et 
al. 1997). The site of the sperm entry will mark the future ventral part of the embryo 
(Vincent, Oster et al. 1986). In the blastula stage, the dorsally accumulated β-catenin acts 
synergistically with Veg1 and VegT which are expressed vegetally and form a gradient 
of Nodal related proteins (Xnr) from the dorsal region, defined as Nieuwkoop center to 
the ventral one (Agius, Oelgeschlager et al. 2000) (Fig 1-7B). Depletion of the β-catenin 
mRNA leads to the loss of dorsal structures (Heasman, Crawford et al. 1994), whereas 
injection of β-catenin antibodies induces axis duplication in Xenopus embryos (McCrea, 
Brieher et al. 1993). Xnrs are potent mesoderm inducers. High Xnr concentration induces 
the overlying cells to become dorsal mesoderm and this is the region specified as 
Spemman-Mangold organiser where gastrulation is initiated (Fig 1-7B). Low Xnr 
concentrations induce ventral mesoderm. The Spemman organizer induces the expression 
of the BMP antagonists Chordin, Noggin and Follistatin (De Robertis and Kuroda 2004). 
Micro-injection of BMP inhibitors induces an ectopic partial secondary axis (Sasai, Lu et 
al. 1994, Graff 1997). In addition to BMP inhibitors, the Spemman organizer also induces 
the expression of the Wnt inhibitors Cerberus, Frzb, Dickkopf and Crescent 
(Bouwmeester, Kim et al. 1996, Leyns, Bouwmeester et al. 1997, Wang, Krinks et al. 
1997, Glinka, Wu et al. 1998, Piccolo, Agius et al. 1999, Pera and De Robertis 2000). 
The inhibition of both BMP and Wnt signalling at the dorsal side promotes the formation 
of the most anterior part of the embryo, the cement gland, eyes and nasal placodes 
(Bouwmeester, Kim et al. 1996, Kiecker and Niehrs 2001). 
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 Opposite of the Spemman organiser, the ventral gastrula centre displays high 
BMP activity, which induces the formation of lateral plate mesoderm and blood islands 
(Bier and De Robertis 2015). Proteins such as Bambi, Xlr, Sizzled, CV2 and Tsg are 
secreted from the ventral centre and act as BMP agonists (De Robertis and Kuroda 2004). 
The BMP gradient across the D-V axis is kept by opposite transcriptional regulation in 
the dorsal and ventral centre (Reversade and De Robertis 2005). In the posterior part, an 
opposite gradient of Wnt signals is established from gastrulation to early development, 
defining the anterior-posterior axis (A-P) (Hikasa and Sokol 2013). 
Upstream of the BMP signals, Wnt signals, like xWnt8, act to maintain the ventral 
cell fates (Itoh and Sokol 1999). Over expression of several Wnt ligands and Wnt pathway 
components, as the β-catenin mentioned above, induces the formation of a secondary axis 
in Xenopus embryos (McCrea, Brieher et al. 1993, Baker, Beddington et al. 1999). It is 
remarkable that the same β-catenin mechanism is employed for the induction of two very 
distinct embryonic parts in early Xenopus development; at an earlier stage, it specifies the 
dorsal axis from the Spemman organiser whereas it modulates the ventral mesoderm 
development later on. 
In summary, two distinct signalling centres shape the D-V patterning during early 
Xenopus embryonic development (Fig 1-7), namely the dorsal signalling centre, which 
displays high Wnt/β-catenin activity and secretes BMP antagonists, and the ventral 
signalling centre, where BMP signalling functions. Perturbations of these signalling 
pathways impact D-V patterning. For example, activation of the Wnt signalling pathway 
results in a dorsalised phenotype characterised by the formation of a secondary axis, 
whereas activation of the BMP signalling leads to ventralised embryos. Microinjection of 
cloned mRNAs or the use of antisense DNA nucleotides, are commonly used by 
developmental biologists to examine their effect on body axis formation. These methods 
can reveal novel regulators of Wnt and BMP pathways according to the resulting 
dorsalised or ventralised phenotypes.    
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Figure 1- 7 Organiser formation in early Xenopus embryo  
A. Sperm entry in the oocyte initiates the internal re-organisation of the yolk which 
determines the dorso-ventral axis of the embryo.  
B. At the early blastula stage, the Nieuwkoop centre is formed at the dorsal-most and 
ventral-most region of the embryo, where the VegT/Vg1 and β-catenin signalling 
meet. A gradient of Nodal signalling at late blastula is formed. High Nodal 
signalling induces the Spemman organiser at the dorsal side whereas low Nodal 
signalling is needed for the induction of the ventral signalling centre. At gastrula, 
the ventral and dorsal signalling centres maintain a BMP and Wnt signalling 
gradient required for the D-V patterning of the embryo. Figure adapted from De 
Robertis and Kuroda, 2008. 
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1.5 The Wnt signalling pathway 
The Wnt signalling pathway is an evolutionarily conserved signal transduction 
pathway in metazoan animals (Loh, van Amerongen et al. 2016). Research into Wnt 
signalling has a long history of over 35 years. Its name is derived from the Drosophila 
segment polarity gene wingless and its vertebrate homologue integrated or int-1 (Nusse 
and Varmus 2012).  
Wnts are secreted Cys-rich glycoproteins, which are encoded by 19 different 
genes in humans (Kikuchi, Yamamoto et al. 2011). Binding of Wnts to their cell 
membrane receptors initiates intracellular signalling cascades, which have been 
traditionally classified as canonical (β-catenin dependent) and non-canonical (β-catenin-
independent) Wnt signalling. There are more than 15 Wnt receptors and co-receptors, 
including members of Frizzled (FZD), the highly homologous low-density-lipoprotein 
receptor-related proteins 5 and 6 (LRP5/6), receptor Tyr kinase-like orphan receptor 
(ROR), protein Tyr Kinase 7 (PTK7), receptor Tyr kinase (RYK), muscle skeletal 
receptor Tyr kinase (MUSK) and proteoglycan families (Niehrs 2012). The combination 
of different Wnt ligands with receptors and co-receptors designates the downstream 
signalling output (Grumolato, Liu et al. 2010). The presence of multiple extracellular Wnt 
agonists and antagonists adds another level of complexity and regulation to the Wnt 
signalling pathway (summarised in Fig 1-8). 
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Figure 1- 8 Wnt antagonists and agonists  
A. Dickkopf (DKK) and SOST binding to LRP5/6 disrupts the Wnt-induced FZD–
LRP6 complex formation. Insulin-like growth-factor binding protein 4 (IGFBP-
4) binds to LRP5/6 and FZD, thereby preventing signal transduction by Wnt. 
secreted Frizzled-related proteins (sFRPs), Wnt-inhibitory factor (WIF) and 
Cerberus (Cer) sequester Wnt, thereby inhibiting Wnt signalling. sFRPs may also 
inhibit Wnt signalling by binding to FZD.  
B. Wnts are the primary agonists and form a complex with LRP5/6 and FZD to 
activate signalling. Norrin acts similarly to Wnt, but binds specifically to FZD4. 
R-spondinS (Rspo) are vertebrate-specific proteins that bind to Leucine-rich 
repeat-containing G-protein coupled receptors 4, 5, 6 (LGR 4/5/6) and the E3 
ligases ZNRF3/RNF43. This induces receptor endocytosis so the internalised 
ZNRF3/RNF43 are unable to ubiquitinate Wnt receptors for degradation, 
sustaining thereby Wnt signalling. Figure modified from (Cruciat and Niehrs 
2013). 
1.5.1 The canonical (β-catenin-dependent) signalling 
The canonical Wnt signalling pathway is the best characterised Wnt pathway to 
date. The transcriptional co-activator β-catenin plays a central role in mediating the Wnt 
pathway and it regulates several cell responses to Wnt signals (Fig 1-9). In the absence 
of Wnt ligands, β-catenin is captured by the so-called β-catenin destruction complex 
(Stamos and Weis 2013). The destruction complex consists of the scaffold proteins Axin 
and adenomatous polyposis coli (APC), the kinases glycogen synthase kinase 3 (GSK3) 
and Casein kinase 1 (CK1), the protein phosphatase PP2A and the SKP1-CUL1-F-box 
protein (SCF) E3 ubiquitin-protein ligase complex β-transducin repeat-containing protein 
(β-TrCP) (Liu, Kato et al. 1999). Within the destruction complex β-catenin is 
phosphorylated by CK1 at Ser45, which primes it for subsequent sequential 
phosphorylation by GSK3 at Thr41, Ser37 and Ser33 (Liu, Li et al. 2002). APC binds to 
phosphorylated β-catenin and protects it against de-phosphorylation by PP2A (Su, Fu et 
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al. 2008). Subsequently, phosphorylated β-catenin is targeted for ubiquitylation by β-
TrCP followed by proteasomal degradation (Liu, Li et al. 2002, Wu and He 2006). 
Binding of Wnts to the FZD/LRP5/6 receptors, leads to the translocation of Axin to the 
activated LRP5/6 receptor, where it binds to its phosphorylated tail. However, the precise 
mechanisms that regulate Axin translocation have not been elucidated yet. Then, the 
destruction complex becomes saturated with phosphorylated β-catenin and as a result, the 
newly synthesised and unphosphorylated, therefore stabilised β-catenin accumulates in 
the cytosol and subsequently translocates into the nucleus (Li, Ng et al. 2012). In the 
nucleus, the T cell factor (TCF) binds and represses the Wnt-target genes in unstimulated 
cells together with the transcriptional co-repressor Groucho. Generally, upon Wnt 
activation, the nuclear β-catenin displaces Groucho and binds to TCF and lymphoid 
enhancer-binding factor (LEF), recruiting the transcriptional co-activators Bcl9 and 
Pygopus (Cavallo, Cox et al. 1998, Kramps, Peter et al. 2002) and the histone modifiers 
Brg1 and CBP (Stadeli, Hoffmans et al. 2006), thereby initiating the transcription of many 
Wnt-target genes (Fig 1-9). 
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Figure 1- 9 Overview of the canonical Wnt signalling pathway  
A. In the absence of Wnt ligands, β-catenin is captured by the destruction complex, 
which is mainly composed of Axin, APC, GSK3, CK1 and β-TrCP. Sequential 
phosphorylation of β-catenin by CK1 and GSK3 leads to its ubiquitination by 
β-TrCP followed by its degradation by the proteasome, so that the cytosolic levels 
of β-catenin remain low. In the nucleus, binding of Groucho to TCF blocks the 
transcription of Wnt-target genes. 
B. Wnt ligands bind to their receptors, causing phosphorylation of LRP5/6 and the 
formation of the Wnt signalosome which is mainly composed of polymerised 
DVL and Axin which recruits the whole destruction complex to the membranes. 
β-catenin is stabilised in the cytosol and enters the nucleus where it displaces 
Groucho from TCF and together with LEF they activate the TCF target genes.  
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1.5.2 The non-canonical (β-catenin-independent) signalling 
Non-canonical Wnt signalling refers to the Wnt-triggered pathways that do not 
involve β-catenin, but signal through other factors, that trigger different transcriptional or 
non-transcriptional responses. The non-canonical pathway is further sub-divided into 
several, poorly studied branches. Among these, the two most characterised ones are the 
Planar Cell Polarity (PCP) pathway and the Wnt/Ca2+ pathway (Semenov, Habas et al. 
2007). 
 In the PCP pathway, Wnts signal through the FZD receptors without the need for 
the LRP5/6 co-receptors (Fig 1-10A). The activated cascade includes the small GTPases 
RAC1 and RHOA and the kinases JUN-N-terminal kinase (JNK) and Rho-associated 
kinase (ROCK). This pathway results in cytoskeletal rearrangements, which govern cell 
motility, migration and cell polarity as well as transcriptional activation of the JNK-
dependent transcription targets such as cJUN (Simons and Mlodzik 2008) (Fig 1-10A). 
In vertebrates, the PCP pathway is primarily involved in embryonic development during 
gastrulation, where it modulates cell movements, and in adult tissues, where it regulates 
cell polarity and ciliary function (Simons and Mlodzik 2008). 
 The other non-canonical Wnt pathway is the Wnt/Ca2+ pathway (Fig 1-10B). Wnt 
binding to FZD activates G-proteins, which then activate phospholipase C (PLC). This 
leads to accumulation of diacylglycerol (DAG) and inositol triphosphate (IP3), which 
triggers intracellular Ca2+ release. Intracellular calcium accumulation activates several 
Ca2+-sensitive proteins, such as protein kinase C (PKC), calcium/calmodulin-dependent 
kinase 2 (CaMK2) and the protein phosphatase calcineurin, which then de-phosphorylates 
and activates the transcriptional regulator nuclear factor associated with T cells (NFAT) 
(Sheldahl, Slusarski et al. 2003) (Fig 1-10B). In Xenopus embryos, NFAT promotes 
ventral cell fates (Saneyoshi, Kume et al. 2002) and enhances the expression of numerous 
genes in neurons, cardiac and skeletal muscle cells, and promotes pro-inflammatory gene 
expression in lymphocytes (De Boer, Mordvinov et al. 1999). 
In addition to the Wnt signalling pathways described above, several other 
Wnt-FZD combinations as well as Wnt-binding to receptors other than FZD, trigger 
different β-catenin-independent responses (Bovolenta, Rodriguez et al. 2006, Inoki, 
Ouyang et al. 2006, Schambony and Wedlich 2007). These pathways might be activated 
in a tissue-specific manner and they could share overlapping components with the 
canonical and non-canonical Wnt signalling pathways. Because the main focus of this 
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thesis is the canonical Wnt signalling pathway, in the next section it will be discussed in 
more detail how the pathway is modulated by its core components, during each stage of 
the signalling cascade, in addition to the biology related to it. 
 
Figure 1- 10  Simplified overview of the PCP and the Wnt/Ca2+ signalling pathways.  
A. The PCP pathway: Wnt binding to FZD leads to the activation of RAC1 and 
RHOA which in turn activate JNK and ROCK kinases resulting in the activation 
of the downstream target genes in the nucleus. 
B. The Wnt/Ca2+ pathway: Activation of the Wnt/Ca2+ pathway signals through 
PLC which leads to the accumulation of IP3 and DAG that trigger the intracellular 
Ca2+ release. Ca2+ accumulation activates PKC, CaMK2 and Calcineurin which 
then activates NFAT which activates its target genes in the nucleus. 
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1.5.3 Modulation of the canonical Wnt signalling 
1.5.3.1 Wnt secretion 
 During their synthesis, all Wnt proteins are modified with the attachment of the 
lipid palmitoleic acid. This is performed by the palmitoyl transferase Porcupine (Porc) on 
the endoplasmic reticulum. The lipid on the Wnts serves as a binding site to the FZD 
receptor, but also adds hydrophobicity properties so that Wnts are tethered to membranes 
(Janda, Waghray et al. 2012). Palmitoylated Wnts are then transported to the plasma 
membrane by the transmembrane protein Wntless/Evi (Wls) to be secreted (Banziger, 
Soldini et al. 2006, Bartscherer, Pelte et al. 2006).. 
1.5.3.2 The binding of Wnts to their receptors and the formation of the Wnt 
signalosome 
 As discussed earlier, Wnts bind to their receptors FZD/LRP5/6 on the surface of 
the target cells. FZDs have a 7-transmembrane domain and a cysteine-rich extracellular 
domain, which binds Wnts (Bu, Li et al. 2017). How different Wnts bind to different 
FZDs is not fully understood. Binding of Wnt to FZD causes the dimerization of FZD 
with the single-pass transmembrane proteins LRP5/6, promoting a conformational change 
of both receptors (Cong, Schweizer et al. 2004). It has been hypothesised that 
extracellular Wnt binds to FZD dimers, which then form complexes with LRP dimers, for 
canonical Wnt signalling activation (DeBruine, Xu et al. 2017). The extracellular part of 
LRP5/6 consists of YWTD (Tyr, Trp, Thr and Asp)-type β-propeller domains, epidermal 
growth factor (EGF)-like domains and LDLR domains, which bind extracellular ligands 
but it is still not known whether Wnt ligands bind LRPs or not (Semenov, Habas et al. 
2007). The intracellular domains of LRP are critical for signal transduction upon Wnt 
stimulation (Tamai, Zeng et al. 2004, Zeng, Tamai et al. 2005). The conformational 
change on receptors caused by Wnt-binding, allows for immediate sequential LRP 
phosphorylation by GSK3 and CK1γ at PPPSP repeats (Davidson, Wu et al. 2005, Zeng, 
Tamai et al. 2005). Next, the Axin complex is recruited to the membrane, promoting the 
Wnt signalosome formation (Bilic, Huang et al. 2007). The formation of signalosomes is 
a hallmark of signal transduction pathways. An extracellular signal mediates the 
recruitment of cytoplasmic polymerised proteins to the activated transmembrane 
receptors, where they are assembled in large dynamic protein clusters (Gammons, Renko 
et al. 2016).  
The formation of the Wnt signalosome depends on the polymerisation of the 
cytoplasmic protein Dishevelled (DVL), which is recruited to FZD upon Wnt stimulation 
26 
 
(Cong, Schweizer et al. 2004). DVL is an evolutionarily conserved component of the Wnt 
pathway and it gets polymerised via its N-terminal DIX domain, promoting the formation 
of large protein clusters beneath the plasma membrane and mediating signal transduction 
by cytoplasmic effectors (Gammons, Renko et al. 2016). Polymerisation of DVL is 
critical for Wnt signal transduction, as mutations that block polymerisation fail to 
transduce the Wnt response in mammalian cells (Schwarz-Romond, Fiedler et al. 2007). 
DVL recruits Axin to the plasma membrane via direct binding through their respective 
DIX domains (Schwarz-Romond, Merrifield et al. 2005). Therefore, the whole β-catenin 
destruction complex is relocated to the plasma membrane, resulting in its disruption or 
inactivation of its function, which in turn leads to the accumulation and nuclear 
translocation of active/non-phosphorylated β-catenin. There are several models (as 
discussed below) describing the mechanisms of complex inactivation although most of 
them were formulated on over-expression-based studies (Li, Ng et al. 2012).  
1.5.3.3 Inactivation of the destruction complex 
By immunoprecipitating the endogenous form of Axin, Li et al. (2012) 
demonstrated that the destruction complex is functionally active upon Wnt stimulation 
despite its recruitment to the plasma membrane. In other words, there is no change on the 
phosphorylation status of β-catenin following Wnt signalling (Li, Ng et al. 2012). 
However, the destruction complex-associated β-catenin is no longer subjected to 
ubiquitylation and proteasomal degradation due to immediate dissociation of the β-TrCP 
ligase from the complex. At the same time, β-catenin stabilisation may be further 
promoted by phosphorylated LRP PPPSP motifs, which act as pseudo-substrates for the 
Axin-bound GSK3, inhibiting its kinase activity (Stamos, Chu et al. 2014). Consequently, 
there is an accumulation of non-phosphorylated β-catenin in the cytosol, which then 
translocates into the nucleus to activate Wnt-responsive target genes. An alternative 
model by Kim et al. (2013) suggests that phosphorylation of Axin by GSK3 is inhibited 
upon its membrane translocation following Wnt stimulation. The protein phosphatase 1 
(PP1) de-phosphorylates Axin, altering Axin’s conformation, preventing its association 
with β-catenin and phospho-LRP, thereby resulting in disassembly of the destruction 
complex (Kim, Huang et al. 2013). The identification of a consensus model that describes 
the mechanisms of the destruction complex regulation might be further hampered by the 
transient nature of the protein-protein interactions within the complex. Nevertheless, 
conclusions based on overexpression studies should be considered with caution given the 
dual activating and inhibitory role of some of the pathway components, as slight changes 
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in their protein levels might significantly perturb the downstream outcome. On the 
contrary, kinetic analysis of the pathway and quantitative approaches may provide a better 
understanding on how the signalling functions physiologically. 
1.5.3.4 The nuclear/cytosolic shuttling of β-catenin 
 One of the least understood stages of the canonical Wnt signalling pathway is the 
nuclear import and export of β-catenin. There is no evidence supporting the presence of 
a NLS (nuclear localisation signal) or importin-mediated nuclear entry of β-catenin. On 
the contrary, it was shown recently that β-catenin interacts with nucleoporins (Nups) that 
mediate bidirectional translocation through the nuclear envelope pores (Sharma, Johnson 
et al. 2014). However, whether Wnt signalling itself regulates the β-catenin localisation 
remains unknown. The only indirect evidence so far comes from studies by Wu et al. 
(2008), who showed that phosphorylation of β-catenin at Ser191 and Ser 605 by JNK 
after Wnt stimulation is essential for the nuclear translocation of β-catenin (Wu, Tu et al. 
2008). Of note, APC and Axin were reported to regulate β-catenin localisation 
(Henderson and Fagotto 2002, Cong and Varmus 2004). Ran binding protein 3 (RanBP3), 
which binds to β-catenin in a Ran-GTP-dependent manner was also reported to participate 
in the nucleocytoplasmic transport of β-catenin (Hendriksen, Fagotto et al. 2005). 
Nevertheless, research on this topic is more complicated, as most of the cellular β-catenin 
pool has been reported to be present at the plasma membrane, where it forms adherens 
junctions through its association with α-catenin and E-cadherin (Gottardi and Gumbiner 
2004, Baum and Georgiou 2011, Tan, Gardiner et al. 2012). 
 On the other hand, the interaction of β-catenin with binding partners, such as LEF, 
TCF1, 2, 3 and 4 and BCL9 inside the nucleus enhances its nuclear retention, resulting in 
positive regulation of the pathway (Krieghoff, Behrens et al. 2006, Jamieson, Sharma et 
al. 2011). There, β-catenin associates with multiple TCF and non-TCF transcription 
factors to activate the transcription of target genes. The genes that are traditionally defined 
as direct β-catenin targets contain the TCF binding motif 5’-AGATCAAAGG-3’ (van de 
Wetering, Cavallo et al. 1997), which is also known as Wnt-responsive element (WRE). 
Notably, WRE has been exploited by researchers who created artificial reporters with 
multiple WRE repeats upstream of the luciferase gene (Veeman, Axelrod et al. 2003). 
These reporters can be transfected into cells to provide a quick way to measure Wnt-
dependent transcriptional activity, through luciferase activity measurement (TOPflash 
assay).  Although the activation of Wnt-target genes is highly context-dependent (cell- 
and developmental stage- specific), one main marker for proper Wnt activation is the 
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expression of Axin2 (Jho, Zhang et al. 2002). Activation of Wnt-target genes including 
Axin2, DKK1 and Naked, or suppression of LRP6 and FZD, can also participate in 
negative feedback loops that dampen the pathway. In contrast, the activation of LEF/TCF 
reinforces the signal via a positive feedback loop (Logan and Nusse 2004, Arce, 
Yokoyama et al. 2006). Indisputably, the key output of Wnt signalling is the re-
programming of the target cells via the activation of transcriptional programs which 
govern growth (FGF4, VEGF), proliferation (Cyclin D1, MYC), differentiation (Siamois, 
Brachyury) and adhesion (E-Cadherin) in the developing cell or during adult tissue 
homeostasis (Reya and Clevers 2005). 
1.5.3.5 The biological outcomes of the canonical Wnt activation 
 As emphasised earlier, Wnt signalling plays a pivotal role in defining the body 
axis formation and cell fate decisions during early embryonic development. It controls 
the balance between cell proliferation and differentiation. This is highlighted through the 
fact that mutations of components of the canonical Wnt pathway are linked to 
developmental defects including abnormalities in the central nervous system (Thomas 
and Capecchi 1990, Wang, Thekdi et al. 2002), kidney defects (Stark, Vainio et al. 1994) 
lung and hair follicle abnormalities (Li, Rheaume et al. 2007) as well as focal dermal 
hypoplasia (Grzeschik, Bornholdt et al. 2007).  
In addition to its prominent role in embryonic development, Wnt signalling 
remains active in self-renewing tissues throughout the adult life. Nowadays, one of the 
most attractive areas of research on Wnt signalling is investigating its role in specification 
and maintenance of the stem cells in various tissues and organs. Stem cells are pluripotent 
cells that are able to both self-renew and differentiate into specialised cell types. It was 
first shown in 1998 that loss of the β-catenin binding partner TCF4 leads to the depletion 
of the stem cells compartment of the small intestine (Korinek, Barker et al. 1998). Since 
then, Wnt signals have been reported to play major roles in the maintenance of 
pluripotency of almost all stem cell types (ten Berge, Kurek et al. 2011).  
Finally, mutations in the destruction complex components have been individually 
implicated in human tumours. APC is the most commonly mutated gene in colorectal 
carcinoma (Sparks, Morin et al. 1998). Loss of APC function from colon cancer cell lines 
is associated with constitutive β-catenin-TCF4 interaction and activation of downstream 
target genes (Korinek, Barker et al. 1998). Other colorectal tumours without APC 
mutations were found to carry mutations in the N-terminal part of β-catenin, near its CK1 
and GSK3 phosphorylation sites (Sparks, Morin et al. 1998). Similar mutations on 
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β-catenin were identified in uterine endometrium (Fukuchi, Sakamoto et al. 1998), 
ovarian (Palacios and Gamallo 1998), stomach (Park, Oh et al. 1999), lung (Sunaga, 
Kohno et al. 2001) and liver cancer (Miyoshi, Iwao et al. 1998). Furthermore, mutations 
on Axin1 and Axin2 were identified in several tumours, such as hepatocellular carcinoma 
(Satoh, Daigo et al. 2000), adenocarcinomas (Koppert, van der Velden et al. 2004) and 
colorectal cancer (Liu, Dong et al. 2000). Of note, most of these mutations are described 
as activators of the Wnt signalling via β-catenin stabilisation. Such mutations may lock 
the Wnt pathway into a constitutively active state independent of Wnt stimuli, thereby 
resulting in stem cell-like phenotypes and neoplasia (Ewan and Dale 2008). 
Therefore, there has been a lot of interest from the pharmaceutical industry for 
designing anticancer therapeutics that target members of the Wnt signalling pathway. An 
example is the Porcupine inhibitor LGK794, which blocks Wnt palmitoylation and 
therefore its secretion. LGK794 is currently in clinical trials for patients with solid 
malignancies (https://clinicaltrials.gov/ct2/show/NCT01351103). However, a major 
challenge of targeting the Wnt pathway is that it is utilised by both cancer and healthy 
tissues of multiple organs. Furthermore, Wnt signalling cross-talks with other pathways 
that are critical for healthy tissue homeostasis, such as the EGF (Lu, Ghosh et al. 2003), 
Notch (Gu, Watanabe et al. 2013) and Sonic Hedgehog (SHH) (Kim, Shin et al. 2010) 
signalling pathways. In addition to this, many of the Wnt pathway components have dual 
roles in both activation and dampening of the Wnt signal transduction. Examples of this 
are the Casein Kinase 1 (CK1) isoforms, which are discussed in more detail below. 
Ultimately, a deeper understanding of the precise regulation of the Wnt pathway, 
including the specificity of protein-protein interactions of its components, is necessary in 
order to devise successful pharmacological interventions. 
1.6 The Casein Kinase 1 (CK1) family of proteins 
1.6.1 The Casein Kinases 
 The term ‘casein kinase’ has been widely used to describe three different classes 
of protein kinases that can phosphorylate casein in vitro. The secreted milk protein casein 
was the first phosphoprotein to be identified in 1883. This was the first indication of the 
existence of the protein kinases (Tagliabracci, Pinna et al. 2013). Some 70 years later, 
Burnett and Kennedy described the phosphate transfer from ATP to purified casein in 
liver homogenates (Burnett and Kennedy 1954). The enzymes responsible for catalysing 
casein phosphorylation were named Casein Kinase 1 (CK1) and Casein Kinase 2 (CK2) 
(Burnett and Kennedy 1954, Pinna, Clari et al. 1969). However, these are now considered 
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misnomers because casein, which is a secreted protein, is not a physiological substrate 
for either enzyme found inside the cells. A genuine casein kinase (G-CK) was isolated 
from the Golgi-enriched fractions of the mammary gland, where casein is synthesised, 
but for decades it remained an ‘orphan’ enzyme (Lasa-Benito, Marin et al. 1996). Only 
recently the G-CK was identified as Fam20C (Family with sequence similarity 20C), 
which belongs to a new branch of the human kinome tree, termed the four-jointed family 
of secreted protein kinases (Tagliabracci, Engel et al. 2012, Tagliabracci, Wen et al. 
2016). This family of secreted kinases has been shown to phosphorylate casein as well as 
other proteins in the extracellular matrix of bone and teeth (Tagliabracci, Engel et al. 
2012, Tagliabracci, Wen et al. 2016).  
 Apart from their ability to phosphorylate casein in vitro, CK1, CK2 and Fam20C 
are very distinct and have little in common. CK1 and CK2 are pleiotropic enzymes that 
control a plethora of substrates, and impact a diverse range of biological processes. For 
the purpose of this thesis, I will focus on the CK1 family, which I will discuss in more 
detail in the following sections. 
1.6.2 The CK1 biology  
 The CK1 family consists of a group of Serine/Threonine protein kinases that form 
a small branch in the human kinome tree (Fig 1-11). CK1 proteins are evolutionarily 
conserved and are present in organisms that range from bacteria, fungi and plants to 
mammals (Rowles, Slaughter et al. 1991, Fish, Cegielska et al. 1995, Gross and Anderson 
1998). In humans, there are seven CK1 isoforms encoded by different CSNK1 genes (α, 
αL, γ1, γ2, γ3, δ and ε), with several splice variants also reported for some (Fig 1-11, 
1-12). The N-terminal kinase domain is highly conserved among all the isoforms but their 
C-terminal region is significantly different (Fig 1-12).  
CK1α and CK1αL display high sequence similarity (over 90%), with only 25 
amino acids different over the whole protein sequences. Their kinase domains and the 
ATP-binding site are almost identical (Fig 1-12). For this reason, there has been a lot of 
confusion in distinguishing these two gene products and often the name CK1α is 
commonly used indistinguishably for both. The only reference to CK1αL is by Xu et al. 
(2008), who identified CK1αL as the only isoform to phosphorylate the osmo-sensitive 
transcription factor OREBP, thereby regulating its nucleocytoplasmic trafficking upon 
hypertonic stress (Xu, Wong et al. 2008).  CK1δ and CK1ε are more closely related to 
each other, displaying almost 85% sequence similarity, than to CK1α andCK1αL. The 
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three CK1γ isoforms differ significantly from the rest of the family as they are the only 
ones that carry a palmitoylation site at their C-terminus, which anchors them to the plasma 
membrane, whereas all the other CK1 isoforms localise to the cytoplasm and nucleus 
(Davidson, Wu et al. 2005).  
 CK1 members are thought to be constitutively active (Rivers, Gietzen et al. 1998). 
They show a preference for acidic substrates (D/E-x-x-S/T), although in many cases the 
preference for the acidic amino acid in position n-3 (where n denotes the CK1 
phoshorylation residue) can be replaced by a phosho-Ser or a phospho-Thr (Flotow et al., 
1990). Since the CK1 phosphorylation consensus motif is common in many target 
proteins, the enzymatic activity of the CK1 isoforms must be spatiotemporally regulated. 
Additionally, some CK1 substrates, such as β-catenin, do not possess the consensus 
phosphorylation motif. The wide range of CK1 targets is further appreciated by the 
diverse substrates that have been reported over the years. These include transcription 
factors, adhesion proteins, cytoskeletal components, membrane receptors, ribosomal 
proteins, vesicle-associated proteins, metabolic enzymes and other signalling molecules, 
such as adaptors, scaffold proteins and protein kinases and phosphatases (Knippschild, 
Gocht et al. 2005, Cheong and Virshup 2011). However, as a complete phospho-proteome 
landscape for each CK1 isoform has not yet been reported, we might still be looking at a 
subset of the total CK1 substrates. It is evident that the spectrum of CK1 substrates is very 
wide and combined with the fact that CK1 isoforms are ubiquitously expressed, there 
must be precise and tight regulation of both CK1 isoform activity and localisation in cells.  
 Given the diverse range of target substrates that CK1 isoforms phosphorylate, it 
is not surprising that CK1 isoforms are involved in controlling many cellular processes. 
Among these are: regulation of cell cycle progression, cell proliferation, circadian 
rhythm, response to DNA damage, and apoptosis (see below 1.6.5). The CK1 family 
influences many signalling pathways to modulate these diverse biological processes. 
Dysfunction of CK1 activity is thus associated with many diseases, including cancer. For 
this reason, the CK1 family has gained some interest from the pharmaceutical industry, 
leading to the development of small molecules that modulate its activity. To date, a few 
small molecules that inhibit CK1 kinase activity have been developed, but all of them 
lack selectivity (see 1.6.5.4).  
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Figure 1- 11 The human CK1 family 
A. The red circles highlight the position of the casein kinases in the human kinome 
tree (modified from https://www.cellsignal.com/contents/science-protein-
kinases/protein-kinases-human-protein-kinases-overview/kinases-human-
protein). A zoom in the dotted box show the CK1 isoforms.  
B. Phylogenetic relation of the human CK1 family members. The phylogenetic tree 
was constructed with Jalview based on sequence alignment of their kinase domain 
that was performed with ClustalO. 
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Figure 1- 12 The human CK1 isoforms have a conserved N-terminal kinase domain 
A. Multiple sequence alignment of the main human CK1 isoforms was performed 
with ClustalO in Jalview 2.10.3 and colouring indicates the % of sequence 
identity. 
 
B. Schematic overview of the human CK1 isoforms. The conserved kinase domain 
is depicted in pink. The percentage amino-acid identity within the kinase domains 
of each isoform to that of CK1α kinase domain is indicated. NLS: nuclear 
localisation signal; CLS: centrosomal localisation signal; Palm: Palmitoylation 
site. 
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1.6.3 Regulation of CK1 activity 
 Although the CK1 isoforms are ubiquitously expressed, the levels of expression 
and activity of each isoform across different cell lines and tissues differ widely (Nakajo, 
Hagiwara et al. 1987, Fu, Chakraborti et al. 2001, Davidson, Wu et al. 2005, Lohler, 
Hirner et al. 2009). The mechanisms that regulate their expression and activation are not 
fully elucidated. Extracellular signals, such as Wnt, insulin, topoisomerase inhibitors, 
irradiation and viral transformation can potentially increase CK1 activity (Knippschild, 
Gocht et al. 2005). The crystal structure of mammalian CK1δ provides some insights into 
the mechanism of its enzymatic regulation, as it was shown to form homo-dimers that 
could potential inhibit ATP binding, thereby potentially impairing its kinase activity 
(Longenecker, Roach et al. 1998). However, this hypothesis has not been validated yet. 
Currently, it is thought that substrate specificity is achieved via (i) post-translational 
modifications of CK1 isoforms, including auto-phosphorylation, (ii) interaction with 
scaffold proteins (iii) regulated subcellular localisation/compartmentalisation and (iv) 
substrate phosphorylation priming. 
 CK1δ and CK1ε have been reported to be negatively regulated via auto-
phosphorylation (Gietzen and Virshup 1999). The phosphorylated part on their 
C-terminus might act as a pseudo-substrate, which inhibits their catalytic activity. The 
presence of phosphatases is thought to keep these kinases active in cells (Rivers, Gietzen 
et al. 1998). However, the specific phosphatases that accomplish this have not been 
identified yet. It is still not clear if the other CK1 isoforms are regulated through 
autophosphorylation. Notably, CK1α and CK1γ have a short C-terminal domain, which 
makes it unlikely for autophosphorylation to be a regulatory mechanism for their activity, 
even though autophosphorylation sites have also been also found on these isoforms in in 
vitro studies (Budini, Jacob et al. 2009). 
 Apart from autophosphorylation, phosphorylation by other cellular kinases can 
also negatively regulate the kinase activity of CK1 isoforms. In particular, CK1δ has been 
found to be phosphorylated by Protein Kinase A (PKA) (Giamas, Hirner et al. 2007), 
checkpoint kinase 1 (Chk1) (Bischof, Randoll et al. 2013), cyclin-dependent kinase 2 
(CDK2/E) and cyclin-dependent kinase 5 (CDK5/p35) (Ianes, Xu et al. 2016) which in 
turn reduces its activity. Interestingly, over-expression of a CK1δ phospho-mutant 
(S370A) enhances the formation of an ectopic secondary body axis in Xenopus laevis 
embryos (Giamas, Hirner et al. 2007). 
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 Interaction between CK1 and scaffold proteins can potentially regulate the kinase 
activity, as scaffold proteins can dictate substrate proximity to the particular CK1 isoform. 
In the Wnt signalling pathway for example, CK1α binds Axin, which serves as a scaffold 
that brings CK1 to close proximity with its substrates β-catenin and APC (Ha, Tonozuka 
et al. 2004). Furthermore, CK1 isoforms form high molecular weight complexes by 
binding to proteins which contain an F-x-x-x-F motif.  This CK1 binding motif was first 
identified in NFAT1 and PER1/2 proteins, in which mutation of the two phenylalanines 
abolishes their interaction with CK1 (Okamura, Garcia-Rodriguez et al. 2004). 
Specifically, the F-x-x-x-F motif on NFAT1 serves as a docking site for CK1 which then 
regulates its own phosphorylation. The molecular basis through which CK1 recognises 
the F-x-x-x-F motif has not been established yet. It is still unclear whether the F-x-x-x-F 
motif is necessary and sufficient for any protein substrate to interact with CK1. Thus, 
although reversible phosphorylation implies transient interaction between the kinase and 
its substrate, CK1 isoforms might form tight interactions with some of their targets -  a 
feature that could potentially enhance the rate of their phosphorylation. 
 An alternative mechanism for CK1 regulation was suggested by Cruciat et al. 
(2013), in which the ATP-dependent DEAD-box RNA helicases 3 (DDX3) acts as an 
allosteric activator of CK1ε by enhancing its catalytic velocity (Cruciat, Dolde et al. 
2013). In this study, Wnt stimulation promoted the interaction between DDX3 and CK1ε, 
which in turn stimulated its kinase activity towards its substrates, such as Dvl2. The 
enzymatic activity of DDX3 is not required for CK1 association and activation and the 
authors suggest that this multifunctional protein is a new regulatory subunit of CK1 
isoforms (Cruciat, Dolde et al. 2013). However, it is still unclear how DDX3 is recruited 
to CK1 upon Wnt stimulation and how the binding to CK1 enhances the kinase activity. 
Another example of allosteric activation of CK1 has been shown with the small molecule 
Pyrvinium pamoate, a drug used in the clinic to inhibit Wnt signalling (Thorne, Hanson 
et al. 2010) and a more recently identified compound SSTC3 (Li, Orton et al. 2017) (see 
1.6.6). However, the mechanisms of their actions are yet to be determined. 
 Furthermore, the subcellular localisation of CK1 determines the access to specific 
substrates and therefore defines the CK1 function and regulation (Knippschild, Kruger et 
al. 2014). This is probably the most critical mode of regulation, as it limits the substrate 
availability and accessibility. Considering the broad range of potential substrates that 
CK1 targets in the cell, such spatio-temporal mechanisms may help explain how substrate 
selectivity is achieved. One example of spatio-temporal regulation of CK1 activity is the 
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association of CK1α with distinct cellular structures and compartments at different stages 
of the cell cycle (Behrend, Stoter et al. 2000).  
 Finally, CK1 activity towards some of its targets might depend on the 
phosphorylation status of its substrates (Flotow, Graves et al. 1990). For instance, it has 
been shown that efficient phosphorylation of α-synuclein at S129 by CK1 requires 
priming phosphorylation at Y125 by an unknown kinase in mammalian cells (Kosten, 
Binolfi et al. 2014). Another example of a priming phosphorylated residue for CK1-
mediated phosphorylation was shown upon induction of the unfolded protein response 
(UPR) due to viral infection (Bhattacharya, HuangFu et al. 2010). UPR was shown to 
promote phosphorylation of the interferon α receptor (IFNAR1) at S532 by an unknown 
kinase, which acts as a priming event for subsequent phosphorylation of IFNAR1 by CK1 
for the recruitment of β-TrCP ligase that degrades the receptor (Bhattacharya, HuangFu 
et al. 2010). 
1.6.4 CK1 isoforms are both positive and negative regulators of Wnt 
signalling 
 CK1 isoforms mediate the phosphorylation of several components of canonical 
Wnt signalling, resulting in either inhibition or activation of the pathway (Cruciat 2014). 
The first implication of CK1 in Wnt signalling was in 1999 when Peters et al., showed 
that overexpression of CK1α, δ and ε causes axis duplication in Xenopus embryos (Peters, 
McKay et al. 1999). It was thus believed that CK1 has a positive role in Wnt signalling 
activation. The same year, it was shown that overexpression of CK1ε in human cells leads 
to β-catenin stabilisation and Wnt-target genes activation and it was suggested that CK1ε 
is in the same complex with Axin, GSK3β and DVL (Sakanaka, Leong et al. 1999). Later 
it was confirmed that CK1δ and CK1ε interact with DVL and phosphorylate multiple 
components of the destruction complex including, Axin and β-catenin (Ikeda, Kishida et 
al. 1998, Kishida, Hino et al. 2001, Gao, Seeling et al. 2002). Subsequently, it was 
suggested that in response to Wnt signals, CK1ε (or CK1δ) is activated, binds and 
phosphorylates DVL at S139 and S142 which in turn promote the dissociation of the 
phosphatase PP2A from the destruction complex, resulting in stabilisation of β-catenin 
and enhancement of Wnt signalling (Cheng, Syder et al. 1992, Gao, Seeling et al. 2002, 
Cong, Schweizer et al. 2004, Klimowski, Garcia et al. 2006). Furthermore, it has been 
suggested that CK1ε-mediated phosphorylation of DVL increases the affinity of DVL for 
the Wnt receptor complex and enhances the recruitment of Axin, which is required for 
the Wnt signallosome assembly (Del Valle-Perez, Arques et al. 2011). 
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Apart from DVL, Wnt signals induce the phosphorylation of LRP6 by CK1γ at 
T1479 (Davidson, Wu et al. 2005). As mentioned earlier this phosphorylation step is 
required for the formation of the Wnt signalosome in human cells. Additionally, it is 
thought that CK1-mediated LRP6 phosphorylation is required for subsequent 
phosphorylation of LRP6 by GSK3 at its five PPPSPxS motifs that lie downstream of the 
T1479 residue (Zeng, Tamai et al. 2005, MacDonald, Yokota et al. 2008). It was shown 
that at least four of these motifs must be phosphorylated for β-catenin stabilisation to 
occur (MacDonald, Yokota et al. 2008). Because these phosphorylation events are strictly 
Wnt-dependent, T1479 phosphorylation by CK1γ is widely used to monitor acute Wnt 
signalling with a T1479 phosho-specific antibody (Bilic, Huang et al. 2007). CK1γ might 
also phosphorylate the second Ser of the PPPSPxS motif although CK1α, δ and ε have 
also been implicated in this Wnt-induced phosphorylation of LRP6, contributing to the 
recruitment of the Axin complex to the cell membrane and thus suggesting a redundancy 
and overlapping role of CK1 isoforms in early Wnt responses (Zeng, Tamai et al. 2005).  
Biochemical studies have revealed that CK1ε binds and phosphorylates TCF3 in 
the cytoplasm of Xenopus eggs and mammalian cells (Lee, Salic et al. 2001). It was shown 
that TCF3 inhibits β-catenin phosphorylation by GSK3, potentially by sequestering 
β-catenin away from the Axin:GSK3 complex. TCF3 phosphorylation by CK1ε was 
demonstrated to be both necessary and sufficient for its interaction with and subsequent 
stabilisation of β-catenin. Inhibition of CK1ε acts negatively on TCF3-β-catenin binding, 
increasing the β-catenin degradation levels (Lee, Salic et al. 2001). 
On the other hand, CK1 isoforms can also be negative regulators of the Wnt 
signalling. The best characterised mode of their action is at the level of the β-catenin 
destruction complex (Liu, Li et al. 2002). Although the phosphorylation of β-catenin at 
Ser45 is attributed to CK1, it is not clear which isoform (α, δ or ε) is mainly responsible 
for this event or if the CK1 isoforms can act redundantly.  All three isoforms have been 
identified as potential components of the destruction complex and they all phosphorylate 
β-catenin in vitro (Amit, Hatzubai et al. 2002). Other than β-catenin, CK1δ and ε have 
been reported to phosphorylate Axin and APC, which enhance β-catenin degradation in 
human cells (Gao, Seeling et al. 2002). In the nucleus CK1ε interacts with, and 
phosphorylates LEF, thereby preventing its association with β-catenin and the 
transcription of its target genes (Hammerlein, Weiske et al. 2005). 
Lastly, CK1 isoforms act in feedback loops to either re-activate or cease Wnt 
signalling. For example, phosphorylation of DVL by CK1ε promotes DVL binding to the 
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E3-ubiquitin ligase HUWE1, which interacts with the DIX domain that is responsible for 
DVL polymerisation. Inhibition of DVL polymerisation thus blocks the assembly of Wnt 
signalosome complex and ultimately inhibits Wnt signalling (de Groot, Ganji et al. 2014). 
Furthermore, Wnt stimulation induces the phosphorylation of more CK1 substrates on the 
cell membrane, including E-cadherin and its binding partner p120-catenin. In the 
adherens junctions, E-cadherin is stabilised by p120 but it also mediates the interaction 
between p120 and LRP6. Phosphorylation of E-cadherin and p120 upon Wnt stimulation, 
disrupts the interaction of E-cadherin with p120 and LRP6. Consequently, p120-catenin-
bound CK1ε is released from the signalling complex, which in turn prevents further DVL 
phosphorylation by CK1ε, terminating the initial signalling (Del Valle-Perez, Arques et 
al. 2011). In conclusion, local modulation of CK1 isoforms can have different effects on 
the outcome of Wnt signalling. 
1.6.5 Roles of CK1 beyond Wnt signalling 
1.6.5.1 CK1 and circadian rhythm 
 One of the most ancient mechanisms of timekeeping, from plants to humans, is 
modulated by the activity of CK1 (van Ooijen, Hindle et al. 2013). CK1 was the first 
enzyme that was found to regulate circadian rhythm in Drosophila, through 
phosphorylation of the transcription factor PERIOD (PER) (Kloss, Price et al. 1998, Price 
and Kalderon 2002). In the mammalian brain and in the periphery, oscillatory 
transcriptional feedback includes the positive regulator complex CLOCK:BMAL, which 
activates the transcription of PER1 and PER2, which in turn form heterodimers with CRY 
and negatively regulate CLOCK:BMAL, thereby completing one circadian circle 
(Shanware, Hutchinson et al. 2011). CK1δ or CK1ε-dependent phosphorylation of PER1 
and PER2 induces their degradation by the β-TrCP-containing E3 ligases and the 
proteasome, ultimately leading to initiation of a new cycle (Eide, Woolf et al. 2005). 
Recent studies have shown that the activity of CK1δ against PER degradation is regulated 
via phosphorylation by different kinases including cyclin-dependent kinases (Eng, Edison 
et al. 2017). Mutations of the phosphorylation sites on CK1δ and CK1ε, leading to 
increased kinase activity, have a protective role in the development of familial advanced 
phase sleep syndrome (FASPS) (Shanware, Hutchinson et al. 2011). Moreover, FASPS 
patients carry a missense mutation on the binding site of PER to CK1ε which results in 
PER hypo-phosphorylation and thus a negative regulation on the patients’ circadian 
rhythm. Corroborating evidence from CK1ε null mutant mice support the role of CK1 in 
circadian rhythm regulation as the free-running periods of the locomotor activity rhythm 
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of the CK1ε-/- mice was shown to be significantly longer than wild type controls (Meng, 
Logunova et al. 2008, Etchegaray, Machida et al. 2009). Similarly, CK1δ+/- mice exhibit 
longer circadian period compared to wild type controls, while CK1δ-/- were embryonic 
lethal (Etchegaray, Machida et al. 2009). Collectively there is strong evidence supporting 
that the critical roles CK1δ and CK1ε play in maintaining the daily circadian cycle length. 
1.6.5.2 CK1 in cell cycle progression 
 The eukaryotic cell cycle is divided into two main phases: interphase, which is the 
stage that the cell develops between two divisions, and M phase, in which the cell divides 
to create two genetically identical daughter cells. Interphase is divided into the G1 phase, 
in which the cell grows and prepares for DNA replication, the S phase, where the DNA 
is replicated and the G2 phase, in which the cell prepares for division. The M phase is 
divided into mitosis, when DNA is condensed and separated into two nuclei, and 
cytokinesis, in which the cellular context is segregated and the cell divides into two 
(Cooper 2000). Checkpoint mechanisms, mediated by for example, cyclin-dependent 
kinases, regulate the completion of each phase and the progression to another. The yeast 
homologue of CK1 was the first to be found to have a role in the regulation of cell cycle 
progression and cell division (Hoekstra, Liskay et al. 1991). In mammals, the precise roles 
of CK1 isoforms in the cell cycle are not very well understood. CK1α, δ and ε localise to 
the centrosome and mitotic spindle, where they might function to control mitotic 
progression (Sillibourne, Milne et al. 2002). Furthermore, CK1δ displays high affinity for 
microtubules and the spindle apparatus from mitotic cell extracts after DNA damage, 
suggesting a regulatory role of CK1δ in mitosis (Behrend, Stoter et al. 2000). Inhibition 
of CK1δ/ε activity with the IC261 inhibitor (see 1.6.5.4) has been associated with mitotic 
defects, caused by dysregulation of checkpoint control, which inhibits cytokinesis 
resulting in mitotic arrest (Behrend, Milne et al. 2000). Antibodies against CK1α block 
cell cycle progression during M phase in mouse oocytes, suggesting a role of CK1α in 
chromosomal segregation and mitotic spindle formation (Brockman, Gross et al. 1992, 
Gross and Anderson 1998). 
1.6.5.2 CK1 in apoptosis 
 Programmed cell death is an evolutionarily conserved pathway which is critical 
during embryonic development and in the maintenance of adult tissue homeostasis. In 
short, various death receptors, such as FAS, TNFR1 and DR4/5 transduce the extrinsic 
apoptotic signal for the formation of the intracellular Death-Inducing-Signalling-
Complex (DISC), consisting of proteins with death domains (DD) and death effector 
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domains (DED). These proteins then recruit caspases for propagation of the apoptotic 
signal. A considerable amount of literature has been published on the role of CK1 in 
apoptosis through different molecular pathways. Most of these studies are based on the 
use of CK1 inhibitors or RNAi approaches. CK1 isoforms can phosphorylate the tumour 
necrosis factor receptor p75 and negatively regulate p75-mediated apoptosis (Beyaert, 
Vanhaesebroeck et al. 1995). Inhibition of CK1 isoforms or knock-down of CK1α 
sensitises tumour cells to TRAIL-induced apoptosis mainly by recruiting FADD and 
procaspase-8 to the receptor complex (Izeradjene, Douglas et al. 2004). Furthermore, 
CK1 can phosphorylate the pro-apoptotic protein Bid and inhibition of its activity is 
associated with Fas-mediated apoptosis, whereas hyperactive CK1 delays apoptosis 
(Desagher, Osen-Sand et al. 2001). Recent research has demonstrated that the inhibition 
of CK1δ and CK1ε with the IC261 inhibitor (see 1.6.5.4) leads to decreased expression 
of anti-apoptotic proteins and increased apoptotic sensitivity of pancreatic tumour cells 
(Brockschmidt, Hirner et al. 2008). Finally, CK1α has been proposed as a negative 
regulator of apoptosis induced by agonists of retinoid X receptors (RXRs) (Zhao, Qin et 
al. 2004). Agonists of RXRs are potent inducers of growth arrest and apoptosis in many 
cancer cells (Altucci and Gronemeyer 2001). CK1α was shown to negatively regulate 
RXR agonist-mediated apoptosis through interaction with and phosphorylation of RXR 
(Zhao, Qin et al. 2004). 
1.6.5.3 CK1 in Hedgehog signalling  
 Members of the Hedgehog (Hh) family of signalling proteins mediate several 
processes during embryonic development, including organogenesis, chondrogenesis and 
polarity in the central nervous system (CNS) and in adult tissue homeostasis (Ingham and 
McMahon 2001). Uncontrolled activation of Hh pathway has been associated with 
tumorigenesis (Barakat, Humke et al. 2010). CK1 isoforms were found to play a dual role 
in both receptor activation (Chen, Sasai et al. 2011) and inhibition of the Hh-target gene 
transcription (Shi, Li et al. 2014). In mammals, activation of Hh signalling results in the 
transcription of Hh-target genes through the activation of the glioma-associated oncogene 
homolog (Gli) transcription factors. In the absence of Hh, PKA phosphorylates Gli, 
priming it for subsequent phosphorylation by GSK3 and CK1 (Price and Kalderon 2002, 
Shi, Li et al. 2014). Phosphorylated Gli is then ubiquitinated by the E3 ligase β-TrCP and 
targeted for proteolytic processing, which creates the truncated transcriptional repressor 
(GliR), which inhibits the activation of Hh-target genes. Activation of Hh signalling 
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induces the phosphorylation of the Hh receptor Smoothened (Smo) by CK1and G-protein 
coupled receptor kinase 2 (GRK2), leading to the activation of Hh-target genes. 
1.6.5.4 CK1 in neurodegeneration 
 CK1 isoforms have been suggested to regulate synaptic transmission in the brain 
(Chergui, Svenningsson et al. 2005). In mice, it was shown that all the CK1 isoforms are 
distributed in different regions of the brain and inhibiting their kinase activity results in 
increased neuronal excitation in response to the neurotransmitter glutamate. Therefore, it 
was proposed that CK1 isoforms might be negative regulators of the glutamatergic 
synaptic transmission in nerve cells (Chergui, Svenningsson et al. 2005). 
Furthermore, there has been a positive correlation between the mRNA and protein 
levels of CK1δ and neurofibrillary lesions in the brains of patients with neurodegenerative 
diseases, such as Alzheimer’s disease (AD) (Kuret, Johnson et al. 1997, Schwab, 
DeMaggio et al. 2000, Yasojima, Kuret et al. 2000). A hallmark of AD is hyper-
phosphorylation of the microtubule-associated protein tau. Tau hyper-phosphorylation is 
accompanied by tau aggregation into filaments, which correlate with neuronal cell loss 
and cognitive decline (Bramblett, Goedert et al. 1993). It was found that CK1δ binds and 
phosphorylates Tau, which then dissociates from microtubules resulting in microtubule 
destabilisation and neuronal death (Li, Yin et al. 2004).  
Finally, CK1δ was shown to regulate dopamine neurotransmission in vivo (Zhou, 
Rebholz et al. 2010). Genetically modified mice that overexpress CK1δ specifically in 
the forebrain, exhibited decreased levels of dopamine receptors, lower anxiety-like 
behaviours and hyperlocomotion compared to wild type mice (Zhou, Rebholz et al. 2010). 
Although the exact mechanisms of CK1δ function are not known, the CK1δ 
overexpression mouse model showed characteristics similar to the behaviour of attention-
deficit/hyperactivity disorder (ADHD) patients suggesting that CK1δ could be involved 
in ADHD progression in humans. 
1.6.5.5 CK1 and cancer 
 In view of all that has been mentioned so far, it is evident that CK1 can impact 
tumorigenesis and cancer. In addition to its dual role in Wnt and in Hh signalling and its 
inhibitory role in apoptosis, CK1 isoforms are involved in p53 phosphorylation, thereby 
mediating tumorigenesis via different signal transduction pathways. p53 is a short-lived 
transcription factor that is stabilised and activated upon stress, such as DNA damage, 
causing cell cycle arrest for DNA repair or the initiation of apoptosis (Horn and Vousden 
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2007). The ubiquitin ligase murine double minute clone 2 (MDM2 or HDM2) mediates 
p53 ubiquitylation and degradation in normal tissue, retaining the p53 protein in low 
physiological levels (Horn and Vousden 2007). Huart et al. (2009) found that CK1α 
phosphorylates p53 in cells infected with viral DNA and this blocks the interaction 
between p53 and MDM2, leading to p53 stabilisation (Huart, MacLaine et al. 2009). 
Another binding partner of p53, MDMX is also a CK1α substrate and inhibition of CKα 
activity, leads to decreased MDMX phosphorylation and activation of p53 (Chen, Li et 
al. 2005). Under normal conditions, CK1δ phosphorylates MDM2, abrogating its 
interaction with p53 and thus stabilising and activating p53 (Winter, Milne et al. 2004).  
Hence, under different conditions, CK1α and δ can positively or negatively regulate p53 
activity either by direct phosphorylation or by phosphorylating its binding partners 
MDM2 and MDMX.  
An overview of the RNA levels of CK1 isoforms in different tumours, based on 
different databases, was performed by Schittek and Sinnberg (2014) (Schittek and 
Sinnberg 2014). This shows that the RNA levels of CK1δ and CK1ε are mainly up-
regulated in various tumour types whereas CK1γ is downregulated. CK1α RNA is more 
variable as it is up-regulated in brain and prostate tumours, in lymphomas and in 
leukemia, but it is down-regulated in melanomas and in bladder and lung cancer. 
However, confirmation of these data at the protein level, and determination of kinase 
activity levels are required for defining any biological significance that explains the 
differences among the various tumour types. Nevertheless, these differences potentially 
highlight the context-specific nature of CK1 isoform activity. Indeed, recent studies 
showed that in RAS-mutant cancer cells, CK1α levels are increased and that CK1α targets 
the tumour suppressors FOXO3A and FOXO4, priming them for proteasomal 
degradation in the nucleus (Cheong, Zhang et al. 2015, Zhang, Virshup et al. 2017). 
Conversely, pharmacological or RNAi-mediated inhibition of CK1α activity, stabilises 
FOXO4 and induces apoptosis (Zhang, Virshup et al. 2017). 
Furthermore, it has been suggested that CK1 isoforms have a negative role in FGF 
signalling because they can phosphorylate SPROUTY2, allowing it to interact with GRB2 
and inhibit downstream signalling (Yim, Ghosh et al. 2015). In gastric cancer cells with 
high FGF expression, CK1ε expression is down-regulated, suggesting that CK1ε is an 
inhibitor of the FGF signalling pathway through activation of the negative regulator 
SPROUTY2 (Yim, Ghosh et al. 2015). 
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Figure 1- 13 The major biological functions of CK1 
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1.6.6 Pharmacological targeting of CK1 isoforms 
 Given the many roles of CK1 in human disease and tumorigenesis, there has been 
a lot of interest in the last few decades in developing selective small molecules that inhibit 
CK1 kinase activity (Table 1-2). However, the development of inhibitors capable of 
selectively targeting each CK1 isoform remains challenging. The first characterised CK1 
inhibitor was the ATP-competitive quinoline derivative CK1-7 (N-(2-amino-ethyl)-5-
chloroisoquinoline-8-sulfonamide), which does not show any specificity for CK1 
isoforms (Chijiwa, Hagiwara et al. 1989). The next CK1 inhibitor, IC261, was developed 
in 2000 and was derived from iodolinone (Mashhoon, DeMaggio et al. 2000). IC261 is 
also an ATP-competitive inhibitor and it is the first compound that showed selectivity 
towards CK1δ and ε. IC261 also inhibits the polymerization of microtubules and 
enhances apoptosis in a CK1-independent manner (Cheong and Virshup 2011, Stoter, 
Kruger et al. 2014). More recently, it was demonstrated that the same IC261 concentration 
used for blocking 50% of CK1δ/ε activity also inhibits sodium channels (Fohr, 
Knippschild et al. 2017). The first ATP-competitive inhibitor that showed improved 
potency and selectivity for the δ isoform was the imidazole derivative, D4476 (4-[4-(2,3-
dihydro-benzo[1,4]dioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl]benzamide) (Rena, 
Bain et al. 2004). However, low doses of D4476 also inhibit the TGFβ receptor ALK5 
and p38 (Rena, Bain et al. 2004). More recently, D4476 was found to inhibit CK1α and 
also showed high therapeutic efficacy on acute myeloid leukemia and multiple myeloma 
cells (Jaras, Miller et al. 2014, Hu, Song et al. 2015). Several other compounds have been 
reported to inhibit CK1 isoforms but all of them lack specificity as they have many off-
target effects (Table 1-2). However, the most promising one seems to be the 
immunomodulatory drug (IMiD) Lenalidomide (Lena) which is used for the treatment of 
myelodysplastic syndrome (MDS) with deletion of chromosome 5q (del(5q)). Lena binds 
CRBN, the substrate adaptor of the CRL4CRBN E3 ubiquitin ligase, inducing 
ubiquitylation and degradation of its substrates (Kronke, Fink et al. 2015). CK1α was 
found to bind CRBN in the presence of Lena and to be subsequently subjected to 
proteasomal degradation. Interestingly, the CSNK1A1 gene, which encodes CK1α, is 
located in the deleted 5q region of the MDS patients and the levels of CK1α expression 
in the affected cells are 50% lower than the healthy controls. It was demonstrated that 
these lower expression levels of CK1α account for the increased sensitivity of these 
cancer cells to Lena compared to healthy controls (Kronke, Fink et al. 2015). 
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 Novel approaches for targeting kinases nowadays also involve activators instead 
of inhibitors, depending on the disease context. The first CK1 activator described in the 
literature is the FDA-approved anthelmintic drug Pyrvinium Pamoate (PyrPam) (Thorne, 
Hanson et al. 2010). It was shown that PyrPam binds to all CK1 isoforms but selectively 
activates CK1α. It was suggested that PyrPam alters CK1 conformation, which then 
impacts the kinase activity leading to inhibition of Wnt signalling through enhanced β-
catenin phosphorylation. However, a subsequent study by Venerando et al. (2013) 
showed a role for PyrPam in downregulation of the Akt pathway, which subsequently 
inhibits the Wnt pathway independent of CK1α (Venerando, Girardi et al. 2013). 
Nevertheless, these results do not rule out a potential role of CK1α misregulation in the 
Akt pathway. More recently, the small molecule SSTC3 was identified as a CK1α 
activating Wnt inhibitor (Li, Orton et al. 2017). SSTC3 binds to CK1α and enhances its 
kinase activity. It blocks Wnt-induced axis duplication phenotypes in Xenopus embryos 
and displays stronger efficacy in cells with low levels of CK1α expression, such as in 
colorectal tumours (Li, Orton et al. 2017). (Bain, Plater et al. 2007, Bettayeb, Oumata et 
al. 2008, Cozza, Gianoncelli et al. 2008, Oumata, Bettayeb et al. 2008, Walton, Fisher et 
al. 2009, Bischof, Leban et al. 2012, Bibian, Rahaim et al. 2013, Delehouze, Godl et al. 
2014, Richter, Bischof et al. 2014, Halekotte, Witt et al. 2017) 
 
Table 1- 2 Pharmacological molecules targeting CK1  
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Aims of the thesis 
 
 Previously, PAWS1 had been identified as an interactor of SMAD1 and shown to 
impact the non-canonical BMP pathway. PAWS1 also regulated transcription of many 
genes independent of BMP signalling, suggesting roles beyond BMP signalling. In 
collaboration with Jim Smith (The Francis Crick Institute, London) it was shown that 
ectopic expression of PAWS1 mRNA in Xenopus embryos resulted in complete axis 
duplication (two-head phenotype) at the tadpole stage, while PAWS1 depletion led to 
embryonic defects and lethality. In the developing Xenopus embryo, opposing gradients 
of BMP and Wnt activities help pattern the dorso-ventral axis, with the highest levels of 
BMP or Wnt signalling promoting formation of the most ventral tissues and most dorsal 
tissues, respectively. Therefore, either inhibiting BMP or activating Wnt signalling 
forcefully in Xenopus embryos could lead to such two-head phenotypes. With these 
developments in place, the main aims of this thesis were to: 
- Elucidate the signalling pathways (either BMP or Wnt; or both) that PAWS1 
impacts to mediate axis duplication during Xenopus embryogenesis.  
This aim was tackled by employing a collaborative approach, in which Xenopus 
embryogenesis assays were performed by Dr. Kevin Dingwell (Jim Smith lab at the 
Francis Crick Institute) and human cell-line based assays were performed in Dundee. 
Cutting-edge technologies, including the use of CRISPR/Cas9 genome editing, were 
employed to assess the impact of PAWS1 on BMP and Wnt signalling. 
- Establish the molecular mechanisms by which PAWS1 regulates the Wnt 
signalling pathway.  
As soon as it was evident that PAWS1 activated Wnt signalling in Xenopus embryos and 
human cell lines, it became important to establish the molecular mechanisms by which it 
did so. This was addressed by employing a proteomic approach to identify key PAWS1 
interactors that could explain the activation of Wnt signalling, using PAWS1-GFP 
knockin U2OS cells generated with CRISPR/Cas9 – a cell line which allowed robust 
enrichment of the endogenous PAWS1 interactome following subjection of cell extracts 
to immunoprecipitations with GFP beads. Validation of key targets were performed by 
biochemical and cell-based assays and the information gleaned was exploited 
collaboratively to assess the mechanisms in Xenopus embryo assays. 
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- Explore the post-translational regulation of PAWS1 function by novel interacting 
protein kinases.  
Regulation of PAWS1 by post-translational modifications is poorly understood. From 
endogenous PAWS1 proteomics data, novel interactors, in particular protein kinases, 
were identified. These interacting proteins, particularly those with intrinsic catalytic 
activity, hinted at possible roles in PAWS1 function. These were characterised further. 
- Examine the role of pathogenic PAWS1 mutations on its function. 
Several mutations in PAWS1 have been identified that appear to cause various skin and 
hair morphological conditions, including hereditary footpad hyperkeratosis and 
trichillemal cysts. How the mutations impact PAWS1 function is not known.  
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2. Materials and methods 
 
2.1 Materials 
2.1.1 Chemicals and other reagents 
The chemicals used in this thesis are listed in table 2-1. 
Reagent Source 
4‐(2‐Hydroxyethyl)piperazine‐1‐ethanesulfonic acid  
(HEPES) 
Sigma-Aldrich 
4',6-diamidino-2-phenylindole (DAPI) Thermo Fisher Scientific 
A23187 Sigma-Aldrich 
Acetic acid Sigma-Aldrich 
Acetone Sigma-Aldrich 
Acetonitrile (HPLC grade) Rathburn Chemicals 
Acrylamide:bis-acrylamide 40% (w/v) 29:1 Flowegene Bioscience 
Adenosine 5'-triphosphate (ATP) Roche 
Agarose (electrophoresis grade) Thermo Fisher Scientific 
Ammonium bicarbonate BDH 
Ammonium hydroxide (NH4OH) Sigma-Aldrich 
Ammonium persulphate (APS) Sigma-Aldrich 
Ampicillin ForMedium 
Ataluren Selleckchem 
Autocamtide-3 derived inhibitory peptide (AC3-I) Anaspec 
Baffilomycin A1 Enzo 
BAPTA-AM Sigma-Aldrich 
Blasticidin Thermo Fisher Scientific 
BMP2 (#355-BM) R&D Systems 
BMP4 (#314-BP-010) R&D Systems 
Bortezomib LC Laboratories 
Bovine serum albumine (BSA) Sigma-Aldrich 
Bromophenol blue Sigma-Aldrich 
C18 columns Thermo Fisher Scientific 
C18 StageTip 3M Empore 
CellTiter 96® AQueous One Solution Cell 
Proliferation Assay 
Promega 
CHIR99021 Axon 
CK1tide DSTT 
Coelenterazine (CTZ) native Nanolight 
Compartment protein extraction kit (#2145) Merck 
Complete protease inhibitor cocktail tablets Roche 
Coomassie protein assay reagent (Bradford reagent) Thermo Fisher Scientific 
D4476 DSTT 
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Reagent Source 
Dimethyl sulphoxide (DMSO) Sigma-Aldrich 
Dithiobis succunimidyl propionate (DSP) Thermo Fisher Scientific 
Dithiothreitol (DTT) Sigma-Aldrich 
D-luciferin Synchem 
DNeasy Blood and Tissue (#69504) Qiagen 
Doxycycline (hydrochloride) Sigma-Aldrich 
Dulbecco's modified Eagle medium (DMEM) Thermo Fisher Scientific 
Dulbecco's phosphate buffer saline (PBS) Thermo Fisher Scientific 
EGF (#236-EG-200) R&D Systems 
Enhanced Chemiluminescence (ECL) reagent GE Healthcare 
Ethanol Sigma-Aldrich 
Ethylene glycol-bis(β-aminoethyl ether)-N,N,N’,N’-
tetraacetic acid (EGTA) 
Sigma-Aldrich 
Ethylenediaminetetraacetic acid (EDTA) ForMedium 
FGF2 (#8910F) CST 
FGF4 (#100-31) Peprotech 
FLAG-agarose Sigma-Aldrich 
Foetal bovine serum (FBS) Labtech 
Formic acid Sigma-Aldrich 
Gelatin (from porcine skin) Sigma-Aldrich 
Geneticin (G418) Thermo Fisher Scientific 
GFP-Trap agarose beads Chromotek 
Glutathione Sigma-Aldrich 
Glutathione-sepharose GE Healthcare 
Glycerol VWR 
Glycine VWR 
HA-agarose Sigma-Aldrich 
Hexadimethrine bromide (polybrene) Sigma-Aldrich 
Hydrochloric acid (HCl) VWR 
Hygromycin-B Thermo Fisher Scientific 
IGF (#8917LF) CST 
Immobilon-P Polyvinylidene fluoride (PVDF) 0.45 
µm membrane, 
Merck 
InstantBlue Commasie stain Expendeon 
Iodoacetamide Sigma-Aldrich 
Ionomycin Sigma-Aldrich 
iScript cDNA synthesis kit BioRad 
Isobaric Tandem Mass Tag™ 6plex reagent Thermo Fisher Scientific 
Isopropanol Sigma-Aldrich 
Isopropyl β-D1-thiogalactopyranoside (IPTG) Sigma-Aldrich 
Kanamycin Sigma-Aldrich 
KOD hot start polymerase kit Toyobo 
LDS sample buffer (4x) Thermo Fisher Scientific 
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Reagent Source 
L-glutamine Sigma-Aldrich 
Lipofectamine RNAiMAX Thermo Fisher Scientific 
Lithium Chloride BDH 
Lithium dodecyl sulphate (LDS) sample buffer 4x Invitrogen 
Luria Bertani broth (LB) and LB agar plates Central Technical Service team, 
University of Dundee 
Lysozyme chicken egg Thermo Fisher Scientific 
Magnesium Acetatate Sigma-Aldrich 
Magnesium cloride (MgCl2) Sigma-Aldrich 
Methanol VWR 
NE-PER nuclear and cytoplasmic extraction kit Thermo Fisher Scientific 
NiNTA raisin Qiagen 
Nonidet P-40 substitute Sigma-Aldrich 
NuPAGE Novex 4-12% Bis-Tris polyaclylamide gels Thermo Fisher Scientific 
Opti-MEM Thermo Fisher Scientific 
Orange G Sigma-Aldrich 
Paraformaldehyde 4% (v/v) Sigma-Aldrich 
Passive Lysis buffer 5x Promega 
Penicillin/streptomycin Thermo Fisher Scientific 
Plasmid Maxi, Midi and Mini kits Qiagen 
Polyethylenimine (PEI) Polysciences 
Polyoxyethylene(23) lauryl ether (Brij-35) Sigma-Aldrich 
Ponceau S Sigma-Aldrich 
Precision Plus ProteinTM All Blue Standards BioRad 
Prolong Gold mounting reagent Thermo Fisher Scientific 
Protein G-sepharose GE Healthcare 
Puromycin Sigma-Aldrich 
RNeasy kit Qiagen 
Sep-Pak SPE cartridges Waters 
Sequencing grade modified trypsin Promega 
SKF 96365 Abcam 
Skimmed milk powder Marvel 
Sodium 2-glycerophosphate Sigma-Aldrich 
Sodium Chloride (NaCl) VWR 
Sodium ethylene glycol tetra acetic acid (EGTA) Sigma-Aldrich 
Sodium fluoride Sigma-Aldrich 
Sodium orthovanadate (Na3VO4) Sigma-Aldrich 
Sodium pyrophosphate Sigma-Aldrich 
SsoFast Evagreen Supermix BioRad 
StrataClone Blunt PCR Cloning Kit Agilent 
Sucrose VWR 
SuperSignal West Pico Chemiluminescent Substrate  Thermo Fisher Scientific 
SYBR Safe Thermo Fisher Scientific 
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Reagent Source 
Tetramethylethylenediamine (TEMED) Sigma-Aldrich 
TGFB1 R&D Systems 
TiO2 beads GL Sciences 
t-octylphenoxypolyethoxyethanol (Triton) X-100 Sigma-Aldrich 
TransFectin BioRad 
Triethylammonium bicarbonate Sigma-Aldrich 
Tris (hydroxymethyl) aminomethane (Tris) BDH 
Trypsin/EDTA Thermo Fisher Scientific 
Urea Sigma-Aldrich 
Wnt3A (#5036-WN) R&D Systems 
X-gal Sigma-Aldrich 
Zeocin Thermo Fisher Scientific 
γ32P-ATP PerkinElmer 
Table 2- 1 Reagents used in this thesis 
2.1.2 Buffers and solutions 
 Commonly used buffers and solutions, as well as their composition are listed in 
table 2-2. 
Buffer/Solution Composition 
8-12% acrylamide 
resolving gels 
375 mM Tris/HCl (pH 8.6), 0.1% SDS (w/v) and 8-12% (w/v) 
acrylamide. 0.1% (w/v) ammonium persulfate (APS) and 0.1% (v/v) 
TEMED were used to polymerise the gels. 
Bacterial Cell lysis 
buffer 
50 mM Tris/HCl pH 7.5, 300 mM NaCl, 10% (v/v) glycerol, 1 mg/ml 
lysozyme, 10 μg/ml DNAase, 0.075% (v/v) β-mercaptoethanol, 1 tablet 
of Complete protease inhibitor cocktail (tablet was added just prior to 
use) 
Binding assay 
buffer 
50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.03% (v/v) Brij-35, 1 mM 
EGTA, 1 mM DTT 
Blocking solution 5% (w/v) milk powder, TBST 
BSA primary 
antibody solution 
5% (w/v) BSA, TBST, 0.02% (w/v) sodium azide 
Buffer A 50 mM Tris-HCl pH 7.5, 0.1 mM EGTA 
Cell freezing 
medium 
50% (v/v) FBS, 40% DMEM,10% DMSO 
GST-tag protein 
elution buffer 
50 mM Tris-HCl pH 7.5, 0.03% (v/v) Brij-35, 0,1 mM EGTA, 20 mM 
glutathione, pH 7.5 
GST-tag protein 
wash buffer 
50 mM Tris-HCl pH 7.5, 250 mM NaCl, 0.03% (v/v) Brij-35, 0.1 mM 
EGTA, 0.1% (v/v) β-mercaptoethanol 
His-tag protein 
binding buffer 
500 mM NaCl, 10 mM Imidazole in PBS 
His-tag protein 
dialysis buffer 
25 mM Tris-HCl pH 7.4, 150 mM NaCl 
His-tag protein 
elution buffer 
1 mM DTT, 250 mM Imidazole in PBS 
52 
 
Buffer/Solution Composition 
Hypotonic lysis 
buffer 
10 mM Tris-HCl (pH 7.4), 2 mM EDTA, 10 mM KCl, 1 tablet of 
Complete protease inhibitor cocktail 
IF blocking solution 3% (w/v) BSA, 0.1% (v/v) Triton X-100 in PBS 
IF quenching buffer 10 mM Hepes pH 7.4, DMEM 
Kinase assay buffer 50 mM Tris pH 7.5, 0.1 mM EGTA, 10 mM Magnesium Acetate (or 
MgCl2), 2 mM DTT 
LB plates 1% (w/v) tryptone peptone, 0.5% (w/v) yeast extract, 86 mM NaCl, 2% 
(w/v) bactoagar, 100 μg/ml ampicillin or 25 μg/ml kanamycin after 
autoclaving for 20 min 
Luciferase assay 
buffer (2x) 
50 mM Tris/Phosphate, pH 7.8, 16 mM MgCl2, 1 mM ATP, 30% (v/v) 
Glycerol, 1% (w/v) BSA, 0.25 mM D-Luciferin, 8 μM Sodium 
Pyrophosphate 
Luria Bertani broth  
(LB) 
1% (w/v) tryptone peptone, 0.5% (w/v) yeast extract, 86mM NaCl, 100 
μg/ml ampicillin or 25 μg/ml kanamycin after autoclaving for 20 min 
Lysis buffer with 
DSP 
40 mM HEPES pH 7.4, 120 mM NaCl, 1 mM EDTA pH 8.0, 10 mM 
sodium β-glycerophosphate, 50 mM sodium fluoride, 1 mM sodium 
orthovanadate, 5 mM sodium pyrophosphate, 1% (v/v) Triton X-100, 1 
tablet of complete protease inhibitors per 25 ml lysis buffer, 2.5 mg/ml 
DSP (in DMSO) (DSP was added just prior to use) 
Mammalian cell 
lysis buffer 
50 mM Tris-HCl pH 7.5, 1 mM EGTA pH 8, 1 mM EDTA pH 8, 1 mM 
activated Na3VO4, 10 mM Na β-glycerophosphate, 50 mM NaF, 5 mM 
Na Pyrophosphate, 270 mM, Sucrose, 1% (v/v) Nonidet P-40 and a 
protease inhibitor cocktail (1 tablet per 25 ml buffer) 
MOPS running 
buffer (Purchased 
from Formedium) 
50 mM MOPS, 50 mM Tris base, 0.1% (w/v) SDS, 1 mM EDTA, pH 
7.7 
PEI 1 mg/ml PEI in 25 mM HEPES, pH 7.5 
Phosphate-buffered 
saline (PBS) 
137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.47 mM KH2PO4, pH 
7.4 
Renilla assay buffer 
(3x) 
0.06 mM PTC124 (in DMSO), 0.01 mM CTZ, 45 mM Na2EDTA, 30 
mM Na-pyrophosphate, 1.425 M NaCl 
Sample buffer (5x) 312.5 mM Tris-HCl, pH 6.8, 50% (v/v) glycerol, 10% (w/v) SDS, 
0.10% (w/v) bromophenol blue, 5% (v/v) β-mercaptoethanol 
SDS-PAGE buffer 25 mM Tris/HCl pH 8.3, 192 mM glycine, 0.1% (v/v) SDS 
Stacking gel 125 mM Tris/HCl (pH 6.8), 0.1% SDS (w/v) and 4% acrylamide (w/v). 
0.075% (w/v) ammonium persulfate (APS) and 0.1% (v/v) TEMED 
were used to polymerise the gels 
TAE buffer 40 mM Tris-Acetate pH 8, 1mM EDTA 
TBSΤ buffer 50 mM Tris-HCl, pH 7.5, 0.15 M NaCl and 0.1 % Tween 20 
Transfer Buffer 25 mM Tris/HCl pH 8.3, 192 mM glycine, 20% (v/v) methanol 
Tris-buffered saline 
(TBS) 
20 mM Tris/HCl pH 7.5, 150 mM NaCl 
Urea lysis buffer 8 M Urea, 2% (w/v) SDS, 250mM NaCl, 50mM HEPES pH 8.5, 
PhosSTOP (Roche), 2 mM Sodium orthovanadate 10 mM Na B 
glycerophosphate, 5 mM Na pyrophosphate, 50 mM NaF, 1 tablet of 
Complete protease inhibitor cocktail (tablet was added just prior to use) 
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Table 2- 2 Buffers and solutions used in this thesis 
2.1.3 Antibodies 
 All the non-commercial antibodies were raised in sheep or rabbit (Table 2-3) by 
the Division of Signal Transduction and Therapy (DSTT), School of Life Sciences, 
University of Dundee. The antigens used to generate the antibodies are also indicated 
(Table 2-3). The antibodies were affinity purified on CH Sepharose covalently coupled 
to the antigens used to raise the antibodies. For the purification of phospho-specific 
antibodies, the antibodies purified on the column containing the phospho-peptide 
immunogen were passed through a peptide column made with the non-phosphorylated 
form of the peptide immunogen. The antibodies that did not bind to the non-
phosphorylated peptide column were collected and used. Antibodies were eluted with 50 
mM glycine pH 2.5 and were then dialyzed for 16 hours in PBS. 
 Species-specific HRP-coupled secondary antibodies were obtained from either 
Thermo Fisher Scientific or CST. The antibodies used for immunofluorescence are listed 
in Table 2-4. Alexa Fluor® 488 donkey anti-sheep IgG (A11015) and Alexa Fluor® 594 
goat anti-rabbit IgG (A11012) were used at 1:1000 dilution for immunofluorescence 
studies and purchased from Thermo Fisher Scientific.  
Antibody Company Cat Number Ab 
dilution 
Ab 
conditions 
active β-catenin Millipore #05-665 1:500 milk 
AXIN1 CST #2074 1:1000 BSA 
AXIN2 CST #76G6 1:1000 BSA 
CaMK2D Abcam #ab181052 1:1000 BSA 
CK1α Bethyl Laboratories #Α301-991A-M 1:1000 BSA 
CK1δ CST #12417 1:1000 milk 
CK1ε CST #12448 1:1000 BSA 
EGFR CST #4267 1:1000 BSA 
FLAG-HRP Sigma #8592 1:5000 milk 
GAPDH CST #2118 1:5000 BSA 
GSK3-α CST #9315S 1:1000 BSA 
GSK3-α/β Santa Cruz #sc-7291 1:1000 BSA 
HA-HRP Roche 2013819001 1:5000 milk 
Lamin A/C CST #2032 1:1000 BSA 
LC3 MBL #PM036 1:1000 BSA 
LRP6 CST #C47E12 1:1000 BSA 
Myc tag Sigma 9E10 #M5546 1:1000 BSA 
PAWS1 
 (residues 715-815 
from human PAWS1) 
 
DSTT 
 
DU 33022 
 
1:2000 
 
milk 
phospho-CaMK2 T286 Novusbiologicals NBP1-64741 1:1000 BSA 
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Antibody Company Cat Number Ab 
dilution 
Ab 
conditions 
phospho-LRP6 S1490 CST #2568 1:1000 BSA 
phospho-PAWS1 S365 
(CYALYKAKS*VDEIAKI) 
DSTT RA0400 (3rd bleed) 1:500 milk 
phospho-SMAD1 
S463/S465 
CST #9516 1:1000 BSA 
phospho-SMAD2 
S465/S467 
CST #3108 1:1000 BSA 
phospho-SMAD3 
S423/S425 
CST #9520 1:1000 BSA 
phospho-β-catenin 
S33/37/T42 
CST #9561 1:1000 BSA 
phospho-β-catenin S45 CST #9564 1:1000 BSA 
SLC5A10 Abcam #ab167156 1:1000 BSA 
SMAD1  
(residues 144-268 from 
human SMAD1) 
 
DSTT 
 
DU 19291 
 
1:1000 
 
milk 
SMAD2/3 CST #3102 1:1000 BSA 
Ubiquitin Dako Z0458 1:1000 milk 
Vimentin CST #5741 1:1000 BSA 
α-tubulin Thermo Fisher Scientific #MA1-80189 1:10000 BSA 
β-catenin CST #D10A8 1:1000 BSA 
Table 2- 3 Antibodies used for Western Blotting in this thesis 
 
Antibody Company Cat Number Ab dilution 
PAWS1 Abcam ab121750 1:250 
CK1α Santa Cruz sc6477 1:100 
Phospho-SMAD1 S463/465 CST #9511 1:1000 
Table 2- 4 Antibodies used for immunofluorescence in this thesis 
 
2.1.5 Primers 
Human and Xenopus qPCR primers (Table 2-5) were designed using PerlPrimer 
software and generated by Thermo Fisher Scientific. For genomic sequence 
amplification, primers (Table 2-5) were designed with a melting temperature (Tm) of 60 
ºC.  
Target Sequence (5' - 3') 
AXIN2 
F- TACACTCCTTATTGGGCGATCA 
R- TTGGCTACTCGTAAAGTTTTGGT 
CYCLIN D1 
F- GCTGCGAAGTGGAAACCATC 
R- CCTCCTTCTGCACACATTTGAA 
CK1α 
F- GAGGCAGCTATTCCGCATTC 
R- TGGGGAGAAACAAATGCTGC 
GAPDH F- TGCACCACCAACTGCTTAGC  
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Target Sequence (5' - 3') 
R- GGCATGGACTGTGGTCATGAG 
β-ACTIN 
F- CCAACCGCGAGAAATGACC 
R- GGAGTCCATCACGATGCCAG 
ID1 
F- AGGCTGGATGCAGTTAAGGG  
R- GGTCCTTTTCACCAGCAAGCT 
SIAMOIS 
F- AACCACTTTCCACTCTCCCC 
R- GAAGTCAGTTTGGGTAGGGC 
VNT1 
F- GCATCTCCTTGGCATATTTGG 
R- TTCCCTTCAGCATGGTTCACC 
MSX1 
F- GCAGGAACATCACACAGTCC 
R- GGGTGGGCTCATCCTTCT 
TGFBI 
F- ATCACCAACAACATCCAGCA 
R- CCGTTACCTTCAAGCATCGT 
WASF3 
F- CATGCTGAAGACATATTTGGTGAG  
R- TCCTGTAGTGAGACCTCTTCC 
MMP13 
F- CAGTCTTTCTTCGGCTTAGAGG  
R- GGGTGTAATTCACAATTCTGTAGG 
LGR5 
F- TCTTCACCTCCTACCTGGACCT 
R- GGCGTAGTCTGCTATGTGGTGT 
CCNA1 
F- CCCTATGCTGGTAGATTCATCTC 
R- GTGCCTTATTTCAGCTTCCCT 
AR 
F- CCTGGCTTCCGCAACTTACAC 
R- GGACTTGTGCATGCGGTACTC 
CHORDIN 
F- AACTGCCAGGACTGGATGGT 
R- GGCAGGATTTAGAGTTGCTTC 
Table 2- 5 qPCR primers used in this thesis 
 
Target Sequence (5' - 3') 
PAWS1-
GFP 
F- TAGGGATAAAGACGGCTTCCCAGG 
R- TGTTGTAGTTGTACTCCAGCTTGT 
PAWS1 
luciferase 
reporter 
F- CAAGCTGGGAGTACAACTACAACAGC 
R- GAGAGGAAGTCTCGGATGTTCTCC 
PAWS1 
luciferase 
reporter 1 
(N-term) 
F- 
CAGCAGTGCCCGGGCAGGCGGCGCCATGGAAGATGCCAAAAACATT
AAGA 
R- 
TCTTAATGTTTTTGGCATCTTCCATGGCGCCGCCTGCCCGGGCACTG
CTG 
PAWS1 
luciferase 
reporter 2 
(C-term) 
F- 
TGACGTGGAGGAGAATCCCGGCCCAGCtTTCagcCAaGTGCAGTGTCT
GG 
R- 
CCAGACACTGCACtTGgctGAAaGCTGGGCCGGGATTCTCCTCCACGTC
A 
Table 2- 6 Genomic PCR primers used for sequencing in this thesis 
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2.1.6 siRNA oligonucleotides 
 All siRNA oligonucleotides were purchased from Dharmacon. The product 
references for siRNAs against human CK1α are J-003957-13, J-003957-14, J-003957-15 
and J003957-16, against human CaMK2D siRNAs are J-004042-08, J-004042-09, J-
004042-10, and J-004042-11, and against human CaMK2G siRNAs are J-004536-07, J-
004536-08, J-004536-09 and J-004536-10. 
2.1.7 Plasmids 
All plasmids encoding mammalian expression constructs were cloned into 
pCMV5, pBABE-puro, pCS2+ or pcDNA/Frt/TO vectors with N-terminal or C-terminal 
FLAG, haemagglutinin (HA) or green fluorescent protein (GFP) tags. pcDNA-Frt/TO 
plasmids (Thermo Fisher Scientific) were used to generate stable doxycycline-inducible 
U2OS cell lines following manufacturer’s protocol. pBABE-puro constructs were used to 
generate stable cell lines to achieve appropriate protein expression close to physiological 
levels.  
For bacterial protein expression, appropriate constructs were cloned into 
pGEX6P1 vectors with N- or C-terminal GST- or 6xHis- tags.  
All human-origin plasmids used in this thesis are listed in Table 2-7 and were 
generated by the DSTT (University of Dundee) cloning team. All DNA constructs used 
were verified by DNA sequencing, performed by DNA Sequencing & Services using 
Applied Biosystems Big-Dye Ver 3.1 chemistry on an Applied Biosystems model 3730 
automated capillary DNA sequencer. The details of all plasmids used in this thesis, which 
are publicly available to the research community worldwide, can be found on 
https://mrcppureagents.dundee.ac.uk/.  Super 8x TOPFlash (#12456) and Super 8x 
FOPFlash (#12457) were gifts from Prof Randall Moon (University of Washington, USA) 
via Addgene. pCS2 NFAT-mCherry was provided by Kevin Dingwell (Crick Institute, 
London). Renilla-luciferase was obtained from the J. Massagué lab (MSKCC). 
Xenopus Addgene constructs pCS2AxinMT (#16298) and pCS2 GSK3β 9SA 
(#16333) were a kind gift from Peter Klein, pCS2LRP6-m5 (#27283) from Xi He; pCS2 
b-catenin-GFP (#16839) and xCK1ε D128N (#16726) from Randall Moon; CK1α 
(#23355) from William Hahn and David Root; and pCS2C-cadherin (#17023) from Barry 
Gumbiner. The ORFs of Xenopus FAM83G (xPAWS1; Image Clone MGC:98851 Source 
Bioscience), CK1δ (image clone #5571715 Source Bioscience), CK1ε (Image Clone 
#6316339, Source Bioscience) were cloned into pENTR-D-TOPO (Thermo Fisher 
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Scientific) vector and then transferred into pCS2_N-MT (myc-tag), pCS2_N-HA, 
pCS2_C-HA, pCS2_cmCherryHA destination vectors using LR clonase (Thermo Fisher 
Scientific).  
 
2.1.8 Proteins 
 N-terminally GST-tagged proteins were expressed and affinity purified by the 
Protein Production Team (DSTT, University of Dundee). These include GST-CK1α 
(DU329), GST-CK1α D136N (DU28371), GST-CaMK2D and GST-β-catenin. FAM83A 
(DUF1669)-GST was provided by Dr Alex Bullock (Oxford). GST-PAWS1-6xHis and 
GST-PAWS1F296A/F300A were expressed and purified by the author as described below 
(2.2.3.10). 
Protein Vector DU number 
PAWS1 R52P-GFP pBabe 28090 
PAWS1 G640R-GFP pBabe 28091 
PAWS1 A34E  pBabe 28382 
PAWS1 S356AE pBabe 28380 
PAWS1 pBabe 33460 
PAWS1 F296A pBabe 28044 
PAWS1 F300A pBabe 28045 
PAWS1 F296A/F300A pBabe 28046 
PAWS1 S356A pBabe 42136 
PASW1S356E pBabe 28380 
PAWS1 G640R pBabe 24545 
PAWS1 R52P pBabe 24544 
PAWS1 D262A pBabe 24843 
PAWS1 GFP-KI sense gRNA pBabe 48793 
GFP pBabe 33932 
Frt/TO-PAWS1-GFP pcDNA5 42816 
Frt/TO-GFP pcDNA5 41455 
PAWS1 S614A-FLAG pCMV 28377 
FAM83G S356A-FLAG pCMV 28378 
FLAG-CK1γ pCMV 5580 
GFP-CAMK2D PCMV5 28369 
GFP-CAMK2G pCMV5 28424 
FLAG-PAWS1 pCMV5 33274 
FLAG-PAWS1 F296A/F300A pCMV5 28026 
FLAG-PAWS1 F296A pCMV5 28024 
FLAG-PAWS1 F300A pCMV5 28025 
FLAG-TTBK2 pCMV5 28024 
HA-CK1A pCS2+ 28216 
HA-CK1A D136N pCS2+ 28217 
HA-CK1ε pCS2+ 28190 
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Protein Vector DU number 
HA-CK1δ pCS2+ 28189 
HA-vector pCMV5 44059 
PAWS1-GFP donor pEX-K4 48585 
GST-PAWS1-6His pGEXP-1 28293 
GST-PAWS1 S614A pGEXP-1 33321 
GST-PAWS1 F296A/F300A pGEXP-1 28049 
GST-PAWS1 F296A pGEXP-1 28047 
PAWS1 GFP-KI antisense gRNA pX335 48826 
FLAG-CAMK2D pcDNA 24985 
FLAG-vector pCMV5 44060 
GST-CAMK2D pGEX6P-1 33795 
Table 2- 7 List of human plasmids used in this thesis 
 
2.2 Methods 
2.2.1 Mammalian cell culture 
2.2.1.1 Cell culture 
U2OS osteosarcoma, human embryonic kidney HEK293, retrovirus production 
HEK293-FT cells, HaCaT human keratinocytes, mouse fibroblast L-cells that stably 
overexpress Wnt3A (L3; ATCC: CRL-2647), or L cells (L; ATCC: CRL-2648) were 
grown in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% (v/v) 
FBS, 2mM L-glutamine, 100 units/ml penicillin and 100 μg/ml streptomycin. U2OS 
TRex cells were maintained in growth medium supplemented with 15 μg/ml blasticidin 
and 100 μg/ml zeocin. All cells were maintained at 37 ºC in a humidified atmosphere with 
5% CO2. Cell media was pre-warmed at 37 ºC prior to use and all procedures were carried 
out in aseptic conditions. 
Cells were grown to 80-90% confluency in a 10 or 15 cm culture dish. For 
passaging the cells, the medium was aspirated from the dish, cells were washed once with 
sterile PBS and then incubated with 1-2 ml trypsin/EDTA at 37 ºC until all cells were 
detached from the culture dish. Cells were re-suspended in culture medium and cell 
clumps were broken by pipetting up and down several times. The cell number in the 
suspension was counted using Countess™ automated cell counter (Thermo Scientific) 
and then cells were seeded into new culture dishes at required densities. 
2.2.1.2 Freezing/thawing cells 
 Confluent cells were detached from the culture dish using trypsin/EDTA and 
resuspended in growth medium. The cell suspension was briefly centrifuged (3 min, 1000 
59 
 
rpm) to pellet the cells. The medium was then aspirated and cells were re-suspended in 
cell freezing medium (Table 2-2). Cells were equally split into 1 ml cryovials and stored 
in a cell-freezing chamber (Mr. Frosty™ Freezing Container; ThermoFosher Scientific) 
for 24 h at -80 ºC. The cryovials were then transferred into liquid nitrogen for long-term 
storage. 
 To thaw cells, cryovials were placed in a 37 ºC water bath for 2 min and cells were 
re-suspended in 5 ml of culture medium, followed by brief centrifugation to pellet the 
cells. The freezing medium was aspirated off and cells were resuspended in 5 ml culture 
medium and transferred into a 6-cm dish. 
2.2.1.3 Cell transfections 
 Transient cDNA plasmid transfections were carried out at ~60% confluence. For 
one 10 cm culture dish, 2.5 μg of plasmid DNA was mixed with 20 μl of PEI in 1 ml 
Opti-MEM. The mixture was immediately vortexed for 10 sec and left to stand for 20 min 
at room temperature. The DNA/PEI suspension was then added dropwise to the cells, 
which were incubated for 24-48 h post-transfection. 
2.2.1.4 RNA interference (RNAi) 
 Cells were seeded at ~1 x 105 cells per well in 6-well cell culture dishes. Cells 
were transfected with 5, 10 or 20 nM of the relevant small interfering RNA (siRNA) 
oligonucleotides using 4 μl Lipofectamine RNAiMAX or TransFectin per well in 
Opti-MEM, as recommended by the manufacturers. After 16 h, the transfection medium 
was removed and replaced with normal DMEM culture medium. Cells were lysed 48 h 
post-transfection. 
2.2.1.5 Retroviral infection 
 Stable cell lines were generated by retroviral infection in accordance with the 
appropriate biological safety regulations. To generate the retrovirus particles encoding 
the protein of interest, 6 μg of the pBabe-puro plasmid encoding the protein of interest 
was incubated with 3.8 μg of GAG/POL and 2.2 μg of vesicular stomatitis virus G 
(VSV-G) expression plasmids in 300 μl Opti-MEM. In a separate mix, 24 μl of PEI was 
added to 300 μl Opti-MEM. Both mixes were vortexed for 10 sec and incubated for 5 min 
at room temperature. Then, they were combined, vortexed for 10 sec and incubated for a 
further 15 min at room temperature. The transfection mix was added drop-wise to a 10-cm 
dish of ~70% confluent HEK293-FT cells. 16 h post-transfection, fresh medium was 
added to the cells. 24 h later, the retroviral medium was collected and filtered through 
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0.45 µm filters. Target cells (~60% confluent) were infected with the optimised titre of 
the retroviral medium, which was diluted in fresh medium containing 8 µg/ml polybrene 
(final) for 4 h to assist retroviral infection (Hesse et al., 1978). The retroviral infection 
medium was then replaced with fresh medium and 20 h later the medium was again 
replaced with fresh medium containing 2 µg/ml puromycin for selection of cells which 
had integrated the cDNA construct. Cell survival was dependent on the stable integration 
of the cDNA resistant marker. Successfully infected cells were used for experiments 
following complete death of non-infected cells placed in selection medium in parallel. 
The expression of protein of interest was confirmed by Western blotting. 
2.2.1.5 Generation of doxycycline-inducible Flp-IN U2OS cells 
 Flp-IN TRex U2OS cell lines were maintained in growth medium supplemented 
with 15 μg/ml blasticidin and 100 μg/ml zeocin. The antibiotics zeocin and blasticidin 
were added for selection of the Flp recombination sites (FRT) and the doxycycline 
repressor sequence respectively. Flp-IN TRex U2OS cells grown in 10-cm dishes were 
transfected with 1 μg pcDNA5-Frt/TO vector encoding PAWS1-GFP or GFP only and 
9μg pOG44 Flp recombinase encoding vector, diluted in 1 ml OPTIMEM and 20 μl of 1 
mg/ml PEI. 24 h post-transfection, cells were cultured in medium containing 15 μg/ml 
blasticidin and 50 μg/ml hygromycin-B for 2-3 weeks (by replacing fresh medium every 
two days) until positive clones were selected, verified and expanded. Hygromycin B was 
added to ensure integration of the cDNA sequence of interest. Protein expression was 
induced with 20 ng/ml doxycycline for 16 hours prior to lysis and monitored by Western 
blotting and fluorescence microscopy. 
2.2.1.6 Generation of PAWS1-GFP and PAWS1-luciferase reporter knock-in cell 
lines using the CRISPR/Cas9 system 
 Genome editing was performed using the CRISPR/Cas9 technology (Cong et al., 
2013). The guide RNAs (gRNAs) used in this thesis are listed in Table 2-7. Cell 
transfections were carried out at ~60% confluence. For one 10 cm culture dish, 20 μl PEI 
was combined with 1 μg of the plasmid carrying sense gRNA and puromycin and 1 μg of 
plasmid carrying antisense gRNA and Cas9 D10A nickase and 3 μg of the donor vector 
in 1 ml Opti-MEM. The nickase cleaves one strand of the DNA complementary to gRNA; 
therefore, the generation of a double stranded break requires target-specific nicks on 
individual strands recognised by both sense and antisense gRNAs thereby reducing the 
potential off-target double stranded breaks. The DNA/PEI mixture was immediately 
vortexed for 10 sec and incubated for 20 min at room temperature, before being added 
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drop-wise to the cells. 24 and 48 h post-transfection, cells were cultured in medium 
containing 2 μg/ml puromycin for selection of transfected cells. Cells were then cultured 
in normal medium and the transfection was repeated, which was then followed by 2 days 
of puromycin selection. GFP-positive cells were then sorted by flow cytometry and single 
GFP-positive cells were plated on individual wells of two 96-well plates. Viable clones 
were expanded and the knock-in efficiency was analysed by immunoblotting cell extracts 
and DNA sequencing (Sections 2.2.3.7, 2.2.2.7). 
2.2.1.6 Generation of Wnt3A-conditioned medium 
 L (control) and L3 (Wnt3A producing) cells were grown in 10 cm dishes to 
confluency and the culture medium was collected and sterile-filtered through 0.2 µm 
filters. 10 ml of fresh medium was added to cells for an additional 3 days. Then, the 
medium was collected, filtered, combined with the first batch of the collected conditioned 
medium and stored at 4 ºC. At this stage, cells were discarded. 
2.2.1.7 Stimulation of cells with small molecules inhibitors and ligands 
 The small molecule inhibitors used in this thesis are included in Table 2-1. 10 mM 
stocks of small molecule inhibitors dissolved in DMSO was provided by the DSTT 
(University of Dundee), and stored in aliquots at -20 ºC. The commercial small molecule 
inhibitors were also dissolved in DMSO unless stated otherwise. The small molecule 
inhibitors were added directly into the cell culture medium and incubated for the desired 
time (indicated in the figure legends) at 37 ºC. An equivalent volume of DMSO was used 
as a control.  
 For ligands, typically a 1000-fold stock of the desired concentration was prepared 
in PBS and stored at -20 ºC. The solutions were added directly into the culture medium 
at the indicated concentrations. For Wnt3A stimulation, 100% of the conditioned medium 
was added directly to the cells for the time points indicated in the figure legends. For 
TGFβ and BMP ligands, cells were serum starved for 16 h at 37 ºC prior to treatment. 
2.2.1.8 Luciferase reporter assays 
 PAWS1-luciferase reporter U2OS cells were seeded in 12-well plates and grown 
to 60-70% confluence, ensuring three replicates for each condition. Then, they were 
treated with the ligands as indicated in the figure legends for 1 h and were lysed with 
passive lysis buffer (Promega) after being washed twice with PBS. The lysis was allowed 
on a rocking platform for 15 min at room temperature. Extracts were collected and 
centrifuged at 14000 rpm for 5 min. To assay the luciferase reporter activity, the lysates 
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(20 μl) were transferred into each well of a 96-well plate (#655083, Greiner Bio-one) 
containing equal volume of 2 x Luciferase assay buffer. Data were obtained using 
Envision 2104 plate reader (PerkinElmer). The luciferase counts were normalised to the 
protein concentration and averaged. Plots and statistical analysis were performed using 
Prism6 software, as indicated in the figure legends. 
2.2.1.8 Dual luciferase reporter assays 
 Cells (2 x 105) were plated in 6-well plates, ensuring three replicates for each 
condition. 24 h later, 500 ng of Super TOPflash or Super FOPflash and 10 ng of Renilla-
luciferase plasmids were co-transfected using 4 μl PEI and 200 μl OPTI-MEM. For 
transient PAWS1 expression, 500 ng of pBabe PAWS1 was included to the transfection 
mix. 24 h later, cells were treated with L-conditioned medium or L-Wnt3A-conditioned 
medium or 20 mM LiCl for 16 h, washed twice with PBS and lysed in passive lysis. 
Firefly luciferase activity was measured as described in 2.2.1.7. Immediately after the 
measurement of the Firefly luciferase activity, 20 μl of Renilla assay buffer was added to 
each well of the 96-well plate and mixed by pipetting. Renilla luciferase activity was then 
measured using Envision 2104 plate reader. Firefly luciferase counts were normalized to 
Renilla luciferase counts, which represented a measure of transfection efficiency in each 
sample. Plots and statistical analysis were performed using Prism6 software, as indicated 
in the figure legends. 
2.2.1.9 Cell lysis 
 Unless indicated otherwise, for general cell lysis, cells were washed twice with 
ice-cold PBS and scraped on ice in lysis buffer, supplemented with protease inhibitor 
cocktail as described (Table 2-2). Extracts were transferred to Eppendorf tubes and 
incubated on ice for 10 min before clarification by centrifugation at 14000 rpm for 20 
min at 4 ºC.  
 When the chemical cross-linking reagent DSP was used, cells were lysed in lysis 
buffer with DSP (Table 2-2). Extracts were incubated at 4 ºC for 30 min before cross-
linking reaction was quenched with Tris/HCl pH 7.5 at a final concentration of 0.2 M. 
Cell extracts were further incubated at 4 ºC for 30 min with vortexing every 5 min. 
Extracts were then centrifuged 14000 rpm for 20 min at 4 ºC and processed immediately 
or snap-frozen in liquid nitrogen and stored at -80 ºC. 
63 
 
 For DNA and mRNA isolation, cells were processed using an RNA extraction kit 
according to the manufacturer’s instructions (Qiagen DNeasy blood and tissue, and 
RNeasy kits respectively). 
2.2.1.10 Cell proliferation assay 
 Cells were seeded in a 96-well plate in four different densities (103, 2 x 103, 3 x 
103 and 4 x 103) and were left for 16 h at 37 ºC. Cell proliferation assay was carried out 
using the CellTiter 96® AQueous One Solution Cell Proliferation Assay, according to the 
manufacturer’s instructions (Promega). Plots and statistical analysis were performed 
using Prism6 software with 2way ANOVA and post-hoc Bonferroni correction for 
multiple comparisons (Bland and Altman 1995). 
2.2.1.11 Cell migration assay 
 U2OS cells (4-6 x 104) were plated into migration chambers (Ibidi) and grown to 
confluency (typically 18 hours), before being subjected to 2-dimensional migration 
assays by removing the silicone insert. Images were taken every 4 h by a Photometrics 
Cascade II CCD camera with Nikon NIS elements software. Wound closure was 
measured by Image J and reported as a percentage of closure relative to the starting wound 
size. Plots and statistical analysis were performed using Prism6 software with 2way 
ANOVA and post-hoc Bonferroni correction for multiple comparisons. 
2.2.1.12 β-catenin stabilisation assay 
 Cells were stimulated with Wnt3A-conditioned medium or control-conditioned 
medium, as indicated. Cells were washed and collected in ice-cold PBS. Cell pellets were 
then resuspended in hypotonic lysis buffer (Table 2-2). Cell suspensions were incubated 
on ice for 30 min and passed multiple times through a 28G needle. Lysis of cells was 
controlled by checking under the microscope. Nuclear proteins, including the unlysed 
cells, were pelleted by centrifugation at 2000 rpm for 2 min at 4°C. The supernatant, that 
contained both cytoplasm and membrane proteins. was then centrifuged at 14000 rpm for 
30 min at 4°C. The supernatant was collected and analysed further by SDS-PAGE 
followed by Western blotting (sections 2.2.3.5-7). 
2.2.1.13 Xenopus laevis embryo manipulations 
 Xenopus laevis embryos were obtained by in vitro fertilization and staged 
according to Nieuwkoop and Faber (Nieuwkoop and Faber, 1994). Microinjections were 
carried out in 4% Ficoll in 75% Normal Amphibian Medium, and when they reached 
stage 8, they were transferred to 10% NAM. Embryos were injected with capped RNA 
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synthesized using SP6 mMessagemMachine kit (Thermo Fisher Scientific). For axis 
duplication assays, mRNA was injected into a single ventral blastomere at the 4- cell 
stage. Secondary axes were scored at stage 32 and were classed as complete if the second 
axis had eyes and a cement gland. Animal caps assays were performed as described 
previously (Jones et al., 1993). Dissociated animal caps were plated onto μ-Slide 8 well 
glass bottom chamber slides (#80827, Ibidi) or 12 well μChamber slides (#81201) coated 
with 3 μg/ml recombinant human E-cadherin protein (#8505-EC-050; R&D Systems) in 
0.7 x Marc’s Modified Ringers solution (MMR; 0.1 M NaCl, 2 mM KCl, 1 mM MgSO4, 
2 mM CaCl2, 5 mM HEPES pH7.8, 0.1 mM EDTA). All experiments on Xenopus were 
performed by Kevin Dingwell (The Francis Crick Institute, London).  
2.2.2 General molecular biology 
2.2.2.1 Plasmid transformation, amplification and isolation 
 Competent E. coli DH5α (plasmid isolation) or BL21 (protein expression) cells, 
expanded and maintained by the DSTT, (University of Dundee), were thawed on ice and 
1 µl of plasmid DNA (~10 ng) was added to the cells, followed by incubation for 30 min 
on ice. Cells were then heat-shocked at 42 ºC for 1 min to facilitate DNA uptake and 
placed on ice for 5 min. 500 μl of LB medium was added to the cells and they were placed 
in a 37 ºC thermomixer for 30 min to recover. Subsequently 50 μl was transferred onto 
an LB agar plate containing 100 μg/ml ampicillin or 50 μg/ml kanamycin as appropriate 
and left overnight in a 37 ºC incubator. To amplify the plasmids, one transformed colony 
was used to inoculate 200 ml LB medium containing 100 μg/ml ampicillin or 50 μg/ml 
kanamycin as appropriate for 16 h on a shaking incubator at 37 ºC. The cells were pelleted 
by centrifugation (3000 rpm, 20 min, 4 ºC) and the plasmid DNA was extracted using the 
Qiagen DNA Midi or Maxi kit according to the manufacturer’s instructions. 
2.2.2.2 Measurement of DNA and RNA concentration  
Using a NanoDrop® spectrophotometer (Thermo Scientific) the absorbance of 
isolated DNA or RNA in aqueous solution was measured at 260 nm, after previous 
calibration with nuclease-free water. 
2.2.2.3 Agarose gel electrophoresis 
  The size and the purity of DNA products were assessed by electrophoresis on 1% 
agarose gels. Each gel contained a 1:10000 dilution of SYBR Safe nucleotide gel stain. 
Gels were submerged in 1 x TAE running buffer. DNA (0.5 μg) was loaded onto the gel 
together with 1 x DNA loading dye. 0.5 μg of a 1 kbp DNA ladder was used as a marker. 
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Gels were run at 100 V for 30 min. The stained nucleotide complexes were visualised 
using a UV transilluminator. 
2.2.2.4 Real time quantitative reverse transcription PCR (qRT-PCR; qPCR) 
 Total RNA was isolated from cells using the QIAGEN RNeasy kit. cDNA was 
made from 1 μg of isolated RNA using the SuperScript cDNA kit (BioRad) according to 
the manufacturer’s protocol. qPCR reactions were performed in triplicates in 12 μl 
reaction final volume for 96-well plates or in quadruplicates in 10 μl reaction final volume 
for 384-well plates (Biorad). Each reaction included 0.5 μM forward primer, 0.5 μM 
reverse primer, 50% SsoFast EvaGreen Supermix (BioRad), and cDNA equivalent to 1 
ng/μl of RNA in a CFX96 or CFX384 real-time system qPCR machine (BioRad). All 
primers were designed using PerlPrimer and purchased from Thermo Fisher Scientific. 
The data were normalized to the geometrical mean of the house-keeping gene GAPDH 
or β-actin and analysed with the 2-ΔΔCt method for comparing relative gene expression 
results in Microsoft Excel (Livak and Schmittgen 2001). Plots and statistical analysis 
were performed using Prism6 software with 2way ANOVA and post-hoc Bonferroni 
correction for multiple comparisons. 
2.2.2.5 PCR 
DNA was isolated from cells using a DNeasy Blood and Tisssue Kit (Qiagen) 
according to the manufacturer’s instructions. PCR was performed on a PCR Thermal 
Cycler (PT-200; MJ Research) using the KOD Hot Start DNA Polymerase kit (Toyobo) 
as per the manufacturers protocol. Each 50 μl reaction included 25 mM MgSO4, dNTPs 
(2 mM each), 10 μM each of forward and reverse primers, 200 ng template DNA, 1 U 
KOD Hot Start DNA Polymerase, 3 μl DMSO and 1 X buffer for KOD Hot Start DNA 
Polymerase. The PCR products were assessed by electrophoresis on 1% agarose gels. 
2.2.2.6 Subcloning of PCR products  
PCR products were cloned into a pSC-B vector using the StrataClone Blunt PCR 
Cloning Kit (Agilent) as per the manufacturer’s instructions. Each reaction contained 3 
μl StrataClone Cloning Buffer, 2 μl of a 1:10 dilution of the PCR product and 1 μl 
StrataClone Vector Mix. StrataClone SoloPack Competent Cells (Agilent) were then 
transformed with the vector as per the manufacturer’s instructions. Following 
transformation, 10 μl culture samples were plated on LB plates containing 2% X-Gal. 
Plates were inverted and incubated for 16 h at 37°C. White colonies were subsequently 
picked and used to inoculate a 4-ml culture of LB medium which was grown for 16 h at 
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37°C. Plasmid DNA was then purified using a Plasmid Mini Kit as per the manufacturer’s 
instructions.  
2.2.2.7 DNA sequencing  
DNA plasmid sequencing was performed by the DNA Sequencing Service 
(University of Dundee) using Applied Biosystems Big-Dye v 3.1 chemistry on an Applied 
Biosystems model 3730 automated capillary DNA sequencer, using appropriate 
sequencing primers (Table 2-6). 
2.2.2.8 DNA mutagenesis 
 DNA mutagenesis of all plasmids (Table 2-7) was performed by the DSTT 
(University of Dundee) cloning team using the QuikChange site directed mutagenesis 
method (Stratagene) with KOD polymerase (Novagen). All mutations were verified by 
DNA sequencing. 
2.2.3 General biochemistry 
2.2.3.1 Measurement of protein concentration 
 Protein concentration was determined by the Bradford method (Bradford, 1976). 
In principle, this is a colourimetric protein assay based on an absorbance shift from 465 
nm to 595 nm once Coomassie dye binds to proteins in acidic medium. A standard curve 
was generated by plotting absorbance against a serial dilution of BSA standards (0.0625 
mg/ml – 1 mg/ml). Samples were diluted in water by a factor of 10 and were added to a 
96-well plate in triplicates (5 μl) along with 200 μl of Bradford reagent and a blank probe. 
After incubation for 5 min at room temperature, absorbance at 595 nm was measured with 
a VersaMax microplate reader and SoftMax Pro v4.8 software (Molecular Devices). The 
protein concentration of each sample was calculated from the average absorbance by 
reference to the standard curve. Because the colour response of the Coomassie reagent is 
non-stoichiometric with increasing protein concentration, a standard curve was run with 
each assay. 
2.2.3.2 Immunoprecipitation (IP) 
 Cleared cell extracts were further pre-cleared to minimise unspecific binding of 
proteins to the solid phase resins by incubating with agarose or protein-G Sepharose beads 
for 1 hour at 4 °C prior to immunoprecipitation (IP). The pre-cleared extracts (0.5-1 mg 
protein for Western blot applications or 10 mg protein for mass spectrometry 
applications) were then mixed with FLAG- or HA-agarose beads (Sigma-Aldrich), 
GFP-Trap agarose beads (Chromotek) or antibody/IgG-coupled to protein G-Sepharose 
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or Agarose beads for up to 4 h at 4 ºC on a rotating platform. The flow-through was 
retained for Western blot analysis to assess IP efficiency and the beads were washed twice 
in lysis buffer containing 250 mM NaCl, and once in buffer A. For Western blot analysis, 
beads were resuspended in 1 x SDS sample buffer (typically in a final volume of 40 μl). 
IP samples, as well as equal amounts of flow-through and input samples reduced in SDS 
sample buffer were heated at 95 ºC for 5 min prior to SDS-PAGE. 
2.2.3.3 Covalent coupling of antibodies to protein G-Sepharose 
 1 μl of Protein G-Sepharose beads per μg of antibody were incubated for 1 h at 
4°C with gentle agitation. The beads were then washed five times with 10 volumes of 0.1 
M sodium borate, pH 9. Beads were resuspended in 20 mM dimethyl pimelimidate 
dihydrochloride (DMP) in 0.1 M sodium borate, followed by gentle agitation for 30 min 
at room temperature. After repeating the final step one more time, beads were washed 
four times with 10 volumes of 50 mM glycine pH 2.5 to strip the beads of any antibody 
that had not been coupled covalently. Next, beads were neutralized by washing twice for 
30 min at room temperature with 0.2 M Tris-HCl pH 8. Beads were resuspended in PBS 
containing 0.01% (v/v) NaN3 and stored at 4 °C. 
2.2.3.4 Subcellular fractionation 
 For nuclear and cytoplasmic extraction, a NE-PER kit from Thermo Scientific 
(#78833) was used in accordance with the manufactures’ instructions. For membrane and 
cytoskeletal protein extraction a compartment protein extraction kit from Merck (#2145) 
was used according to the manufactures’ instructions. The lysis buffers were 
supplemented with protease inhibitors (Roche). Fractions were reduced in SDS sample 
buffer as stated above. 
2.2.3.5 Separation of proteins by SDS-PAGE 
 SDS-PAGE was carried out using either the NuPAGE Bis-Tris Electrophoresis 
System (Thermo Fisher Scientific) or the ATTO vertical polyacrylamide slab gel 
electrophoresis system (ATTO Corporation, Tokyo, Japan). Protein samples were 
prepared by adding 1 x Sample buffer and denatured by heating at 95°C for 5 min. 
Samples were loaded onto the pre-cast NuPAGE Novex gel using a micropipette 
equipped with gel-loading tips. Pre-Stained Standards with apparent molecular weights 
of 250, 150, 100, 75, 50, 37, 25, 20, 15 and 10 kDa were used as markers. Electrophoresis 
was carried out in an XCell SureLock Mini-Cell filled with 1 x MOPS Running Buffer. 
Electrophoresis was performed at constant voltage of 200 V for 50 min.  
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The ATTO system did not use pre-cast gels and therefore, it was necessary to 
prepare the minigels prior to electrophoresis. Slab minigels (90 mm x 80 mm x 1 mm) 
were poured between glass plates. The separating (resolving) gel was typically prepared 
at an acrylamide concentration of 10% and thus contained 375 mM Tris-HCl pH 8.6, 10% 
(w/v) acrylamide mix (1:29 molar ratio of bisacrylamide:acrylamide) and 0.1% (w/v) 
SDS. Polymerisation was initiated by addition of 0.075% (w/v) APS and 0.1% (v/v) 
TEMED and pouring the mix onto the gel assembly unit. 100% isopropanol was gently 
pipetted on top of the gel to level the surface and extract out bubbles. The separating gel 
was allowed to polymerise for at least 20 min at room temperature. After polymerisation 
was complete, the isopropanol was poured off completely and the stacking gel was 
prepared and poured directly onto the surface of the polymerised resolving gel. A clean 
Teflon comb was immediately inserted and the stacking gel was allowed to polymerise 
for around 30 minutes at room temperature. Gels were introduced into the ATTO 
electrophoresis chamber, in which both the upper and lower buffer tanks were filled with 
SDS-PAGE running buffer. 5 μl of Precision Plus Protein Standards (BioRad) and 20 μg 
(unless stated otherwise) of protein extracts in SDS sample buffer were loaded in a similar 
manner to that described for the NuPAGE system. Electrophoresis was performed at 
constant voltage of 150 V for 90 min.  
2.2.3.6 Coomassie Blue Staining 
 After SDS-PAGE gels were washed in deionised waster and incubated in 20 ml 
of InstantBlue (Expedeon) on a rocking platform for 10 min – 16 h. Following this the 
gel was repeatedly washed in deionised water to de-stain. 
2.2.3.7 Immunoblotting (Western blotting) 
 Following their resolution by SDS-PAGE, protein samples were transferred onto 
PVDF membranes, which had been activated in 100% methanol immediately prior to 
transfer assembly. The transfer was set at 80 V for 80 min in BioRad transfer apparatus 
filled with transfer buffer and a cooling block. 
 To visualise protein transfer efficiency in a reversible manner, PVDF membranes 
were immersed in Ponceau S staining solution for 2 min. The membranes were rinsed 
with dH2O to remove background staining and the bands were visualised. The membranes 
were cut with a scalpel into smaller strips, so that proteins of different molecular weights 
could be probed at the same time, if necessary. Membranes were further washed with 
dH2O until Ponceau S staining disappeared completely. 
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 Membranes were then incubated in blocking solution (Table 2-2) for 30 min at 
room temperature on a rocking platform or orbital shaker. Blots were then incubated with 
primary antibody solution (Table 2-2) for 1 h at room temperature or 16 h at 4 ºC. 
Membranes were washed three times for 10 min in TBS-T before being incubated with 
the HRP-conjugated secondary antibodies (typically 0.2 μg/ml) in blocking solution for 
1 h at room temperature. After washing as before in TBS-T, membranes were incubated 
with enhanced chemiluminescence (ECL) reagent for 1 min, placed in an X-ray cassette 
and exposed to X-ray films under safelight conditions. X-ray films were developed using 
a Konica automatic developer. 
2.2.3.8 Immunofluorescence microscopy 
 U2OS cells were seeded onto 22 x 22 mm sterile coverslips in 6-well culture 
plates. Cells were washed in PBS before fixation with 4% paraformaldehyde for 10 min 
at room temperature. Paraformaldehyde was removed and the cross-linking reaction was 
quenched by washing twice with IF quenching buffer (10 min each wash). Coverslips 
were then washed with PBS and permeabilised with 0.5% Triton X-100 in PBS for 5 min. 
Subsequently, coverslips were washed with IF blocking solution (Table 2-2) and 
incubated in IF blocking solution for 30 min, to reduce non-specific epitope binding. 
Primary antibodies were prepared in IF blocking solution (1:250 for anti-PAWS1 Abcam, 
ab121750 and 1:100 for anti-CK1α, Santa Cruz, sc6477) and added directly into 
coverslips for 1 h. Cells were washed with 0.1% Triton X-100 in PBS, and incubated in 
the dark, with Alexa Fluor conjugated secondary antibodies (ThermoFisher Scientific), at 
a dilution of 1:500 in IF blocking solution, for 30 min at room temperature. Coverslips 
were then subjected to three 10 min washes in IF blocking solution and in the final wash, 
DAPI (1 μg/ml) was added onto the coverslips. Then, coverslips were dipped into sterile 
ddH2O and mounted onto glass slides with Vectashield mounting medium. Once 
coverslips were completely dry, they were imaged using a DeltaVision system (Applied 
Precision) with an immerse-oil x63 objective lens. Z-series were collected at 0.2 μm 
intervals, and deconvolved using SoftWoRx (Applied Precision). Images were processed 
using ImageJ and OMERO software. The images presented correspond to one stack from 
the de-convolved three-dimensional images. 
 For the analysis of SMAD signalling in Xenopus, by Dr Kevin Dingwell, 
dissociated animal cap cells were fixed in MEMFA (0.1M MOPS pH 7.4, 2 mM EGTA, 
1 mM MgSO4, 3.7% formaldehyde) for 10 min at room temperature, followed by three 5 
min washes in PBS. Cells were permeabilised with 0.5% Triton X-100 for 5 min followed 
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by three 5 min washes with PBS and then blocked in Xenopus IF blocking solution (PBS, 
0.1% Tween 20, 1% BSA, 10% goat serum) for 1 h at room temperature. Primary (anti-
P-Smad1, CST #9511), and secondary antibodies (anti-rabbit Alexa568, Invitrogen 
#A11031) were used at 1:1000 in Xenopus IF blocking solution, each for 1 h, and then 
washed three times of 5 min each with PBS/0.1% Tween 20. Cells were mounted using 
Prolong Gold Antifade Mountant with DAPI (Thermo Fisher Scientific, #P36935). 
Images were captured on Zeiss LSM710 confocal microscope controlled by ZEN Black 
2012software. Post-acquisition analysis was performed using ZEN Black, Zen Blue 2012 
and ImageJ software packages.  
2.2.3.9 NFAT assay 
 Cells were seeded om coverslips on 6-well plates and transfected with 500 ng of 
the plasmid encoding for NFAT with a C-terminal mCherry tag. 24 h later, cells were 
treated with 250 nM of the calcium ionophore A23187 or the equivalent volume of 
DMSO as a control. Cells were fixed and analysed by fluorescence microscopy for NFAT 
localisation as described in 2.2.38. 
2.2.3.10 Protein expression and purification from E. coli 
The GST-PAWS1-6xHis was expressed in E. coli BL21 cells. A single bacterial 
colony transformed with pGex6T vector encoding GST-PAWS1-6xHis was inoculated in 
3 ml LB medium (supplemented with 100 μg/ml ampicillin) for 8 hours at 37 °C with 
shaking at 220 rpm. 200 μl of the starter culture was used to inoculate 100 ml LB medium 
containing 100 μg/ml ampicillin and grown overnight at 37 °C at 220 rpm. The following 
day, 50 ml of the overnight culture was used to inoculate 1 L of LB medium containing 
100 μg/ml ampicillin in a 2-litre flask. The cell suspension was incubated at 37 °C with 
shaking at 200 rpm until OD600 reached 0.6. Protein expression was induced with IPTG 
to a final concentration of 50 μM. The cell culture was incubated overnight at 16 °C with 
shaking at 200 rpm. Cells were harvested by centrifugation at 4000 x g for 20 min at 4 
°C. The cell pellet was resuspended in bacterial lysis buffer (10 ml per gram of pellet) 
(Table 2-2). Cells were lysed by sonication and lysates were clarified by centrifugation at 
30000 x g (JA-30.50 Ti rotor) for 30 min at 4 °C. The supernatant was filtered through a 
0.2 micron filter and incubated with pre-equilibrated Ni-NTA resin (1ml per litre of 
culture) at 4 °C for 1 h with gentle agitation. The beads were then transferred to a 20 ml 
BioRad column and washed with His-tag protein binding buffer (~10 column volumes). 
Protein was eluted with His-tag protein elution buffer (Table 2-2) and collected in 1 ml 
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fractions. Peak protein concentration was determined by Bradford. Peak fractions were 
pooled and, dialyzed overnight at 4 ºC in His-tag protein dialysis buffer.  
The recovered sample was further purified using Glutathione (GSH)-Sepharose 
resin (1ml per litre of culture) at 4 °C for 1 h with gentle agitation. The beads were then 
transferred to a 20 ml BioRad column and washed with GST-tag protein wash buffer 
(Table 2-2). Beads were washed until OD595 was at or near zero. Protein was eluted with 
GST-tag protein elution buffer (Table 2-2). 1 ml fractions were collected and the fractions 
for which OD595 was greater than 0.2 were pooled together. The purified product was 
analysed on a 10% SDS gel followed by Coomassie staining. Purified proteins were 
stored at -80 ºC. For proteins expressed as GST-tagged only, the GST purification 
procedure was performed as described here. 
2.2.3.11 Removal of the GST tag from bacterially-expressed protein 
The purified GST-tagged protein was mixed with GSH-Sepharose resin (1 ml 
packed beads per 500 μg of protein) for 3 h at 4 ºC with gentle agitation. After 
centrifugation at 1000 rpm for 1 min at 4 ºC, the beads were washed in 10 ml of binding 
assay buffer (Table 2-2). Beads were then re-suspended in 2 ml of binding assay buffer 
containing 500 μg of PreScission GST-tagged Protease for 16 h at 4 ºC. PreScission 
Protease is a fusion protein of the GST and human rhinovirus 3C protease (Walker, Leong 
et al. 1994) which specifically recognises the amino acid sequence Leu-Glu-Val-Leu-
Phe-Gln/Gly-Pro, cleaving between the Gln and Gly residues (Cordingley, Callahan et al. 
1990). Samples were filtered through a Spin-X column by centrifugation at 14000 rpm 
for 5 min to remove both the GST moiety of the fusion protein and the GST-tagged 
PreScission Protease, which both remained bound to the column while the protein of 
interest eluted in the column flow-through. The flow-throughs were then analysed by 
SDS-PAGE and Coomassie staining. 
2.2.4 In vitro assays 
2.2.4.1 In vitro kinase assays 
25 μl reactions were set up using 200 ng of the kinase and 2 μg of substrate in the 
kinase assay buffer (Table 2-2) containing 0.1 mM γ32P-ATP (~500 cpm/pmol). Reactions 
were performed at 30 °C for 30 min and stopped by adding 10 μl SDS sample buffer with 
5% β-mercaptoethanol and heating at 95°C for 5 min. Samples were resolved by 
SDS-PAGE and gels were stained with InstantBlue Coomassie reagent and dried. 
Radioactivity was analysed by autoradiography by exposing the dried gel on Hyperfilm 
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for different lengths of time. For long exposures, the cassette was placed in -80 ºC to 
enhance the autoradiographic signal. Films were developed using a Konica automatic 
developer. 
For kinase assays against a substrate peptide (CK1tide, DSTT EP5630), reactions 
were set up in triplicates, in a final volume of 50 μl and they were stopped by spotting 40 
μl of sample onto p81 phosphocellulose papers (2x2 cm; Whatman), which were 
immediately immersed in 75 mM phosphoric acid (5 ml of orthophosphoric acid per assay 
sample), being stirred continuously with a magnetic stirrer. The p81 papers were washed 
3 times (5 min each wash) with 75 mM phosphoric acid until the γ32P-ATP that was not 
incorporated into the peptide was washed off. After the final wash, papers were rinsed 
briefly in acetone to remove the phosphoric acid and then dried with a hair dryer. Papers 
were then transferred into an Eppendorf tube and radioactivity was measured in a 
scintillation counter (PerkinElmer). In parallel, radioactivity of 1 μl aliquots of the stock 
1 mM γ32P-ATP was measured to determine the specific radioactivity (cpm/pmol) of the 
γ32P -ATP so that the stoichiometry of the reaction could be determined. 
2.2.4.2 In vitro protein binding assay 
 Purified GST-PAWS1-6xHis and GST-PAWS1F296A/F300A were mixed with GSH-
Sepharose beads (20 μg of recombinant protein per ml of packed beads) for 3 h at 4 ºC 
with gentle agitation. Samples were washed twice in binding assay buffer (Table 2-2). 
Then, 200 ng of recombinant GST-cleaved CK1α was added to the beads followed by 
incubation for 1 h at room temperature. The assay samples were washed three times with 
binding assay buffer (Table 2-2) before being analysed by SDS-PAGE and Coomassie 
staining. 
2.2.5 Mass spectrometry 
2.2.5.1 Preparation of samples for mass spectrometry 
 For mass spectrometry analysis, U2OS cells expressing the protein of interest, 
were lysed in lysis buffer with DSP as described in 2.2.1.9. Extracts were incubated with 
Protein A-agarose beads for 1h on a rotating platform at 4 ºC to pre-clear non-specific 
proteins binding to the solid phase. Pre-cleared extracts were then filtered through a 0.45 
micron filter and then extracts (10 mg of protein) were incubated with 10 μl GFP-Trap 
packed beads for 16 h at 4 ºC. The beads were washed twice in lysis buffer supplemented 
with 500 mM NaCl and once with Buffer A. IPs were denatured in LDS sample buffer 
supplemented with 0.1 M DTT, incubated for 1 h at 37 ºC to reverse the cross-linking 
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reaction and heated at 95 ºC for 5 min. The samples were filtered through a Spin-X 
column by centrifugation at 14000 rpm for 5 min, and the supernatant loaded onto 4-12% 
gradient precast SDS gels and separated by gel electrophoresis. Gels were stained with 
InstantBlue Coomassie reagent for 15 min, followed by destaining with dH2O until the 
background stain was invisible.  
2.2.5.2 In-gel digestion of proteins for mass spectrometry 
 To minimise contamination, all steps from this point onwards were carried out 
under a laminar flow hood (Model A3VB, Bassaire Limited). Disposable scalpels were 
used to excise the protein bands of interest from Coomassie-stained SDS-PAGE gels. Gel 
pieces were cut into 1 mm cubes and transferred into LoBind 1.5 ml Eppendorf tubes. 
After washing once in water, gel pieces were shrunk in acetonitrile (ACN), re-swollen in 
50 mM Tris-HCl pH 8 and shrunk again in ACN (5min). The shrinking-swelling steps 
were repeated once more followed by reduction of the samples in 5 mM DTT/50 mM 
Tris-HCl pH 8 for 20 min at 65 °C.  The proteins were then “in gel” alkylated with 50 
mM iodoacetamide/50 mM Tris-HCl pH 8 for 20 min at room temperature. The gel pieces 
were then shrunk in ACN for 5 min, re-swollen in 50 mM Triethylammonium bicarbonate 
and shrunk again in ACN. Then the proteins were digested using 50 mM 
Triethylammonium bicarbonate containing 5 μg/ml Trypsin for 30 min at   30 °C followed 
by 3 h incubation at 37 °C. Then an equivalent volume of ACN was added to the digest 
for 15 min and the supernatants were collected. Gel pieces were re-swollen in 0.1% TFA 
and peptides were extracted twice with ACN until gel pieces were completely white and 
had shrunk. The supernatants were dried using Speed-Vac, before being submitted for 
analysis by the mass spectrometry team.  
2.2.5.3 Peptide analysis by liquid chromatography-tandem mass spectrometry  
The digested peptides were reconstituted in HPLC grade 5% ACN and 0.1% 
formic acid and injected into a nano liquid chromatography system coupled to a Thermo 
LTQ Orbitrap mass spectrometer. Raw files were converted into a list of identified 
peptides coupled with information given by the precursor intensity of the identified 
peptides and submitted to the in-house Mascot server. Data was searched against the 
International Protein Index human database with variable modifications allowing for 
phosphorylation of Serine/Threonine or Tyrosine residues and for Methionine oxidation, 
dioxidation or carboxy modification. Liquid chromatography-tandem mass spectrometry 
(LC-MS-MS) analysis was performed by Dr David Campbell, Robert Gourlay and Joby 
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Varghese (University of Dundee). Data analysis was performed using Scaffold 4.3 
(Proteome software). 
2.2.5.4 Identification of phosphorylated PAWS1 residues 
 [γ32P]-phosphorylated PAWS1 (see section 2.2.4.1) was digested as described 
above. The dried peptides were reconstituted to a final concentration of 5% ACN/0.1% 
TFA and injected into a C18 column equilibrated with 0.1% TFA with a linear ACN/0.1% 
gradient at a flow rate of 0.2 ml/min and 100 μl fractions were collected. The major eluted 
[γ32P]-peptides were analysed on OrbiTrap Velos LCMS system. To determine the 
phosphorylated residue in each [γ32P]-labelled peptide, the peptides were immobilised on 
a Sequelon-AA membrane and subjected to solid-phase Edman degradation as described 
previously (Campbell and Morrice 2002). HPLC, mass spectrometry and Edman 
degradation were performed by Robert Gourlay (University of Dundee). 
2.2.5.5 Phosphoproteome sample preparation and MS analysis 
2.2.5.5.1 Protein extraction and digestion 
Cells were stimulated with Wnt3A-conditioned medium or control-conditioned 
medium when they reached ~90% confluence, for 3 h. Before lysis, cells were washed 
once in ice-cold PBS and once in ice-cold PBS supplemented with the phosphatase 
inhibitors PhosSTOP (Roche), 2 mM Sodium orthovanadate 10 mM Na B 
glycerophosphate, 5 mM Na pyrophosphate, 50 mM NaF. Each 15-cm dish was lysed by 
scraping in 500 μl of Urea lysis buffer. Extracts were collected in Eppendorf tubes and 
sonicated (40% amplitude, 25 intervals of 5 sec each) on ice. Protein concentration was 
determined by the BCA assay (Thermo Fisher Scientific). Cell extracts were prepared at 
a final concentration of 3 mg/ml and were then reduced with 5 mM TCEP. The reduced 
cysteine residues were alkylated in the dark with 14 mM iodoacetamide before trypsin-
digestion for 3 h at 37 ºC. Digests were acidified with 0.1 % (v/v) trifluoracetic acid 
(TFA) pH 2 for 15 min at 37 ºC. The acidified digests were centrifuged at 10,000 g for 
10 min. The supernatant were subjected to C18 solid-phase extraction (SPE) (Sep-Pak) 
for further cleaning.  
2.2.5.5.2 Phosphopeptide enrichment 
The desalted peptides were resuspended in 1 ml of 2 M lactic acid/50% 
acetonitrile (ACN) and centrifuged at 15000 x g for 20 min. Supernatants were transferred 
to an Eppendorf tube containing 18 mg of titanium dioxide (TiO2) beads (GL sciences, 
Japan) and vortexed for 1 h at room temperature. Beads were washed three times (10 min 
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per wash) with 2 M lactic acid/50% ACN and subsequently dried using a vacuum 
concentrator with a cold trap. Phosphopeptides were eluted twice in 150 μl of 50 mM 
ammonia solution (NH4OH) (pH 10). The combined eluates were dried using a vacuum 
concentrator with a cold trap and then cleaned up using a C18 StageTip desalting (3M 
Empore™). 
2.2.5.5.3 Tandem Mass Tagging (TMT) Labelling 
 TMT labelling for the enriched phosphopeptides was performed using the 6-plex 
TMT reagent (Thermo Fisher Scientific) according to the manufacturer’s protocol 
Briefly, dried peptides were resuspended in 100 μl of 200 mM HEPES pH 8, vortexed 
and centrifuged at 4000 rpm for 3 min. TMT reagents (0.8 mg) were dissolved in 41 μl 
ACN and added to the peptides (12 μl per sample). After 1 h incubation at room 
temperature, reactions were quenched by adding 8 μl of 5% hydroxylamine followed by 
a 30-min incubation at room temperature. Labelled peptides were combined, acidified 
with 20 μl of 20% formic acid (FA) pH 2 and concentrated with C18 SPE on Sep-Pak 
cartridges (Waters).  
2.2.5.5.4 LC-MS/MS analysis 
TMT labelled phoshopeptides were dissolved in 3% ACN/0.1% TFA and then loaded on 
C18 trap column with 3 % ACN/0.1%TFA at a flow rate of 5 μl/min. Peptide separations 
were performed over EASY-Spray column (C18, 2 µm, 75 mm × 50 cm) with an 
integrated nano electrospray emitter at a flow rate of 300 nl/min. The LC separations were 
performed with a Thermo Dionex Ultimate 3000 RSLC Nano liquid chromatography 
instrument. Peptides were separated with a 220-min segmented gradient as follows: 3%–
25% buffer B in 175 min, 25%–35% buffer B for 30 min, 35%–99% buffer B for 5 min, 
followed by a 10 min 99% wash. Eluted peptides were analyzed on an Orbitrap Fusion 
Tribrid platform with instrument control software version 3.0. The mass spectrometer 
was operated in data-dependent most intense precursors Top20 mode. The survey scan 
was acquired from m/z 400 to 1600 with a resolution of 120,000 resolving power with 
AGC target 200,000. The maximum injection time for full scan was set to 100 ms. The 
MS/MS analyses were performed by 1.6 m/z isolation with the quadrupole, normalised 
HCD collision energy of 37.5% and analysis of fragment ions in the Orbitrap using 60,000 
resolving power with auto normal range scan starting from m/z 110. Dynamic exclusion 
was set to 35 seconds. Monoisotopic precursor selection was set to peptide, maxium 
injection time was set to 110 msec. AGC target was set to 50,000. Charge states unknown 
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and 1 or higher than 7 were excluded. LC-MS/MS was performed by Dr Julien Peltier 
(previously University of Dundee; currently Newcastle). 
2.2.5.5.5 Data processing and analysis 
 Proteome Discoverer was used for processing the collected MS raw data. The raw 
data were searched against Uniprot human database (70,947 entries, downloaded on 
March 10, 2017) using MaxQuant (Cox and Mann, 2008). The precursor and fragment 
mass tolerances were set to 10 ppm and 0.01 Da, respectively. A maximum missed 
cleavages for trypsin digestion was set to 2. The cysteine carbamidomethylation and TMT 
modified N-term and Lysine residue were set as fixed modification, while methionine 
oxidation, asparagine and glutamine deamidation were set as variable modifications. 
False discovery rate (FDR) of peptide spectrum matches and identified results were 
validated by the Percolator algorithm at 1% based on q-values. The phosphopeptides were 
quantified using the intensity of TMT reporter ions. Data were further analysed with 
Perseus software and figures were made using Prism6. Analysis was performed by Dr 
Julien Peltier (previously University of Dundee; currently Newcastle). 
2.2.6 Statistical analysis  
All experiments have a minimum of three biological replicates. Additionally, 
luciferase qPCR experiments have three or four technical repeats for each biological 
replicate, respectively unless stated otherwise. Data are presented as the mean with error 
bars indicating the standard error of the mean, unless stated otherwise in figure legends. 
For correlation analyses, Pearson’s coefficient was used, as long as data were normally 
distributed. Statistical significance of differences between experimental groups was 
assessed with Student’s t-test or ANOVA with post-hoc Bonferroni Correction, unless 
stated differently in figure legends, using Prism6 software. Differences in means were 
considered significant if p<0.05. All Western blots and IF images are shown as 
representatives. Quantification of the western blots was performed using ImageJ 
software. 
  
77 
 
3. PAWS1 controls Wnt signalling through association 
with CK1α 
 
3.1 Introduction 
 At the beginning of this research project, the only information on the molecular 
function of PAWS1 was limited to its characterisation by the Sapkota lab as a novel 
mediator of the non-canonical BMP signalling pathway. BMP and Wnt signalling 
pathways play crucial roles in shaping the body axis during embryogenesis (De Robertis 
and Kuroda 2004). Because PAWS1 was established as a SMAD1 interactor and was 
shown to be phosphorylated by BMPR1 in response to BMP, its potential role during 
Xenopus embryonic development was investigated. Remarkably, microinjection of 
PAWS1 mRNA at the early blastula (4-cell) stage of the Xenopus embryos led to the 
formation of a complete secondary body axis at the tadpole stage (Fig 3-1), whereas 
PAWS1 depletion with PAWS1 morpholinos caused embryonic lethality. Such 
phenotypes are mainly associated with either inhibition of BMP signalling or activation 
of the Wnt signalling pathway (see 1.4). The observations that PAWS1 played a 
significant role in dorsoventral patterning during embryogenesis prompted the 
investigation into the molecular role of PAWS1 in BMP and Wnt signalling.  
The activation of BMP signalling results in changes in gene transcription via a 
signalling cascade, which involves the phosphorylation of SMAD1/5/8 proteins. As 
mentioned in the Introduction, PAWS1 did not appear to influence the canonical BMP 
signalling pathway, as the BMP-induced phosphorylation of SMAD1 and most of the 
BMP-target gene transcription was unaffected by knock-down or overexpression of 
PAWS1 (Vogt, Dingwell et al. 2014). However, since the previous research relied on 
PAWS1 overexpression or siRNA technologies, one of the aims of this chapter is to 
validate these findings in PAWS1 knockout cells.  
Wnt signalling, which encompasses a complex network of many components and 
modulators, plays a fundamental role in regulation of embryogenesis, organogenesis and 
adult tissue homeostasis. Perturbation of different components leading to imbalances in 
the Wnt signalling cascade result in tumorigenesis (see 1.5.3.5). A hallmark of the Wnt 
signalling activation is the accumulation of non-phosphorylated β-catenin in the cytosol 
and its translocation in the nucleus, where it regulates the transcription of several 
Wnt-target genes, such as AXIN2 (Polakis 2012). Therefore, two methods to monitor Wnt 
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signalling activation are by detecting the non-phosphorylated β-catenin at S45 and T41 
using the so-called active β-catenin monoclonal antibody (van Noort et al., 2002) and by 
quantifying the relative expression of the AXIN2 mRNA. However, the mechanisms that 
govern the nuclear/cytosolic shuttling of β-catenin are poorly characterised.  
Although Wnt signalling has been studied for over 50 years, and many of the core 
components have been established, many of the regulatory mechanisms remain 
undefined. The main aim of this chapter is to elucidate whether and, if so, how PAWS1 
regulates Wnt signalling. Addressing this aim could not only provide insights into the 
biological function of PAWS1 and the FAM83 proteins but also contribute to a novel 
regulatory node in the regulation of Wnt signalling.  
 
 
Figure 3- 1 PAWS1 causes axis duplication in Xenopus embryos. 
A. Representative images of an uninjected embryo, and embryos injected with 5 pg 
xWnt8 mRNA or 250 pg xPAWS1 mRNA or at the ventral blastomeres of the 4-
cell stage embryos. Representative images were taken at the tadpole stage (x= 
Xenopus). (Performed by K. Dingwell, The Francis Crick Institute, London). 
B. Quantification of (A). Complete axis denotes embryos with a secondary axis with 
a cement gland, while a partial axis does not. (Performed by K. Dingwell, The 
Francis Crick Institute, London). 
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3.2 Results 
3.2.1 PAWS1 does not inhibit canonical BMP signalling 
To investigate if PAWS1 exerts its effect on inducing a secondary axis in Xenopus 
embryos by inhibiting BMP signalling, a series of experiments in dissociated animal caps 
were performed (Fig 3-2; K. Dingwell). It was found that over-expression of xPAWS1 
did not inhibit BMP-induced nuclear translocation of SMAD1, nor did it affect the 
expression of the BMP-target genes Msx-1 and Vent1 (Fig 3-2A, B; K. Dingwell). These 
results indicated that the ability of PAWS1 to induce secondary axes in Xenopus embryos 
does not occur through inhibition of canonical BMP pathway. 
 To further explore if PAWS1 impacts BMP signalling in cells, CRISPR/Cas9 
(clustered regularly interspaced short palindromic repeat (CRISPR) associated protein 9 
(Cas9)) technology was employed for knocking out the endogenous PAWS1 gene.  
CRISPR/Cas9 has been widely applied to successfully knock out genes of interest in 
cultured cells and in mice (Cong, Ran et al. 2013, Mali, Yang et al. 2013). Briefly, this 
method employs a guide RNA (gRNA), designed to specifically target the gene of 
interest, which directs the Cas9 endonuclease at the target site to create a double-stranded 
DNA break (DSB), thereby disrupting the gene sequence. The two strands are then re-
ligated via the non-homologous end-joining repair pathway, which results in repair by 
random insertion or deletion events at the DSB. This results in frameshifts and potentially 
creates both alleles displaying premature stop codons so that the target gene is knocked 
out. Dr T. Cummins employed this technology to knock out PAWS1 (Cummins, Wu et 
al. 2018) from U2OS cells that stably express Cas9 after induction with doxycycline 
(Munoz, Szyniarowski et al. 2014). CRISPR/Cas9 targeting of exon 2 of the PAWS1 gene 
(Fig 3-3A) resulted in PAWS1 loss from both alleles, which was verified by Western 
blotting and genomic sequencing. 
 Consistent with the data generated from Xenopus, PAWS1 loss had no significant 
effect on BMP-induced phosphorylation of SMAD1 at S463/S465 (Fig 3-3B). Similarly, 
stable PAWS1 introduction in PAWS1-/- cells, which resulted in higher PAWS1 protein 
expression compared to the wild type U2OS controls, did not alter the BMP-induced 
phosphorylation of SMAD1 (Fig 3-3B) nor the TGFβ-induced phosphorylation of 
SMAD2 and SMAD3 at S465/467 and S423/425, respectively (Fig 3-3B). Furthermore, 
BMP stimulation induced the transcription of the endogenous BMP-target gene ID1 in 
both wild type and PAWS1-/- cells, confirming that PAWS1 does not significantly 
regulate canonical BMP signalling (Fig 3-3C). 
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Figure 3- 2 PAWS1 does not affect BMP signalling pathway in Xenopus embryos 
A. Embryos were injected into the animal pole of both blastomeres at the 2-cell stage 
with a total of either 1 ng of BMP4 or 1 ng BMP4 and 500 pg of Myc-tagged (MT) 
xPAWS1 mRNAs. Dissociated animal cap cells were stained with antibodies 
against MYC-tag (xPAWS1, green) and for phospho-SMAD1 (p-SMAD1, red). 
(by K. Dingwell, The Francis Crick Institute, London). 
B. Animal cap cells injected at the 2-cell stage with a total of either 1 ng of BMP4 or 
1ng BMP4 and 500 pg of MTxPAWS1 mRNA and the expression of the ventral 
genes Vent1 (black bars) and msx-1 (grey bars) was quantified by RT-PCR (n=3; 
Error bars represent ±SD, ns: not significant, t-test, unpaired, two-tailed with 
unequal variance). (by K. Dingwell, The Francis Crick Institute, London). 
  
81 
 
Figure 3- 3 BMP signalling is not compromised in U2OS PAWS1-/- cells  
A. Schematic illustration of the strategy used for the generation PAWS1-/- cells by 
CRISPR/Cas9 genome editing. (sgRNA: single guide RNA) 
 
B. U2OS wild type (WT), PAWS1-/- and PAWS1WT rescue cells were serum-
deprived for 16 hours. Cells were subsequently stimulated with either 6.25 ng/mL 
BMP2 or 50 pM TGFβ1 for 1 hour prior to lysis. Cell extracts (15 μg) were 
resolved by SDS-PAGE and immunoblotted with the indicated antibodies. Note 
that the upper band in the pSMAD3 blot is a result of the antibody cross-reacting 
with pSMAD1. (by L. Hutchinson). 
 
C. U2OS wild type (WT) and PAWS1-/- cells were serum-deprived for 16 hours. 
Subsequently, cells were either stimulated with 6.25 ng/mL for 6 h or left 
untreated prior to lysis. ID1 gene transcription was examined by qPCR. Transcript 
expression data are represented as fold induction over unstimulated control and 
are internally normalized to β-actin mRNA control. (n=3; Dots represent technical 
replicates; Error bars represent ±SEM of the 3 biological replicates). 
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3.2.2 PAWS1 enhances canonical Wnt signalling 
 Since PAWS1 had no inhibitory effect on canonical BMP signalling that could 
account for the axis duplication phenotype it caused in Xenopus embryos, its role in 
activating canonical Wnt signalling in human cells and in embryos was investigated. First, 
the ability of PAWS1 to impact Wnt/β-catenin reporter activity (see 1.5.3.4) was 
examined in human cells (Fig 3-4A). Control plasmids or those encoding for PAWS1 
were overexpressed in U2OS osteosarcoma and HEK293 embryonic kidney cells, 
together with the TOPflash reporter plasmid, encoding for Firefly luciferase, and a 
plasmid encoding for Renilla luciferase as an internal control for transfection efficiency. 
Because the Firefly requires luciferin as a substrate while Renilla requires coelenterazine, 
the two enzymes can be used together in dual-reporter assays, while the normalised ratio 
of the two luciferase activities represents the relative Wnt/β-catenin reporter activity 
(Inouye and Shimomura 1997, Grentzmann, Ingram et al. 1998). The cells were then 
stimulated with Wnt3A or control-conditioned medium for 12 h prior to lysis and 
measurement of luciferase activities. As expected, in both cell lines transfected with 
control plasmids, Wnt3A induced TOPflash reporter activity compared to the untreated 
controls. LiCl, which potently inhibits GSK3 activity thereby stabilising β-catenin (Klein 
and Melton 1996), induced maximal reporter activity (Fig 3-4B). Overexpression of 
PAWS1 in both cell lines enhanced both basal and Wnt-induced luciferase reporter 
activity (Fig 3-4B), suggesting that PAWS1 overexpression activates Wnt signalling in 
human cells. PAWS1 overexpression had no additive effect on LiCl-induced luciferase 
activity, most likely because LiCl alone achieves maximal activation of the Wnt pathway.    
 In agreement with the results obtained from human culture cells, overexpression 
of xPAWS1 in isolated Xenopus animal cap cells resulted in increased stabilisation of the 
co-expressed GFP-β-catenin compared to the stabilised GFP-β-catenin in the absence of 
xPAWS1 (Fig 3-5A, B; K. Dingwell). Likewise, animal caps injected with xPAWS1 
alone activated the mRNA expression of the Wnt target Siamois and the dorsalising factor 
Chordin, demonstrating that PAWS1 can ectopically activate the canonical Wnt pathway 
(Fig 3-5C; K. Dingwell).  
 To identify the domain of PAWS1 that is required for Wnt activation, different 
xPAWS1 fragments (Fig 3-6A) were tested for their ability to induce Siamois expression 
in naïve animal caps and form a secondary axis when injected into a ventral blastomere. 
The deletion of the PAWS1 c-terminal domain (722, 710), which lacks the BMPRI 
phosphorylation sites S711/S714/S715 (equivalent to human PAWS1 S610/S613/S614) 
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had no effect on its activity (Fig 3-6B, C), suggesting that the BMPRI phosphorylation 
sites of PAWS1 are not required for PAWS1 activity. Deletion or partial deletion of the 
DUF1669 domain (291 and 151 respectively) eliminated the axis-inducing activity 
suggesting that the DUF1669 domain is essential. However, expression of the DUF1669 
domain fragments (DUF, 351) were unable to induce a secondary axis. Only a PAWS1 
fragment spanning residues 1-583, which includes ~200 C-terminal residues after the 
conserved DUF1669 domain displayed axis-inducing activity and Siamois expression, 
indicating that the DUF1669 domain is necessary but not sufficient to activate Wnt 
signalling (Fig 3-6). 
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Figure 3- 4 PAWS1 overexpression enhances canonical Wnt signalling in human 
U2OS and HEK293 cells.  
A. Schematic representation of TOPflash luciferase assay used to measure Wnt 
signalling activity. Cells are transfected with a plasmid that encodes a sequence 
with 7 TCF/LEF elements upstream of a firefly luciferase reporter. Treatment with 
agonists of the canonical Wnt signalling such as Wnt3A-conditioned medium or 
GSK3 inhibitors, results in the binding of β-catenin to the TCF/LEF repeats and 
the promotion of luciferase expression. Incubation of cell extracts with Luciferin 
results in light emission which is measured with a luminometer. FOPflash vector 
with mutated the TCF/LEF sites is used as a negative control. 
B. HEK293 and U2OS cells were transfected with cDNA plasmids encoding PAWS1 
or an empty vector as a control together with plasmids encoding TOPflash 
luciferase and Renilla luciferase (used as transfection control). The luciferase 
activities were measured after treatment with either control conditioned medium 
(L-CM), Wnt3A conditioned medium (L3-CM) or 20 mM LiCl for 12 h. Data are 
normalised to Renilla luciferase internal control. (n=4; Error bars represent 
±SEM). 
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Figure 3- 5 PAWS1 activates canonical Wnt signaling in dissociated Xenopus animal 
caps.  
A. Xenopus embryos were left uninjected or injected at the 1-cell stage with 250 pg 
of xPAWS1_mCherryHA mRNA. At stage 8.5 animal caps were collected from 
injected and uninjected embryos and cultured until control embryos reached stage 
10. Extracts were immunoblotted with the indicated antibodies. (by K. Dingwell, 
The Francis Crick Institute, London). 
 
B. Dissociated animal cap cells injected with either 50 pg of β-catenin_GFP or with 
50 pg β-catenin_GFP and 250 pg xPAWS1_mCherryHA mRNAs were plated on 
coverslips and imaged by confocal microscopy. Only β-catenin_GFP cells co-
injected with xPAWS1_mCherryHA mRNA accumulated robust levels of β-
catenin in the nucleus. (by K. Dingwell, The Francis Crick Institute, London). 
 
C.  Embryos were injected at the 1-cell stage with 250 pg of xPAWS1 mRNA and 
then at stage 8.5, animal caps were collected from injected and uninjected 
embryos and assessed for Chordin and Siamois expression by qPCR.  (n=3; Error 
bars represent ±SD).  (by K. Dingwell, The Francis Crick Institute, London). 
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Figure 3- 6 The DUF1669 domain is necessary but not sufficient to induce a 
secondary axis and activate Siamois expression in Xenopus embryos  
A. Schematic representation of the xPAWS1 fragments used in B and C. 
B. 250 pg of xPAWS1 mRNAs encoding N, and C-terminal truncation fragments 
were injected into one ventral blastomere at the 4-cell stage. Axis induction was 
assessed at stage 28. (by K. Dingwell, The Francis Crick Institute, London). 
C. Embryos were injected at the 1 cell stage with 250pg of Myc-tagged 
(MT)_xPAWS1 mRNAs encoding N- and C-terminal mutants and then at stage 
8.5 animal caps were collected and assessed for Siamois expression by qPCR 
(n=3; Error bars represent ± SD). (by K. Dingwell, The Francis Crick Institute, 
London). 
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3.2.3 PAWS1 deficiency attenuates Wnt signalling  
 After demonstrating the impact of PAWS1 overexpression on Wnt activation in 
human cells and Xenopus embryos, the next aim was to study how loss of PAWS1 
expression influences Wnt signalling. In comparison to wild type U2OS cells, 
Wnt-induced TOPflash luciferase activity in PAWS1-/- cells was substantially reduced 
(Fig 3-7A). As expected, the FOPflash luciferase reporter activity, which was employed 
as a negative control, was not enhanced by Wnt stimulation (Fig 3-7A).  
Next, the expression of the endogenous Wnt-target genes AXIN2 and CYCLIN D1 in wild 
type and PAWS1-/- U2OS cells was examined by qPCR. In wild type U2OS cells, the 
expression of AXIN2 and CYCLIN D1 transcripts was significantly enhanced over a time 
course of Wnt stimulation (Fig 3-7B). In contrast, under these conditions, the 
Wnt-induced expression of these transcripts was significantly inhibited in PAWS1-/- 
U2OS cells (Fig 3-7B). The previous observation that PAWS1-/- U2OS cells activated the 
mRNA transcription of ID1 in response to BMP stimulation (Fig 3-3C), excluded the 
possibility of PAWS1 being a general activator of transcription, validating that loss of 
PAWS1 does not affect global gene transcription. 
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Figure 3- 7: Loss of PAWS1 expression attenuates cell responses to Wnt signalling  
A. As in Fig 3-4B, except PAWS1WT and PAWS1-/- U2OS cells were used. Relative 
TOPflash luciferase activity of PAWS1WT and PAWS1-/- U2OS cells after 
treatment with conditioned media (L-CM) or Wnt3A conditioned media (L3-CM) 
are plotted. 
B. Wnt3A-induced activation of the endogenous target genes AXIN2 and Cyclin D1 
was examined by qPCR at the indicated time points in PAWS1WT and 
PAWS1-/- U2OS cells. Transcript expression data are represented as fold induction 
over unstimulated control and are internally normalized to β-actin control. (n=3; 
Error bars represent ±SEM; ***: p<0.0001). 
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3.2.4 PAWS1 functions downstream of the β-catenin destruction complex 
To assess whether the loss of PAWS1 had an impact on the known components 
of the Wnt signalling cascade, the levels of the endogenous proteins were analysed by 
Western blotting in a time course experiment using control or Wnt3A conditioned 
medium (Fig 3-8). To exclude the potential off-target effects of using conditioned 
medium, cells that had been grown in regular growth medium and conditioned medium 
for the longest time point of the experiment were used as controls. As discussed in the 
Introduction, Wnt binding to LRP6 causes its phosphorylation at Ser1490, which then 
triggers a cascade of events leading to the stabilisation and accumulation of β-catenin. No 
significant differences in the Wnt-induced levels of phospho-LRP6 or in its 
phosphorylation kinetics were observed between wild type and PAWS1-/- cells (Fig 3-8). 
This indicated that the loss of PAWS1 does not affect the phosphorylation or activation 
of the Wnt receptor. Hence, the decreased responses to Wnt signals observed in PAWS1-
/- cells must be due to downstream events. Next, the post-translational modification of β-
catenin was examined since elevated phosphorylation levels can lead to enhanced 
proteasomal degradation and inhibition of Wnt-target genes activation. Wnt stimulation 
induced an acute loss of both CK1 (pS45) and GSK3 (pS33/pS37/pT41) phospho-
residues on β-catenin within 30 min in both wild type and PAWS1-/- cells, while the levels 
then slowly recovered in a time-dependent manner (Fig 3-8). 
To confirm that there was no effect of PAWS1 on the Wnt-induced cytosolic 
accumulation of β-catenin, β-catenin stabilisation assay was performed. As shown in Fig 
3-9, no difference in total β-catenin protein levels were observed between wild type and 
PAWS1-/- cells after 6h of stimulation with control- or Wnt3A-conditioned medium. 
Similarly, PAWS1 loss had no substantial impact on the phosphorylation of β-catenin at 
CK1 and GSK3 sites (Fig 3-9). Wnt stimulation resulted in a slight decrease of the GSK3 
phospho-sites (S33/S37/T41) on β-catenin in both wild type and PAWS1-/- cells, with no 
substantial differences between the cell lines. The CK1 phospho-site (S45) on β-catenin 
was also not substantially altered under the conditions tested. In addition to β-catenin, the 
protein levels of the destruction complex GSK3, Axin2 and CK1α were also examined. 
No differences between wild type and PAWS1-/- cells were observed under basal 
conditions in regard to GSK3 protein levels and, Wnt stimulation had no effect either (Fig 
3-9). Interestingly, the Wnt-induced elevation of the protein levels of Axin2 was less 
pronounced in PAWS1-/- cells compared to the wild type cells (Fig 3-9). The most striking 
result to emerge from this data was that the protein levels of CK1α in PAWS1-/- cells were 
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substantially lower compared to wild type cells under both basal and Wnt-stimulated 
conditions (Fig 3-9). However, the lower CK1α levels in PAWS1-/- cells did not result in 
lower phosphorylation levels of its reported physiological substrate pS45-β-catenin (Liu 
et al., 2002). This could suggest either that the lower CK1α levels do not mean lower 
levels of its enzymatic activity or that other CK1 isoforms might mediate, or compensate 
CK1α for the phosphorylation of β-catenin at S45. Nevertheless, the data indicated that 
CK1α might be a promising factor that could account for the role of PAWS1 in Wnt 
signalling. Overall, these results support the hypothesis that PAWS1 functions at the level 
of the β-catenin destruction complex or downstream of it and that there is an association 
between PAWS1 loss and a decrease in the protein levels of CK1α. 
To further elucidate where within the Wnt signalling cascade that PAWS1 acts at, 
epistasis experiments were performed in Xenopus embryos. First, naïve animal caps were 
injected with xWnt8 or xPAWS1 mRNA with or without co-injection of the dominant-
negative Wnt receptor Lrp6m5 and the induction of the direct Wnt-target gene Siamois 
was tested. Injection of either xWnt8 or xPAWS1 induced Siamois expression whereas 
injection of Lrp6m5 alone or in the presence of xWnt8 completely inhibited Siamois 
expression in animal caps. Notably, Lrp6m5 was unable to inhibit Siamois expression 
injected with xPAWS1 suggesting again that PAWS1 acts downstream of the Wnt 
receptor (Fig3-10A).  
Next, the impact of the selective GSK3 inhibitor CHIR99021 on Wnt activity in 
wild type and PAWS1-/- U2OS cells using TOPflash assay, was employed. Inhibition of 
GSK3 activity results in accumulation of β-catenin by preventing its phosphorylation and 
subsequent proteasomal degradation. GSK3 inhibition yielded maximal induction of Wnt 
reporter activity in wild type cells but failed to activate the reporter activity to the same 
extent in PAWS1-/- cells (Fig 3-10B). Collectively these data supported the observation 
that PAWS1 acts downstream of both the Wnt receptor and the destruction complex. 
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Figure 3- 8 PAWS1 loss does not affect the phosphorylation and protein levels of the 
major Wnt components.  
U2OS wild type (WT) and PAWS1-/- cells were grown in either Wnt3a or control 
conditioned medium (CM) for the indicated time points prior to lysis. Cell extracts (15 
μg of protein) were subjected to SDS-PAGE followed by Western blot analysis with the 
indicated antibodies. 
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Figure 3- 9 Loss of PAWS1 does not affect the Wnt-induced cytosolic accumulation 
of total β-catenin protein.  
U2OS wild type (WT) and PAWS1-/- cells were grown in control- or Wnt3A-conditioned 
medium for 6 hours and lysed in lysis buffer with or without detergent to get the total 
lysate and the cytosolic fraction only respectively. Cell extracts (20 μg of protein) were 
resolved by SDS-PAGE followed by immunoblotting with the indicated antibodies. 
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Figure 3- 10 PAWS1 appears to function at the level of the destruction complex. 
A. Xenopus embryos were injected at the 1-cell stage with the indicated mRNAs and 
then at stage 10 animal caps were assessed by qPCR for the expression of Siamois. 
(n=3; Error bars represent ±SD). 
B. Relative TOPflash luciferase activity of PAWS1WT and PAWS1-/- U2OS cells after 
treatment with either conditioned medium (L-CM), WNT3A conditioned medium 
(L3-CM) or 5μM of the GSK3 inhibitor CHIR99021 for 6 h. Data were normalized 
to Renilla internal control (n=4; Error bars represent ±SEM). 
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3.2.5 PAWS1 interacts with CK1α 
  To uncover the mechanisms by which PAWS1 activates the Wnt signalling, a 
proteomic approach was employed to identify potential interactors of endogenous 
PAWS1 was employed. First, U2OS cells were introduced with a GFP tag at the 
C-terminus of the endogenous PAWS1 gene on both alleles using CRISPR/Cas9 genome 
editing. In Xenopus laevis embryos, both untagged C-terminally GFP-tagged PAWS1 
caused axis duplication (personal communication with K. Dingwell), suggesting that 
adding the GFP tag on PAWS1 at the C-terminus still retained Wnt-inducing activity. To 
generate PAWS1-GFP knockin cells, a modified version of the CRISPR/Cas9 technology 
that was described earlier for the generation of PAWS1-/- cells (see 3.2.1) was followed. 
Briefly, a pair of guide (sense and anti-sense) RNAs (gRNAs) targeting a genomic 
sequence just upstream of PAWS1 stop codon and a GFP-donor guide to insert GFP 
in-frame to the C-terminus of PAWS1 were designed by T. Macartney (DSTT, 
MRC-PPU) (Fig 3-11A). In order to reduce potential off-target mutagenesis, Cas9 
harbouring the D10A mutation was encoded in the same plasmid carrying the anti-sense 
gRNA plasmid. Cas9 D10A causes single-strand nicks at the target sites, which two nicks 
close to the target site ensuring target-specific double-strand breaks (Ran et al., 2013). 
The nicks are repaired via homologous DNA recombination using the donor DNA as a 
repair template. Homozygous GFP-positive cells were verified by Western blotting and 
genomic sequencing which confirmed the GFP incorporation in frame with the PAWS1 
gene (Fig 3-11B-F). 
Anti-GFP immunoprecipitations (IP) were performed in the PAWS1GFP/GFP cell 
extracts to pull down endogenous PAWS1-GFP and its interacting partners. Endogenous 
PAWS1-GFP was visualized by Coomassie staining in the SDS-PAGE gel and its identity 
was verified by mass-spectrometry (MS) (Fig 3-12A) Among the interacting partners 
detected (Fig 3-12C), casein kinase 1α isoform (CK1α), which is also visible by 
Coomassie staining, was identified as the major interactor of PAWS1 by mass-
spectrometry (Fig 3-12A-D). Some of the peptides that were identified by MS and were 
assigned to CK1α are shared with another CK1 isoform, CK1αL (Fig 3-12E). Since no 
peptides exclusive to CK1αL were detected (Fig 3-12D, E), it is unclear if this isoform is 
expressed in U2OS cells. With the lack of antibodies that specifically recognise CK1αL 
the focus of this research was shifted towards CK1α.  
The interaction was verified by Western blotting in which endogenous CK1α was 
detected in anti-GFP IPs from PAWS1GFP/GFP knockin cells but not from PAWS1-/- U2OS 
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cells (Fig 3-13A). Similarly, endogenous PAWS1 was detected in IPs of endogenous 
CK1α from wild type but not PAWS1-/- U2OS cells (Fig 3-13B). As expected, control 
IgG IPs from either cell line did not pull down either PAWS1 or CK1α (Fig 3-13B). 
Stimulating cells with Wnt3A did not affect the ability of PAWS1 to interact with 
endogenous CK1α (Fig 3-13C), suggesting that the interaction between PAWS1 and 
CK1α is constitutive and does not depend on Wnt stimulation. 
The CK1 branch of the human protein kinases also includes CK1 γ1, γ2, and γ3 
isoforms, tau tubulin kinases (TTBK) 1 & 2 and vaccinia related kinases (VRK) 1-3 
(Manning, Whyte et al. 2002). In cell extracts, under co-expression conditions in which 
PAWS1 interacted with CK1α, no interaction between PAWS1 and either TTBK2 or 
CK1γ were detected (Fig 3-13D). CK1δ isoform was found to interact with PAWS1 under 
overexpression conditions (Fig 3-13D) but since it was not detected in endogenous 
PAWS1 IPs (Fig 3-12C), this result should be considered with caution.  
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Figure 3- 11 Generation of PAWS1-GFP expressing cells under the endogenous 
promoter  
A. Schematic illustration of the CRISPR/Cas9 genome editing strategy followed to 
generate PAWS1-GFP knock-ins in U2OS cells. A pair of guide RNAs, which 
recognise a genomic sequence upstream of the stop codon of PAWS1 gene, was 
used in combination with a donor vector, which inserts GFP in frame at the 
C-terminus of PAWS1. 
B. Western blot screen of PAWS1-GFP knock-in clones. A homozygous GFP-
knockin would shift the apparent molecular weight of endogenous PAWS1-GFP 
equivalent to that of both proteins, as recognized by the anti-PAWS1 antibody. 
C. Cell extract from clone 17 from (B) (PAWS1GFP/GFP) was compared with the wild 
type and PAWS1-/- cell extract, confirming that the gene in the reverse strand of 
PAWS1, SLC5A10 is not disturbed. 
D. Schematic representation of the predicted genomic PCR products that were 
amplified with a pair of primers targeting the indicated regions. 
 
E. DNA was extracted from U2OS wild type (WT) and PAWS1-GFP knock-in cells 
(clone 17) a pair of primers was used to amplify the genomic region by PCR, as 
shown in (D), followed by agarose gel electrophoresis.  
F. Sequence alignment of four independent PCR products from (E), showing that the 
GFP gene (in green) was integrated in frame with PAWS1. Alignment was 
performed in Jalview 2.10.3 with ClustalO.  
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Figure 3- 12 PAWS1 interacts with CK1α at the endogenous level.  
A. GFP pull downs from U2OS PAWS1-/- and PAWS1GFP/GFP cells were resolved by 
SDS-PAGE and the gel was stained with Coomassie. Each lane was cut in 6 
pieces, which were subsequently processed for protein identification by mass-
spectrometry.  
B. Mass fingerprinting analysis of PAWS1-GFP interactors from (A) identified 
CK1α as a major interactor. The table shows total spectral counts for PAWS1 and 
CK1α tryptic peptides identified in anti-GFP IPs.  
C. PAWS1-GFP interacting proteins were plotted using total spectral counts for 
selected individual protein. Total spectral counts are defined as the sum of all the 
spectra associated with a specific protein within a sample, which includes also 
those spectra that are shared with other proteins. A spectral count of 3 or more in 
PAWS1-GFP IPs and no spectral counts in GFP control IPs were set as threshold 
for inclusion. The spectral counts for PAWS1 were excluded from the graph. 
D. The highlighted tryptic peptides identified by mass-spectrometry on CK1α (top 
panel) and on CK1α (bottom panel) indicate the overall protein coverage. The 
images were obtained using Scaffold V4.3 analysis of the LC-MS/MS data. 
E. Same as (D) but for CK1αL. 
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Figure 3- 13 Validation of the PAWS1:CK1α interaction 
A. GFP pull downs from U2OS PAWS1-/- and PAWS1GFP/GFP cells were resolved by 
SDS-PAGE and analysed by Western blot using the indicated antibodies. 
B. Anti-CK1α IPs from U2OS PAWS1WT and PAWS1-/- cells were resolved by 
SDS-PAGE and analysed by Western blot using the indicated antibodies. 
 
C. PAWS1 interacts with CK1α independent of Wnt stimulation. Stable U2OS Flp-
In Trex cells were subjected to 20 ng/ml doxycycline for inducing PAWS1-GFP 
expression or GFP expression alone for 24 h. Wnt3A or control medium was 
added to the cells for 6 h before lysis. 20 mg of cell extract was subjected to 
GFP-trap IP. Input (20μg of protein), 5% of the pull down and flow-through 
extract (20 μg of protein) were subjected to SDS-PAGE followed by Western blot 
analysis with the indicated antibodies. 
 
D. The indicated FLAG or HA-tagged CK1 family members were co-expressed with 
PAWS1-GFP in U2OS cells. Input extracts and GFP-IPs were resolved by 
SDS-PAGE followed by Western blot analysis with the indicated antibodies. 
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3.2.6 Mapping the interaction sites between PAWS1 and CK1α 
 Having verified the interaction between PAWS1 and CK1α, the next aim was to 
identify the sites on the PAWS1 protein sequence that bind to CK1α. First, the minimal 
domain within PAWS1 that mediates the interaction with CK1α was determined. For this, 
truncated fragments of Myc-tagged xPAWS1 were co-expressed with full-length 
HA-tagged CK1α in U2OS PAWS1-/- cells, followed by HA-IPs (Fig 3-14). HA-CK1α 
was able to co-precipitate only those PAWS1 fragments that contained residues 151-291 
within the DUF1669 domain (Fig 3-14), which are equivalent to the human residues 
165-307. 
 Interestingly, within this mapped region, PAWS1 contains an F-x-x-x-F sequence 
motif which, as mentioned in the Introduction, has been reported to be a CK1 docking 
motif in NFAT and PER1/2 proteins (Okamura et al., 2004). To determine if the 
F296-x-x-x-F300 motif within PAWS1 indeed mediates its interaction with CK1α these 
phenylalanine residues were targeted for mutagenesis. Single FLAG-tagged F296A, 
F300A and double F296A/F300A mutants were generated and overexpressed in U2OS 
cells and extracts subjected to IPs using anti-FLAG beads. The locations of the mutated 
residues are indicated in a schematic representation of PAWS1 (Fig 3-15A). As expected, 
endogenous CK1α was detected in anti-FLAG IPs from wild type FLAG-PAWS1 
expressing extracts resulting in an almost complete immuno-depletion of CK1α from the 
flow-through extracts. Endogenous CK1α was also detected in FLAG-IPs from 
FLAG-PAWS1F300A but not from FLAG-PAWS1F296A and FLAG-PAWS1F296A/F300A 
extracts (Fig 3-15B), suggesting F296 in PAWS1 contributed to the association with 
CK1α. For PER1/2, it had previously been shown that both Phe residues within the F-x-
x-x-F motif were essential for interaction with CK1, as mutating either contributed to the 
loss of interaction with CK1 (Okamura, Garcia-Rodriguez et al. 2004). However, for 
PAWS1, the fact that PAWS1F300A was still able to interact with CK1α suggested that 
perhaps the mode of interaction between PAWS1 and CK1α is mediated through a unique 
mechanism. 
 In the light of the resolved structure of the DUF1669 domain of FAM83A, it was 
observed that an Aspartic residue lies very close to the corresponding F300 residue in 
FAM83A and it was hypothesised that it could impact the interaction with CK1α. Indeed, 
mutating the Asp262 to Ala (PAWS1D262A) also abolished the association with CK1α (Fig 
3-15A, B). Collectively, these data demonstrate that PAWS1 interacts with CK1α at the 
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endogenous level and two residues within the DUF1669 domain of PAWS1, D262 and 
F296, individually contribute to the association with CK1α. 
 To test if the interaction between PAWS1 and CK1α was direct, an in vitro 
binding assay was performed. For this GST-PAWS1WT-6xHis and 
GST-PAWS1F296A/F300A were expressed and purified from E.coli. Recombinant 
GST-CK1α had been previously purified by the Protein Production team in DSTT and 
the GST tag was cleaved with PreScission protease.  As seen in Fig 3-15C, a robust 
interaction between PAWS1WT and CK1α was observed but not with GST alone. In 
concurrence with the co-IP experiment from U2OS cell extracts (Fig 3-15B), no CK1α 
was found to bind to PAWS1F296A/F300A. These results indicate that PAWS1 and CK1α 
bind to each other in a direct manner.  
 Next, whether restoration of PAWS1 expression in U2OS PAWS1-/- cells could 
rescue the PAWS1 interaction with CK1α was assessed. To address this, retroviruses 
encoding the PAWS1WT, PAWS1F296A, PAWS1D262A or GFP control were produced in 
HEK293-FT cells and used at different dilutions to infect PAWS1-/- cells. The expression 
of the infected PAWS1 constructs in PAWS1-/- cell extracts was confirmed by Western 
blotting (Fig 3-16A). Dilution of retroviral titre was performed in order to achieve stable 
PAWS1 expression levels in PAWS1-/- cells as close to the endogenous levels seen in 
wild type U2OS cells. However, as seen in Fig 3-16A, PAWS1 is substantially 
over-expressed in the PAWS1-/- cells rescued with dilutions of retroviral infections 
compared to the wild type cells. With the lack of a better method of restoring PAWS1 
expression in PAWS1-/- cells to the endogenous levels, the cell lines which were generated 
using 1:5 dilution of the retroviral titre were selected for all the experiments described in 
this thesis. Fig 3-16B shows that IPs of endogenous CK1α from rescue cell extracts pulled 
down PAWS1 only from PAWS1WT rescue cells but not from the others. No PAWS1 was 
detected in IgG IPs, that were employed as controls (Fig 3-16B). Furthermore, 
immunofluorescence microscopy of the rescue cells showed overlapping cytoplasmic 
staining of PAWS1WT and CK1α, while no overlapping staining was detected between 
PAWS1F296A and CK1α (Fig 3-17; K. Wu). Predictably, no immunofluorescence signal 
for PAWS1 was observed in the PAWS1-/- cells, while CK1α staining in these cells and 
PAWS1F296A rescue was diminished compared to PAWS1WT rescue cells (Fig 3-17; K. 
Wu).  
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Figure 3- 14 The DUF1669 domain of PAWS1 is sufficient in mediating the 
interaction with CK1α.  
The indicated fragments of Myc-tagged PAWS1 (see Fig 3-3A) were co-expressed with 
HA-CK1α in U2OS PAWS1-/- cells for 48 h. Inputs and Anti-HA IPs were subjected 
SDS-PAGE followed by Western blot analysis with the indicated antibodies. 
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Figure 3- 15 Identification of the residues on PAWS1 that are required for CK1α 
interaction  
A.  Schematic representation of PAWS1 indicating the position of key residues that 
were mutated for the following experiments.  
 
B. U2OS cells were transiently transfected with cDNA encoding FLAG-tagged 
PAWS1WT, PAWS1F296A, PAWS1F300A, PAWS1F296A/F300A, PAWS1D262A and 
FLAG-empty vector. Anti-FLAG IPs were immunoblotted with the indicated 
antibodies.  
 
C. PAWS1 forms a direct interaction with CK1α. Glutathione-sepharose raisin was 
loaded with GST-PAWS1WT-6xHis or GST-PAWS1F296A/F300A and used to pull 
down CK1α. GST-empty was used as a negative control. The pull-down products 
were analysed by Western blot using the indicated antibodies. 
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Figure 3- 16 Restoration of PAWS1 expression in PAWS1-/- cells.  
A. U2OS PAWS1-/- cells were infected with retroviruses in order to stably rescue 
cells with GFP-control, PAWS1WT, PAWS1F296A, PAWS1F300A, 
PAWS1F296A/F300A or PAWS1D2626A at the indicated dilutions from retroviral 
medium collected from 293-FT cells. For example, a 1:5 dilution means that the 
infection medium applied to cells contained one portion of retroviral medium 
mixed with four portions of the fresh medium. Puromycin-selected cells were 
lysed and extracts were resolved by SDS-PAGE and analysed by Western blotting 
using the indicated antibodies. Expression levels were compared to endogenous 
PAWS1 levels from wild type U2OS extracts.  
B. Anti-CK1α IPs and IgG-IPs (from 500 μg of protein) from stable U2OS 
PAWS1WT, GFP, PAWS1F296A and PAWS1D262A rescue cells were resolved by 
SDS-PAGE and analysed by Western blotting using the indicated antibodies. 
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Figure 3- 17 PAWS1 interacts and co-localises with CK1α in U2OS cells.  
PAWS1-/- cells in which PAWS1WT or PAWS1F296A expression was restored, were fixed 
for immunofluorescence using antibodies against PAWS1 and CK1α. Scale bar is 20 m. 
(by K. Wu).  
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3.2.7 Interaction between PAWS1 and CK1α is essential for PAWS1-
dependent axis duplication and the activation of Wnt signalling. 
After establishing that PAWS1 interacts and co-localise with CK1α constitutively, 
the role, if any, of the PAWS1:CK1α complex in the activation of Wnt signalling was 
assessed using Xenopus embryos and U2OS cells. First, the role of the association 
between PAWS1 and CK1α in PAWS1-induced axis duplication in Xenopus embryos 
was investigated. PAWS1-induced axis duplication ability was scored at the tadpole 
stage, following microinjection of Xenopus embryos with wild type PAWS1, three 
separate CK1α-interaction deficient PAWS1 mutants (PAWS1D262A, PAWS1F296A, and 
PAWS1F296A/F300A) as well as the PAWS1F300A mutant that still interacts with CK1α (Fig 
3-18A, B). Both PAWS1WT and the PAWS1F300A mutant that interact with CK1α induced 
partial or complete axis duplication in ~80% of embryos. In contrast, the 
CK1α-interaction deficient PAWS1 mutants, PAWS1D262A, PAWS1F296A, and 
PAWS1F296A/F300A failed to induce secondary axes in the embryos (Fig 3-18B). These 
results demonstrate that the interaction between PAWS1 and CK1α is essential for 
PAWS1-mediated axis duplication in Xenopus embryos.  
Second, whether the induction of the Wnt reporter activity in U2OS cells also 
required interaction between PAWS1 and CK1α was investigated. For this, Wnt-reporter 
activity was assessed in wild type, PAWS1-/- as well as PAWS1-/- cells rescued with either 
PAWS1WT or the CK1α-interaction deficient PAWS1F296A mutant. Stimulation of wild 
type cells with Wnt3A substantially enhanced the luciferase reporter activity over 
unstimulated controls, while in PAWS1-/- cells it did not (Fig 3-18C). In PAWS1-/- cells 
rescued with wild type PAWS1, the Wnt3A-induced luciferase reporter activity was 
restored to levels similar to those seen in wild type cells. In contrast, in PAWS1-/- cells 
rescued with the PAWS1F296A mutant, the Wnt3A-induced luciferase reporter activity was 
not restored (Fig 3-18C), suggesting that PAWS1-mediated activation of Wnt signaling 
necessitates its ability to interact with CK1α.  
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Figure 3- 18 PAWS1:CK1α interaction is critical for the activation of Wnt signalling 
in Xenopus embryos and in human cells.  
A. Representative images of an uninjected Xenopus embryo and embryos injected 
with the indicated mRNAs. PAWS1F296A and PAWS1F296A/F300A mutants that do 
not interact with CK1α fail to induce a secondary axis in Xenopus embryos. (by 
K. Dingwell, The Francis Crick Institute, London).  
B. Quantification of (A) with the inclusion of embryos injected with PAWS1D262A. 
Complete axis denotes embryos with a secondary axis with a cement gland, while 
a partial axis does not. 
C. Relative TOPflash luciferase activity of U2OS WT, PAWS1-/-, PAWS1WT and 
PAWS1F296A rescue cells after treatment with control-conditioned media (L-CM), 
Wnt3A-conditioned media (L3-CM) for 16h. (n=3; Error bars Data were 
normalized to Renilla internal control (n=3; Error bars represent ±SEM). 
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3.2.8 PAWS1 does not affect the composition of the destruction complex  
 As mentioned in the Introduction, CK1 isoforms are known to phosphorylate 
many Wnt components, including β-catenin. Although the loss of PAWS1 did not cause 
any apparent changes in the phosphorylation levels of β-catenin (Fig 3-8, 3-9), Wnt 
signalling was clearly attenuated in PAWS1-/- cells after stimulation with 
Wnt3A-conditioned medium or GSK3 inhibition (Fig 3-6, 3-10). Since PAWS1 was 
shown to function at the level of the destruction complex or downstream of it (Fig 3-10), 
co-immunoprecipitation (IP) assays were performed to assess the potential impact of the 
PAWS1:CK1α interaction on the composition of the destruction complex. Initially, 
endogenous CK1α-IPs were performed at an early stage of the Wnt signalling response, 
namely after 30 min and 1 h of Wnt stimulation (Fig 3-19). No significant levels of 
β-catenin were detected in CK1α-IPs with or without Wnt stimulation and no differences 
were observed in WT and PAWS1-/- cells. This result indicated that PAWS1 does not 
affect the interaction between CK1α and β-catenin. This observation is consistent with 
the findings that phosphorylation of β-catenin on CK1 sites remain largely unaltered in 
PAWS1-/- cells compared to wild type cells (Fig 3-8, 3-9).  
Next, endogenous CK1α, Axin1 and β-catenin were immunoprecipitated from 
WT and PAWS1-/- U2OS cell extracts, following 3h treatment with either control or 
Wnt3A-conditioned medium, and their abilities to interact with components of the 
destruction complex were probed by Western blotting. In endogenous CK1α IPs from 
both WT and PAWS1-/- cells, Axin1, GSK3α/β and β-catenin were not detectable, 
regardless of Wnt3A stimulation, while as expected PAWS1 was identified in CK1α IPs 
from WT cells but not PAWS1-/- cells (Fig 3-20). In Axin1 IPs, GSK3α/β were detected 
robustly, while very low levels of β-catenin were also detected, although neither Wnt3A 
treatment nor the PAWS1-status had any effect on these Axin1 complexes (Fig. 3-19). 
Similarly, in β-catenin IPs, low levels of GSK3β, as well as CK1δ and CK1ε but not 
CK1α were detected (Fig 3-21). This might suggest that either the immunoprecipitation 
conditions used here did not favour the stability of the CK1α-binding to the  β-catenin 
destruction complex or that CK1δ and CK1ε may be the kinases that mediate β-catenin 
phosphorylation at Ser45 and not CK1α.  
 In an effort to elucidate the mechanisms of function of the PAWS1:CK1α complex 
in the Wnt signalling pathway, an unbiased proteomic approach was employed. For this, 
U2OS cells that stably express PAWS1-GFP or GFP control upon doxycycline induction 
were stimulated with control or Wnt3A-conditioned medium for 3 h, lysed and extracts 
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subjected to GFP-IPs. Following resolution by SDS-PAGE, the interacting proteins were 
excised, trypsin-digested and identified by mass spectrometry. Other than CK1α and 
CK1αL, no major known components of the Wnt pathway, especially those of the 
destruction complex, were identified under control or Wnt3A-stimulated conditions (Fig 
3-21). Interestingly, some PAWS1 interactors were enriched in Wnt3A-stimulated 
conditions but with much lower abundance than CK1α and CK1αL. However, these 
interactors are not yet known to play roles in the Wnt signalling pathway and still need to 
be validated as PAWS1 interactors at the endogenous level. 
 
 
Figure 3- 19  PAWS1 has no effect the interaction between CK1α and β-catenin. 
 U2OS wild type (WT) and PAWS1-/- (KO) cells were treated with control conditioned 
medium or Wnt3A-conditioned medium and lysed after the indicated time points. 
Extracts (0.5 mg protein) were subjected to IPs using anti-CK1α or pre-immune IgG 
control (10 µg antibodies coupled to 10 µl packed protein-G sepharose beads). IPs were 
resolved by SDS-PAGE and immunoblotted with the indicated antibodies. 
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Figure 3- 20 PAWS1 does not appear to affect the composition of the destruction 
complex upon Wnt signalling activation.  
U2OS wild type (WT) and PAWS1-/- (KO) cells were treated with control conditioned 
medium or Wnt3A-conditioned medium and the extracts (0.5 mg protein) were subjected 
to immunoprecipitation using antibodies against the endogenous CK1α, AXIN1 and 
β-catenin antibodies or anti-rabbit pre-immune IgG as a control (10 µg antibodies coupled 
to 10 µl packed protein-G sepharose beads). IPs were resolved by SDS-PAGE and 
immunoblotted with the indicated antibodies. 
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Figure 3- 21 PAWS1 interactome before and after Wnt3A stimulation 
A. Stable U2OS Flp-In TRex cells were treated with 20 ng/ml doxycycline for 16 
hours, for induction of PAWS1-GFP or GFP-control protein expression for 24 
hours, and with Wnt3A conditioned medium or control medium for 3 hours prior 
to lysis. GFP pull downs were resolved by SDS-PAGE and the gel was stained 
with Coomassie. Each lane was cut in 5 pieces, which were subsequently 
processed for protein identification by Mass fingerprinting analysis. 
B. PAWS1-GFP interacting proteins were plotted using total spectral counts for 
selected individual protein for both control (filled) and Wnt3A (open) conditions. 
Total spectral counts are defined as the sum of all the spectra associated with a 
specific protein within a sample, which includes also those spectra that are shared 
with other proteins. A spectral count of 3 or more in either control or Wnt3A 
condition in PAWS1-GFP IPs and no spectral counts in GFP control IPs were set 
as threshold for inclusion. All proteins, except those indicated with asterisks, were 
identified as endogenous PAWS1GFP/GFP interactors as well (Fig 3-12). 
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3.2.9 The PAWS1:CK1α complex facilitates the nuclear translocation of 
β-catenin upon Wnt stimulation 
  Wnt stimulation results in the accumulation of non-phosphorylated β-catenin, 
which translocates into the nucleus in order to activate the transcription of Wnt-target 
genes. Since the Wnt-induced phospho- and total β-catenin levels in U2OS cell extracts 
did not appear to change substantially to account for the inhibition of Wnt signalling 
caused by the loss of PAWS1, the cytoplasmic and nuclear distribution of β-catenin was 
analysed in wild type, PAWS1-/-, and PAWS1WT and PAWS1F296A rescue U2OS cells 
after 3h of Wnt-stimulation (Fig 3-22A). The levels of the GSK3 and CK1 phospho-
residues on β-catenin, the total levels and the non-phosphorylated - active β-catenin were 
monitored by Western blotting. Compared to wild type and PAWS1WT rescue cells, both 
basal and Wnt-induced levels of β-catenin-pSer45, β-catenin-p/Ser33/Ser37/Thr41, 
active β-catenin and to some extent total β-catenin in nuclear, but not cytoplasmic, 
fractions were markedly lower in PAWS1-/- and PAWS1F296A rescue cells (Fig 3-22A). 
This was particularly evident after quantification of the levels of active β-catenin in each 
fraction relative to that present in the cytoplasmic fraction of WT U2OS cells (Fig 3-22B), 
suggesting that PAWS1 promotes nuclear accumulation of β-catenin.  
Because most of the β-catenin protein has been reported to be associated with the 
plasma membrane, the potential effect of PAWS1-loss on membrane associated pool of 
β-catenin was assessed. Indeed, β-catenin was enriched in the plasma membrane fractions 
and quite substantial amounts were observed in the cytoskeletal fractions, when compared 
to cytoplasmic and nuclear fractions (Fig 3-23). However, neither the loss of PAWS1 nor 
Wnt3A stimulation changed the protein levels of β-catenin in the membrane and 
cytoskeletal fractions (Fig 3-23). Under these conditions, very low levels of PAWS1 and 
CK1α were detected in the membrane and cytoskeletal fractions (Fig 3-23). 
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Figure 3- 22 PAWS1 promotes Wnt signaling through increased accumulation of 
nuclear active β-catenin.  
A. U2OS wild type (WT), PAWS1-/- (KO), PAWS1WT (+WT) and PAWS1F296A 
(F/A) rescue cells were exposed to either Wnt3A or control medium for 3h 
followed by separation and preparation of cytoplasmic and nuclear fractions. The 
extracts were subjected to SDS-PAGE followed by western blot analysis with the 
indicated antibodies. 
B. The fold changes in active β-catenin intensities in each fraction relative to those 
seen in the cytoplasmic fraction of control WT U2OS cells. The intensities of the 
active β-catenin bands in each fraction were quantified by using the ImageJ 
software. 
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Figure 3- 23 PAWS1 does not affect the membrane-associated pool of β-catenin 
U2OS wild type (WT) and PAWS1-/- cells were treated with control (L-CM) or Wnt3A 
conditioned medium (L3-CM) for 3 h and fractionated into cytoplasmic (C), nuclear (N), 
membrane (M) and cytoskeletal (Cs) fractions. Equal volumes of each fraction were 
resolved by SDS-PAGE followed by Western blotting with the indicated antibodies. 
α-tubulin was used as a cytosolic marker, Lamin A/C as a nuclear, LRP6 and EGFR were 
used as membrane markers and Vimentin was used as a cytoskeletal marker. 
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3.3 Discussion  
 In this chapter, a novel role for the poorly characterised protein PAWS1 in the 
activation of the canonical/β-catenin-dependent Wnt signalling has been presented. 
Canonical Wnt signalling plays critical roles during embryogenesis where together with 
the BMP signalling it shapes the formation of the body axis. PAWS1 was previously 
identified as an interactor of the transcription factor SMAD1 in the BMP signalling 
pathway (Vogt, Dingwell et al. 2014). It was shown to mediate the transcription of a 
subset of non-canonical (SMAD4-independent) BMP-target genes but without affecting 
the activation of the canonical BMP signalling cascade. One of the most striking finding 
about PAWS1 was its ability upon overexpression to induce the formation of a complete 
secondary axis in Xenopus laevis embryos. Similar phenotypes can be explained by either 
inhibition of BMP signalling or activation of the Wnt signalling pathway. Since PAWS1 
was shown to associate with SMAD1, initially it was thought that this phenotype could 
be exerted due to potential inhibition of BMP signalling by PAWS1. However, it has been 
shown here that PAWS1 had no effect on canonical BMP signalling in both Xenopus 
embryos and in human cells.  
Furthermore, PAWS1 was reported to be the first non-SMAD protein to be 
phosphorylated by the BMPR1 receptor in human cells in response to BMP stimulation. 
However, here it is shown that the mutation of the BMP-induced phosphorylation 
residues on PAWS1 did not impact its ability to induce a secondary axis in Xenopus. In 
line with this, the minimum PAWS1 fragment that was sufficient for axis duplication to 
occur lacks the BMPR1 phosphorylation sites. Taken all the above into account, PAWS1 
appears to have no significant role in the regulation of the canonical BMP signalling 
pathway. Therefore, its ability to induce axis duplication cannot be attributed to inhibition 
of the BMP signalling, suggesting that it is likely to be mediated through the activation 
of Wnt signalling. 
Indeed, the data presented in this chapter, clearly demonstrates a significant role 
of PAWS1 in regulating Wnt signalling in both Xenopus embryos and human cells. 
PAWS1 overexpression activated Wnt-transcriptional reporter activity in U2OS and 
HEK293 cells, even in the absence of Wnt stimulation. Similarly, PAWS1 microinjection 
in Xenopus embryos resulted in enhanced stabilisation of the co-injected β-catenin and 
subsequent activation of the Wnt-target genes Siamois and Chordin in the animal caps.  
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Moreover, knocking out PAWS1 gene from U2OS cells resulted in the attenuation 
of the Wnt-reporter activity as well as the transcription of the Wnt-target genes AXIN2 
and CYCLIND1 in response to Wnt3A stimulation, compared to wild type cells. 
Collectively, these results have established that PAWS1 is a novel regulator of the Wnt 
signalling pathway. 
The activation of Wnt signalling involves the binding of Wnt to its receptors FZD 
and LRP5/6, which then initiates a cascade of signalling events, including the 
phosphorylation of the cytoplasmic part of LRP6 and the formation of the Wnt 
signalosome close to the plasma membrane. This results in the stabilisation and the 
accumulation of β-catenin which then translocates to the nucleus to activate the 
transcription of the Wnt-target genes. Any alterations in the signalling cascade that inhibit 
the Wnt responses can be monitored by the reduced transcriptional activity of β-catenin. 
In Xenopus animal cap cells, expression of a dominant negative form of LRP6 (Lrp6m5) 
did not inhibit the PAWS1-induced Siamois expression, suggesting that PAWS1 activates 
Wnt signalling downstream of the Wnt receptor. Rather surprisingly, the loss of PAWS1 
did not result in any substantial changes in either the levels or the phosphorylation of the 
major components of the destruction complex downstream of the LRP6, despite inhibition 
of the transcriptional Wnt/β-catenin activity. Hence, it could be hypothesised that PAWS1 
probably functions downstream of the destruction complex, where it does not affect the 
phosphorylation status/or the stabilisation of β-catenin. Indeed, the data from this study 
support the notion that PAWS1 acts downstream of the destruction complex, as inhibition 
of β-catenin phosphorylation and its subsequent degradation by the GSK3 inhibitor could 
not restore Wnt-reporter activity in PAWS1-/- cells to the extent it did in the wild type 
cells. 
The generation of a U2OS cell line which expresses PAWS1 with a C-terminal 
GFP tag under the endogenous promotor has allowed the identification of endogenous 
PAWS1 interactors that could potentially explain its role in the Wnt signalling pathway. 
Interestingly, the major interactor of PAWS1 was found to be CK1α, which is a central 
component of the Wnt signalling pathway. PAWS1 was shown to interact with CK1α 
independent of Wnt stimulation which might suggest that PAWS1 could be a novel global 
regulator of CK1α in cells, a hypothesis that is going to be discussed in the next chapter. 
Remarkably, the association of PAWS1 with CK1α was proven to be critical for 
the activation of Wnt signalling both in Xenopus embryos and in human cells (Fig 3-24). 
Two residues, D262 and F296, within the conserved domain of unknown function, 
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DUF1669, at the N-terminus of PAWS1 were mapped as key for mediating interaction 
with CK1α. Mutation of either CK1 binding residues on PAWS1 resulted in complete 
loss of the ability of PAWS1 to induce secondary axis in Xenopus embryos an activate 
Wnt signalling. In PAWS1-/- cells, PAWS1F296A failed to rescue Wnt transcriptional 
reporter activity. One obvious explanation of these phenotypes would be that the 
interaction of PAWS1 with CK1α could regulate the sequestration of CK1α from the 
destruction complex resulting in reduced phosphorylation of β-catenin which would lead 
to increased β-catenin stabilisation. If this was true, PAWS1 depletion would result in 
enhanced association of CK1α with the components of the destruction complex and 
increased phosphorylation and degradation of β-catenin which would explain the 
compromised responses of the PAWS1-/- cells to Wnt signals. However, the data 
presented here does not favour this hypothesis, as neither the components of the 
destruction complex nor the CK1-mediated phosphorylation of β-catenin changed in 
PAWS1-/- cells compared to the wild type cells. A possible explanation for this could be 
that the interaction of PAWS1:CK1α occurs away from the destruction complex. This is 
supported by the observation that no other components of the destruction complex were 
identified in the mass spectrometric analysis of the PAWS1-GFP IPs with or without Wnt 
stimulation. 
 The event that follows the cytosolic accumulation of β-catenin in the Wnt 
signalling cascade is its translocation into the nucleus, which is crucial for it to activate 
the transcription of Wnt-target genes. However, the mechanisms that mediate the entry 
of β-catenin into the nucleus in response to Wnt signals are not fully understood. Here, it 
has been demonstrated that the loss of PAWS1 or interference of the PAWS1:CK1α 
interaction results in reduced accumulation of β-catenin in the nucleus and reduced 
transcription of the Wnt-target genes. To date, there are no references associating the CK1 
isoforms with the nuclear/cytosolic shuttling of β-catenin. Both PAWS1 and CK1α were 
shown to localise both in the cytosol and the nucleus. Hence, binding of PAWS1 to CK1α 
could regulate the activity of CK1α towards different subsets of substrates, either in the 
cytosol or in the nucleus, that might be involved in the transport of β-catenin. Identifying 
the potential CK1 substrates that are regulated by its interaction with PAWS1 might help 
to elucidate the mechanisms that regulate the nuclear/cytosolic shuttling of β-catenin in 
the Wnt signaling pathway. 
 PAWS1 belongs to the FAM83 family of proteins, which all share the DUF1669 
domain of unknown function. It is yet unknown if there is redundancy among the FAM83 
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proteins, which could potentially account for the observations that PAWS1-/- cells were 
not found to be completely unresponsive to Wnt stimulation. The possibility of other 
FAM83 members being involved in Wnt signalling as well as being binding partners of 
CK1 isoforms will be discussed in the following Chapter.  
  
 
Figure 3- 24 Summary of the biological outcomes from the PAWS1:CK1α 
interaction in human cells and in Xenopus embryos 
(i) Endogenous PAWS1 associates with CK1α and the complex formed mediates 
physiological responses to Wnt signals in cells and normal embryonic development in 
Xenopus. (ii) Depletion of PAWS1 by knocking out PAWS1 gene in human cells or by 
morpholinos in Xenopus embryos results in inhibition of Wnt signalling activation and 
lethality in cells and Xenopus respectively. Similarly, inhibition of PAWS1:CK1α 
interaction abrogates Wnt signalling activation. (iii) Overexpression of PAWS1 results in 
enhanced PAWS1:CK1α complex formation which leads to Wnt activation and axis 
duplication. 
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4. PAWS1 is a regulator of CK1α in cells 
 
4.1 Introduction 
 CK1 isoforms play central roles in many cellular processes and their mis-
regulation has been associated with human diseases including cancer and 
neurodegeneration (see 1.6.5). CK1 proteins are evolutionarily conserved, from 
prokaryotic organisms, such as bacteria, to all eukaryotic organisms. The conservation of 
the CK1 genes throughout evolution suggests key biological roles for these enzymes. 
Indeed, mice with homozygous deletion of CK1α or CK1δ exhibit early embryonic 
lethality (Etchegaray, Machida et al. 2009, Elyada, Pribluda et al. 2011). Despite 
advances made in establishing many biological roles for different CK1 isoforms, the 
precise mechanisms of their regulation in cells remain poorly defined. To date, our 
understanding about how these pleiotropic kinases achieve substrate specificity is limited 
to substrates that appear to interact with CK1 isoforms and primed substrates that conform 
to the CK1 consensus phosphorylation motif (see 1.6.3). Therefore, establishing how 
specific CK1 isoforms recognise and phosphorylate their substrates in specific subcellular 
compartments in response to specific signaling cues may provide opportunities for drug 
discovery against these enzymes.  
In the previous Chapter, it was demonstrated that the PAWS1:CK1α complex 
plays a crucial role in the transduction of the Wnt signaling pathway. CK1α has been 
reported to play both positive and negative roes in the Wnt signaling pathway (Cruciat 
2014). Overexpression of CK1α in Xenopus embryos has been shown to induce the 
formation of a secondary body axis via activation of Wnt signaling (Peters, McKay et al. 
1999). However, ablation of CK1α from the gut epithelium has been linked to Wnt 
activation in that tissue (Elyada, Pribluda et al. 2011). This apparent discrepancy in CK1α 
function might be attributed to intricate spatiotemporal regulation of CK1α, a mode of 
regulation that would allow it to target unique subsets of substrates, in different cellular 
compartments. Given its robust interaction with CK1α, PAWS1 is a promising candidate 
that might act as key regulatory factor for CK1α in cells.  
In this Chapter, the studies on the PAWS1:CK1α complex have been expanded, with 
the aim of understanding whether and how PAWS1 impacts CK1α function in cells. To 
address this, the following questions were formulated:  
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a) Does PAWS1 regulate the protein levels and/or the stability of CK1α? 
b) Is PAWS1 a substrate of CK1α? If so, is PAWS1 function reliant on this 
phosphorylation event? 
c) Does PAWS1 regulate the kinase activity of CK1α? 
d) Does PAWS1 regulate a subset of CK1α substrates in cells? 
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4.2 Results 
4.2.1 PAWS1 regulates the protein levels of CK1α 
 Driven by the previous observations that the protein levels of CK1α are 
significantly lower in the PAWS1-/- U2OS cells compared to the wild type controls (Fig 
3-9), the expression of CK1α was analysed thoroughly, after restoration of PAWS1 
protein levels in PAWS1-/- cells with wild type (PAWS1WT) or various PAWS1 mutants 
(PAWS1F296A, PAWS1F300A, PAWS1F296A/F300A and PAWS1D262A) (Fig 4-1).  Restoring 
PAWS1WT expression in PAWS1-/- cells resulted in restoration of endogenous CK1α 
levels, to those seen in wild type U2OS cells. Strikingly, restoration of the 
CK1α-interaction deficient mutants PAWS1F296A, PAWS1F296A/F300A and PAWS1D262A, 
did not elevate the endogenous CK1α protein levels to those seen in wild type cells, 
suggesting that the levels of endogenous CK1α protein are controlled by its interaction 
with PAWS1 (Fig 4-1). Consistent with these observations, the restoration of 
PAWS1F300A, which interacts with CK1α, resulted in restoration of the endogenous CK1α 
levels to those seen in wild type U2OS cells (Fig 4-1). As expected, the expression of 
GFP control in PAWS1-/- cells, did not elevate the endogenous CK1α protein levels to 
those seen in wild type cells (Fig 4-1). These data suggest that PAWS1 controls the levels 
of endogenous CK1α protein levels, which could be mediated through enhanced 
stabilisation via reduced protein degradation, enhanced transcription or other 
mechanisms. 
 Proteins that are part of the same complex tend to be under co-ordinated 
expression so that their abundance is co-regulated (Ori, Iskar et al. 2016). Consistent with 
this notion, transient depletion of endogenous CK1α protein with siRNA duplexes led to 
a concomitant substantial reduction of PAWS1 protein levels, as well (Fig 4-2). These 
observations support the reciprocal nature of PAWS1 and CK1α in regulating the cellular 
protein levels of the other protein. 
 Next, the analysis of the correlation between endogenous PAWS1 and CK1α 
protein levels was expanded to a panel of mammalian cell lines (Fig 4-3). PAWS1 protein 
expression was absent in many human cancer cells, including SK-ES (bone), MCF-7 
(breast), SK-N-MC (brain) and PC3 (prostate) cells while robust PAWS1 expression was 
observed in HCT116 (colorectal), HEPG2 (liver), PNTA1 (prostate) and HeLa (cervix) 
cells. Strikingly, the expression of PAWS1 correlated with the levels of CK1α protein in 
these cell lines (Fig 4-3A). Cells that lacked PAWS1 expression generally correlated with 
no detectable or low levels of CK1α protein, whereas cells that had relatively higher 
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PAWS1 levels also expressed higher levels of CK1α (Fig 4-3A). Interestingly 
introduction of PAWS1WT expression in PC3 cells using retroviral infection, also led to 
increased levels of CK1α (Fig 4-3A). No correlation in protein expression was evident 
between PAWS1 and CK1ε, which was not identified as a PAWS1-interactor. The 
immunoblots were analysed by densitometric quantification followed by statistical 
correlation analysis using the Pearson’s correlation coefficient (Pearson 1992), which 
measured the linear relationship between PAWS1 and CK1α protein levels. Pearson’s 
correlation coefficient (r) is constrained as -1 ≤ r ≤ 1, while positive values denote positive 
correlation, negative values denote negative correlation and a value of 0 denoted no 
correlation. The magnitude of the Pearson’s r coefficient determines the strength of the 
correlation, while the p-value denotes the significance of the correlation (Evans 1996). 
Thus, when p<0.05, the correlation is significant whereas when p>0.05 there is no 
significant correlation. Positive correlation was found between PAWS1 and CK1α protein 
levels, (r = 0.4128, p = 0.0281) which confirmed that there is a correlation between the 
variance of PAWS1 and the variance of CK1α protein levels in the panel of the cell lines 
tested. No significant correlation was found between PAWS1 and CK1ε protein levels 
(r= 0.2279, p = 0.1538) (Fig 4-3B, C). 
 In order to test whether the correlation in PAWS1 and CK1α protein levels was 
due to a similar correlation in their mRNA expression, PAWS1 and CK1α mRNA levels 
were assessed in six of the above mammalian cell lines (Fig 4-4).  The Pearson’s 
correlation coefficient, which was used to determine the relationship between the PAWS1 
and CK1α mRNA levels, showed that there is no significant correlation at the mRNA 
level (r = 0.2254, p = 0.0508), indicating that at least in the cell lines tested, the 
interrelationship between PAWS1 and CK1α protein levels occurs post-translationally. 
 To investigate if PAWS1 regulates the turnover of CK1α protein in cells, 
proteasomal and lysosomal inhibitors of protein degradation were used. Poly-K48-linked-
ubiquitinated proteins are targeted for proteasomal degradation, which can be blocked 
with Bortezomib, a selective and potent inhibitor of the proteasome (Adams, 2003). 
Proteasomal inhibition did not rescue the reduced CK1α levels caused by PAWS1 
depletion to those seen in wild type cells (Fig 4-5A). Blocking the autophagic-lysosomal 
degradation pathway with Bafilomycin A1, which inhibits lysosomal acidification 
through blocking the action the vacuolar-type H+-ATPase (Yoshimori et al., 1991), did 
not enhance the stability of CK1α protein either (Fig 4-5B). Therefore, the lower levels 
of CK1α protein observed in PAWS1-/- cells compared to the wild type cells are unlikely 
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to be due to increased CK1α protein degradation via the proteasomal or lysosomal 
pathways. Similarly, the mRNA levels of CK1α were comparable in PAWS1WT, 
PAWS1-/- and PAWS1F296A rescue cells (Fig 4-5C), suggesting that the PAWS1 
regulation of CK1α protein levels is unlikely to be through its transcriptional regulation. 
Collectively, these results suggest that the PAWS1 regulation of CK1α protein levels is 
unlikely to be due to the regulation of CK1α turnover through proteasomal or lysosomal 
pathways, nor through transcriptional modulation. 
 
Figure 4- 1 PAWS1 regulates the protein levels of CK1α in cells. 
Cell extracts (20 μg of protein) from U2OS wild type, PAWS1-/- and PAWS1-/- cells in 
which PAWS1WT, GFP control, PAWS1F296A, PAWS1F300A, PAWS1F296A/F300A or 
PAWS1D262A was stably restored, were resolved by SDS-PAGE and immunoblotted with 
the indicated antibodies. 
 
 
Figure 4- 2 RNAi-mediated silencing of CK1α downregulates PAWS1 protein 
levels 
CK1α expression was silenced in U2OS cells with indicated amounts of siRNA targeted 
against CK1αusing two different transfection methods (RNAi-Max or TransFectin). Cells 
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were lysed after 48 h and cell extracts (20 μg of protein) were resolved by SDS-PAGE 
and immunoblotted with the indicated antibodies. 
 
Figure 4- 3 The protein levels of CK1α correlate with the protein levels of PAWS1 
in mammalian cell lines 
A. Expression of PAWS1 and CK1α protein in the indicated cell line extracts (10 μg 
of protein) was monitored by Western blotting. Cell extracts were kindly provided 
by Dr Christophe Lachaud. 
 
B. Pearson’s correlation plots of PAWS1 and CK1α protein expression (normalized 
to GAPDH) based on densitometric quantification of immunoblots from (A);  
a.u.= arbitrary units. Pearson r coefficient and one-tailed p-values were calculated 
with Prism6 software. 
 
C. Same as (B) except that PAWS1 and CK1ε protein levels were quantified and 
plotted. 
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Figure 4- 4 The mRNA levels of PAWS1 do not correlate with the mRNA levels of 
CK1α in mammalian cell lines  
A. Relative expression of PAWS1 mRNA in the indicated cancer cell lines was 
measured by qPCR and plotted relative to expression in U2OS cells (n=3; Error 
bars represents ±SEM, dots represent technical replicates). 
B. Relative expression of CK1α mRNA in the indicated cancer cell lines was 
measured by qPCR and plotted relative to expression in U2OS cells (n=3; Error 
bars represents ±SEM). 
C. Correlation plot of relative PAWS1 and CK1α mRNA expression (normalized to 
β-actin) in the indicated cancer cell lines. Pearson r coefficient and one-tailed 
p-values were calculated with Prism6 software. 
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Figure 4- 5 PAWS1 regulates the CK1α protein but not mRNA levels in cells 
A. PAWS1WT and PAWS1-/- U2OS cells were treated with 10 μM of the proteasome 
inhibitor Bortezomib for 6 h before lysis and extracts (20 μg of protein) were 
resolved by SDS-PAGE and immunoblotted with the indicated antibodies. 
B. PAWS1WT and PAWS1-/- U2OS cells were treated with 50 μM Bafilomycin A1 
(BafA1) for 2 or 16 h before lysis and extracts (20 μg of protein) were resolved 
by SDS-PAGE and immunoblotted with the indicated antibodies. 
C. CK1α mRNA in PAWS1-/- cells rescued with PAWS1WT or GFP control was 
analysed by qPCR. Data are represented as fold changes over controls and 
normalized internally to β-actin control. (n.s.: no statistical significance; n=3; 
Error bars represent ±SEM, dots represent technical replicates). 
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4.2.2 PAWS1 is phosphorylated by CK1α in vitro 
 CK1 isoforms phosphorylate numerous proteins in cells. Armed with this 
knoweldge, the next aim was to determine whether PAWS1 could be a bona fide substrate 
of CK1α. For this, an in vitro kinase assay was set up using recombinant GST-CK1α 
protein and full-length GST-PAWS1-6xHis, both purified from E. coli. As seen in Fig 
4-6A, PAWS1 was phosphorylated robustly by CK1α, while no signal was observed in 
the absence of PAWS1. To eliminate the possibility that a contaminating bacterial kinase 
might be responsible for this phosphorylation, the DUF1669 domain of FAM83A was 
expressed with a GST-tag and purified at the same time as PAWS1, and included as a 
control. β-catenin is one of the many CK1 substrates (Liu, Li et al. 2002) and therefore 
GST-β-catenin was used as a positive control for the kinase assay. The extent of PAWS1 
phosphorylation by CK1α was similar to that of β-catenin, although comparatively more 
β-catenin than PAWS1 was used in the assay. No signal was observed in the absence of 
CK1α, eliminating the possibility that PAWS1 was phosphorylated by a contaminating 
bacterial kinase. Under the conditions employed, DUF1669-FAM83A-GST was not 
phosphorylated by CK1α (Fig 4-6B). Furthermore, the use of the CK1 inhibitor D4476 
(Rena, Bain et al. 2004) at 10 μM blocked the phosphorylation of PAWS1 by CK1α in 
vitro (Fig 4-6C). 
 Having established that CK1α phosphorylates PAWS1 in vitro, the CK1α 
phosphorylation sites on PAWS1 were determined by Edman sequencing and mass-
spectrometry (Fig 4-7). PAWS1 was phosphorylated by CK1α using γ32P-ATP in vitro 
and the reaction sample was resolved by SDS-PAGE. The γ32P-PAWS1 band was 
excised, digested with trypsin and the resulting peptides were separated by 
chromatography on a C18 column, using an increasing acetonitrile gradient. Three peaks 
of 32P release were observed, with the major peak appearing after 54 min. Analysis of this 
eluted phospho-peptide by mass spectrometry revealed the PAWS1 tryptic peptide 
RPSVASSVSEEYFEVR with an additional single phospho-modification. To determine 
the precise phosphorylated residue in the 32P-labelled peptide, solid-phase Edman 
degradation was employed (Performed by R. Gourlay). 32P radioactivity was released 
after the seventh cycle of Edman degradation, suggesting that CK1α phosphorylates 
PAWS1 on S614 (Fig 4-7B). Analysis of the two minor peaks revealed indiscernible 
phospho-sites, potentially T509/S610/T145 and S614/S781 (Fig 4-7C). 
 To confirm the major phosphorylation site identified by mass spectrometry and 
Edman degradation, an in vitro kinase assay was set up. In this assay, wild type PAWS1, 
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as well as the PAWS1-S614A mutant expressed in bacteria, were used as substrates with 
wild type or catalytically inactive (kinase dead; KD) CK1α. Wild type CK1α 
phosphorylated PAWS1 but not the PAWS1-S614A mutant, confirming that S614 is the 
main residue on PAWS1 that is phosphorylated by CK1α in vitro (Fig 4-7D). CK1α KD 
did not phosphorylate PAWS1 or the PAWS1-S614A mutant (Fig 4-7D). Due to the 
limitations of the pSer614 PAWS1 antibody, it has not been possible to validate whether 
endogenous PAWS1 is phosphorylated at S614 in cells. Therefore, future research will 
reveal if PAWS1 is indeed a bona fide substrate of CK1α in vivo. 
 It was previously demonstrated that the minimum PAWS1 protein fragment that 
is able to induce axis duplication in Xenopus embryos does not include the S614 residue. 
In line with this, mRNA injection of PAWS1S614A phospho-mutant did not inhibit the 
PAWS1-induced axis duplication phenotype (Fig 4-8A). Additionally, 
FLAG-PAWS1S614A could still interact with endogenous CK1α in U2OS cells to a similar 
extent as PAWS1WT did. These results suggest that phosphorylation of PAWS1 is not 
required for its function in Wnt signalling, or its interaction with CK1α. 
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Figure 4- 6 PAWS1 is phosphorylated by CK1α in vitro 
A. In vitro kinase assay with GST-CK1α and GST-PAWS1-6xHis in the presence of 
32P-ATP (500 cpm/pmol). The reaction was stopped after 30 min at 30 °C and the 
samples were resolved by SDS-PAGE. The gel was Coomassie stained and 
radioactivity was analysed by autoradiography. 
 
B. Same as A except that GST-β-catenin and FAM83A (DUF1669)-GST were used as 
substrates, too. 
 
C. Same as A except that the assays were performed in the presence of the indicated 
concentrations of the CK1α inhibitor D4476. 
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Figure 4- 7 CK1α phosphorylates PAWS1 at S614 in vitro 
A. GST-PAWS1-6xHis was phosphorylated by CK1α in vitro as in 4-6A, excised, 
trypsin-digested and resolved by HPLC on a C18 column on an increasing 
acetonitrile gradient as indicated. Three peaks of 32P release were observed (P1-3). 
Analysis of the P1 by mass spectrometry revealed the presence of 
RPSVASSVSEEYFEVR peptide with an additional single phosphor-moiety. 
 
B. Solid-phase sequencing of peak P1 revealed the release of 32P after the seventh 
cycle of Edman degradation corresponding to RPSVASS*VSEEYFEVR 
phospho-peptide, where S* denotes pS614. (Performed by R. Gourlay). 
 
C. Solid-phase sequencing of peak P2 revealed the release of 32P after the third and 
the seventh cycles of Edman degradation. All possible phospho-peptides are 
indicated but none were detected by mass spectrometry. (performed by R. 
Gourlay). 
 
D. In vitro kinase assay with GST-CK1α or GST-CK1α KD (kinase dead) and 
PAWS1 WT (GST-PAWS1-6xHis) or PAWS1 S614A (GST-PAWS1 S614A) in 
the presence of 32P-ATP (500 cpm/pmol). The reaction was stopped after 30 min 
at 30 °C and the samples were resolved by SDS-PAGE. The gel was Coomassie 
stained and radioactivity was analysed by autoradiography. 
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Figure 4- 8 The PAWS1 S614A mutant still binds to CK1α and induces axis 
duplication in Xenopus embryos 
A. Sequence alignment of human, mouse and Xenopus laevis (XNLA) PAWS1 
around the conserved S614 phosphorylation residue, indicated by the blue arrow. 
Alignment was performed with ClustalO in Jalview 2.10.3 and colouring indicates 
the % of sequence identity as shown in the box.  
 
B. Human PAWS1WT, hPAWS1S610A and hPAWS1S610A/S614A induce axis duplication 
in Xenopus embryos. 
 
C. PAWS1-/- U2OS cells were transfected with FLAG-PAWS1WT, 
FLAG-PAWS1F296A, FLAG-PAWS1S614A or FLAG-empty. 48h later, cells were 
lysed and cell extracts (20 μg of protein) were subjected to FLAG-IPs and were 
resolved by SDS-PAGE, followed by immunoblotting with the indicated 
antibodies. 
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4.2.3 PAWS1 does not affect the kinase activity of CK1α in vitro or in 
cells 
To assess whether PAWS1 regulates the kinase activity of CK1α, a kinase assay 
was performed on the PAWS1-associated CK1α, immunoprecipitated from cell extracts, 
against an optimised CK1 peptide substrate (CK1tide). For this assay, endogenous 
PAWS1 was immunoprecipitated from U2OS wild type and PAWS1-/-cell extracts and 
subjected to an in vitro kinase assay using 32P-ATP and the CK1tide peptide substrate. 
Robust CK1α kinase activity was detected in PAWS1 IPs from wild type but not from 
PAWS1-/- cell extracts (Fig 4-9A). The detection of endogenous CK1α in PAWS1 IPs 
from wild type but not from PAWS1-/- cell extracts by Western blotting, correlated with 
the observed in vitro kinase activities against CK1tide (Fig 4-9A). This result indicates 
that association of PAWS1 with CK1α, at the least, does not inhibit the intrinsic CK1α 
kinase activity. 
 Next, it was tested whether PAWS1 could potentiate the kinase activity of 
recombinant CK1α through association. In vitro kinase assays were performed with 
32P-ATP and the CK1tide peptide, using recombinant WT or KD CK1α, with or without 
recombinant PAWS1WT or the CK1α-binding deficient PAWS1F296A mutant. As expected, 
CK1α WT displayed in vitro kinase activity against the CK1tide, while CK1α KD did not 
(Fig 4-9B). The addition of either PAWS1WT or PAWS1F296A did not substantially affect 
the ability of CK1α to phosphorylate CK1tide (Fig 4-9B). Collectively, these data suggest 
that PAWS1 is unlikely to directly regulate the kinase activity of CK1α in vitro or in cells. 
Next, the impact of CK1α kinase activity and the synergistic impact of PAWS1 
were investigated in Xenopus embryos. As shown in Fig 4-10A, overexpression of either 
wild type PAWS1 or wild type CK1α in Xenopus embryos induced a secondary body 
axis. However, overexpression of catalytically inactive mutant CK1α (D136N; kinase 
dead; KD) alone did not induce axis duplication in Xenopus embryos. These results 
indicated that the kinase activity was necessary for CK1α to induce the axis duplication 
phenotype. Given the observations that PAWS1 mutants incapable of binding CK1α do 
not induce axis duplication (Fig 3-18A, B), the potential impact of CK1α activity on the 
ability of PAWS1 to induce axis duplication was investigated. First, to evaluate if PAWS1 
could still interact with CK1α KD, co-expression/IP experiments were performed and 
showed that both CK1α WT and KD interact robustly with FLAG-PAWS1 (Fig 4-10B). 
Nevertheless, in Xenopus embryos, when PAWS1 and WT CK1α were co-expressed, the 
embryos exhibited normal phenotypes (Fig 4-10A). A possible explanation for this is that 
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PAWS1 inhibits CK1α activity, hence overexpression of CK1α counters the PAWS1 
effects on axis duplication. However, as it has been shown above, PAWS1 does not impair 
CK1α activity in vitro. Therefore, these observations suggest that overexpression of either 
PAWS1 or CK1α alone in embryos potentially disrupt the endogenous PAWS1:CK1α 
complex homeostasis, resulting in concurrent disturbances in Wnt signalling that results 
in the axis duplication phenotypes observed. In contrast, when these proteins are co-
expressed, this interference on the endogenous PAWS1:CK1α complex is minimized, 
resulting in normal phenotypes. If this were the case, then one would expect similar 
outcomes using a catalytically inactive mutant of CK1α that still interacts with PAWS1 
with similar affinity to the wild type CK1α (Fig 4-10A). Indeed, co-expression of PAWS1 
and the catalytically inactive CK1α mutant in Xenopus embryos also resulted in 
completely normal embryos (Fig 4-10A). Furthermore, CK1 δ and ε isoforms, which do 
not interact with PAWS1, also induced axis duplication when expressed on their own, 
whereas overexpression of CK1ε KD had no effect on the axis duplication (Fig 4-10A). 
Axis duplication caused by PAWS1 was not affected when co-expressed with CK1ε WT 
or KD, or CK1δ WT (Fig 4-10A).  
The results so far show that PAWS1 and CK1α interact and co-localise in cells 
and this interaction is essential for the activation of the Wnt signalling pathway as well 
as the induction of axis duplication in Xenopus embryos. However, PAWS1 does not 
affect the intrinsic CK1α catalytic activity. Collectively, these data suggest that the 
PAWS1:CK1α complex potentially regulates the phosphorylation of key CK1α substrates 
within the Wnt signalling pathway. Therefore, a global phospho-proteomic approach was 
undertaken to establish PAWS1-dependent CK1α substrates in U2OS cells. 
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Figure 4- 9 PAWS1 does not affect the kinase activity of CK1α in cells or in vitro 
A. Endogenous PAWS1 was immunoprecipitated from wild type and PAWS1-/- 
U2OS cells (n=3) and the associated CK1α kinase activity was measured 
following a kinase assay using 32P-ATP and the CK1tide peptide substrate. One 
third of the PAWS1 IP samples were resolved by SDS-PAGE and immunoblotted 
with the indicated antibodies (bottom panel) (n=3, error bars represent ±SEM). 
 
B. In vitro wild-type (WT) or catalytically inactive (KD) CK1α kinase assay using 
CK1tide as a substrate in the presence or absence of recombinant PAWS1WT or 
PAWS1F296A.
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Figure 4- 10 CK1α kinase activity is required for PAWS1-induced axis duplication 
in Xenopus embryos 
A. 250 pg of xPAWS1 and 300 pg of the indicated CK1 isoform mRNAs were 
injected into 1 ventral bastomere at the 4-cell stage. Axis induction was assessed 
at stage 28 (tadpole stage). (Performed by K. Dingwell, The Francis Crick 
Institute, London). 
 
B. U2OS cells were co-transfected with HA-CK1α (WT or KD) and FLAG-PAWS1 
and cells were lysed after 36 h. Cell extracts (20 μg of protein) were subjected to 
FLAG IP, followed by SDS-PAGE and immunoblotting with the indicated 
antibodies. 
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4.2.3 Global phospho-proteomics comparison of wild type versus 
 PAWS1-/- U2OS cells 
To identify potential CK1α substrates that are regulated by the PAWS1-CK1α 
interaction, a quantitative phospho-proteomics approach was undertaken. Specifically, 
U2OS wild type, PAWS1-/- and PAWS1-/- rescued with wild type PAWS1 (PAWS1WT) 
cells were treated with control- or Wnt3A-conditioned medium for 3 h and cell extracts 
were processed for phospho-proteomics analysis as described in Fig 4-11. The data for 
each experimental condition is representative of four replicates. Overall, 5170 phospho-
peptides were identified, for which the phosphorylation events could be mapped to 
specific residues. For the quantitative analysis of the phosphoproteins under different 
experimental conditions, the change of phospho-peptides have been paired against cell 
lines and in either control or Wnt3A treatments. Student t-tests were performed for 
measuring statistical significance between different comparisons.   
 
 
Figure 4- 11 Overview of the quantitative phosphoproteomics experiment 
Schematic representation of the workflow. U2OSWT, PAWS1-/- and PAWS1WT rescue 
(Res) cells were seeded in 15-cm dishes in quadruplicates and treated with either control- 
or Wnt3A conditioned medium for 3 h prior to lysis in lysis buffer containing 8 M urea. 
Protein extracts (3 mg of protein) were reduced, alkylated, trypsin-digested and acidified. 
Phosphopeptides were enriched by TiO2 and labelled with 6-plex TMT reagents. All the 
labelled phosphopeptides of each biological replicate were pooled together and subjected 
to HPLC fractionation followed by analysis by LC-MS/MS. 
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Statistical analysis of four replicate experiments revealed a set of 333 
phosphorylation sites, that were significantly different between WT and PAWS1-/- cells 
and 495 sites that were significantly different between WT and PAWS1WT under 
unstimulated conditions. 553 phosphorylation sites were significantly different between 
WT and PAWS1-/- cells and 535 sites between WT and PAWS1WT cells in Wnt-stimulated 
conditions. In the WT cells, 213 phosphorylation sites were found to be regulated by Wnt 
stimulation. Of those sites, 92 were identified in the unstimulated cells and 121 in the 
Wnt-stimulated cells. Interestingly, none of the well characterised Wnt pathway 
components, such as β-catenin-pSer45, were identified in any of the above sets, which 
suggests that the coverage of phospho-peptides here was not comprehensive but 
nonetheless the identification of novel Wnt-dependent phospho-events indicates that Wnt 
responses potentially extend vastly beyond the currently established protein networks. Of 
the phospho-peptides identified, a small number with significant changes across different 
conditions could not be clustered according to gene ontology databases (DAVID, 
PANTHER). Therefore, these results need to be interpreted with caution, as they do not 
represent an exhaustive survey of all possible phosphorylation changes using the 
conditions described. Of note, in similar phospho-proteomic approaches undertaken by 
others within the MRC Protein Phosphorylation and Ubiquitylation Unit, ~18,000 
phospho-peptides have been identified. 
To graphically represent the changes in phospho-peptides identified, volcano plots 
(Cui and Churchill 2003) were constructed (Fig 4-12 – 4-14). The log2 of the fold change 
values were plotted against the negative decadic logarithm of the p-value derived from 
the t-test. Proteins with a minimum of 2-fold change (indicated by the vertical dashed red 
lines) combined with a p-value smaller than 0.05 (indicated by the horizontal dashed red 
line) were considered significant.  
As this experiment quantified the global phosphorylation changes in the cell 
proteome, a further refinement was carried out by filtering the dataset for the presence of 
the CK1 phosphorylation consensus motif, D/E-x-x-S*/T*, for phospho-peptides with a 
significant change higher than 2-fold. This refinement could potentially provide the initial 
step in the identification of CK1α-specific substrates that might be regulated by the 
presence or absence of PAWS1 in cells both in unstimulated and Wnt3A stimulated 
conditions (Appendix A-2 – A-4). Moreover, because CK1 can also target S/T residues 
that have a pS/pT-x-x-S*/T* motif (primed motif), the analysis was also refined further 
to consider phospho-peptides with priming phosphorylation (pS/pT) at the n-3 position. 
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Any other phospho-peptides could be considered either as non-canonical CK1 
phosphorylation events or as indirect phosphorylation events mediated by other kinases 
downstream of CK1. 
From the analyses above, one interesting phospho-protein that was specifically 
enriched in both control and Wnt3A treated wild type cells, while being absent from 
PAWS1-/- cells, was Bicaudal C homolog 1 (A6NGY7). The phosphorylated residue was 
mapped to Ser429. BICC1 is an RNA-binding protein that represses mRNA translation 
(Gamberi and Lasko 2012). It has been shown to co-precipitate with mRNAs that regulate 
Wnt signalling, vesicular trafficking and cytoskeletal organisation (Chicoine, Benoit et 
al. 2007). Notably, in Xenopus embryos, the maternal BICC1 protein was shown to form 
a gradient from the animal pole to vegetal pole, which mirrored the repression of the 
BICC1-mediated repression of mRNA translation. Additionally, BICC1 depletion from 
Xenopus oocytes was shown to result in Wnt signalling activation with an excess of 
dorsal-anterior structures (Park, Blaser et al. 2016). To date, it is not known how 
BICC1-mediated repression of mRNA translation is regulated spatiotemporally. An 
emerging hypothesis would be that this precise regulation is controlled through 
phosphorylation. Hence, in wild type cells BICC1 might be negatively regulated via its 
phosphorylation at Ser429, thereby, inhibiting its function as a translational repressor. In 
contrast, the absence of BICC1 phosphorylation in PAWS1-/- cells might mean that 
BICC1 is in an active state in which it is able to bind and inhibit mRNAs from being 
translated. This would not only explain why PAWS1-/- cells do not respond to Wnt 
signalling to the same extent as the wild type cells but it could also provide an indication 
of the lower expression levels of CK1α that follow PAWS1 loss. 
Further research is required for the validation of the phospho-peptides that were 
identified as significantly (more than 2-fold) altered between the experimental conditions 
described above. In vitro validations could be performed with kinase assays using 
recombinant CK1α and the identified proteins, with or without PAWS1 
co-administration. Furthermore, phosphorylation site-specific antibodies for the 
identified phospho-residues can also be exploited in immunoblotting experiments, 
monitoring cell extracts from U2OS wild type and PAWS1-/- cells that were stimulated 
with control or Wnt3A conditioned medium. If no specific phospho-antibodies are 
available, the Phos-tag SDS-PAGE methodology could be employed. This methodology 
has been exploited for visualising protein phosphorylation, as evidenced through a change 
in their electrophoretic mobility shift (Kinoshita, Kinoshita-Kikuta et al. 2006). Briefly, 
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Phos-tag (1,3-bis[bis(pyridin-2-ylmethyl) amino]propan-2-olato dizinc(II) complex) 
agent binds phosphate ions with high affinity and as a result it interacts with proteins and 
peptides with phosphorylated residues (Kinoshita, Yamada et al. 2005). Phos-tag 
acrylamide is added to SDS/polyacrylamide gels and retards the electrophoretic mobility 
of phosphorylated proteins, causing substantial mobility shifts, which can then be 
visualised by Western blotting, using an antibody against the total, unphosphorylated 
form of the protein of interest (Kinoshita, Kinoshita-Kikuta et al. 2006). Following the 
validation of CK1α targets, cell-based assays, including for example, Wnt transcriptional 
reporter activity and nuclear/cytosolic accumulation of β-catenin assays could be 
performed after overexpressing the phospho-deficient and phospho-mimetic mutants of 
each validated CK1α-target, in order to evaluate their impact on Wnt signalling. 
Additionally, the ability of the potential phospho-mimetic mutants of each CK1α target 
to restore Wnt signalling responses in PAWS1-/- cells, to the levels seen in the wild type 
cells, could be examined. 
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Figure 4- 12 Changes in global phosphoprotein abundance under control 
unstimulated conditions 
A. Volcano plot of the phosphoproteins identified in the PAWS1-/- and wild type cells 
under basal unstimulated conditions. Each dot represents a phosphoprotein. The 
log2 of the average phospho-site ratios (n=4) of PAWS1-/- versus wild type (x-
axis) are plotted against the negative decadic logarithm of the p-value derived 
from a t-test (y-axis). Proteins with a minimum of 2-fold change (indicated by the 
vertical dashed red lines) combined with a p-value smaller than 0.05 (indicated by 
the horizontal dashed red line) are considered significant and are labelled with 
their gene symbol. 
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B. Same as (A) but for PAWS1WT and wild type phosphoproteins. 
 
Figure 4- 13 Changes in global phosphoprotein abundance upon Wnt3A stimulation 
A. Volcano plot of the phosphoproteins identified in the PAWS1-/- and wild type cells 
under Wnt3A stimulation (3h). Each dot represents a phosphoprotein. The log2 of 
the average phospho-site ratios (n=4) of PAWS1-/- versus wild type 
phosphoproteins (x-axis) are plotted against the negative decadic logarithm of the 
p-value derived from a t-test (y-axis). Proteins with a minimum of 2-fold change 
(indicated by the vertical dashed red lines) combined with a p-value smaller than 
0.05 (indicated by the horizontal dashed red line) are considered significant and 
are labelled with their gene symbol. Proteins with a potential involvement in the 
Wnt signalling pathway are highlighted with a blue dot.  
 
B. Same as (A) but for PAWS1WT and wild type phosphoproteins. 
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Figure 4- 14 Changes in global phosphoprotein abundance in control versus Wnt3A 
treated cells 
A. Volcano plot of the phosphoproteins identified in the wild type cells treated with 
control conditioned medium versus Wnt3A-treated (3h) cells. Each dot represents 
a phosphoprotein. The log2 of the average phospho-site ratios (n=4) of untreated 
versus Wnt3A-treated phosphoproteins (x-axis) are plotted against the negative 
decadic logarithm of the p-value derived from a t-test (y-axis). Proteins with a 
minimum of 2-fold change (indicated by the vertical dashed red lines) combined 
with a p-value smaller than 0.05 (indicated by the horizontal dashed red line) are 
considered significant and are labelled with their gene symbol. 
 
B. Same as (A) but for PAWS1-/- cells. 
 
C. Same as (A) but for PAWS1WT cells. 
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4.2.4 All FAM83 proteins interact with different CK1 isoforms 
Following the discovery that endogenous PAWS1 interacts with CK1α robustly, 
and the demonstration that the interaction is mediated through two residues within the 
DUF1669 domain of PAWS1, namely D262 and F296, both of which are conserved in all 
FAM83 members (Fig 4-15A), it was hypothesized that all FAM83 proteins might also 
interact with CK1 isoforms. Another PhD student in the lab (L. Fulcher) explored this 
hypothesis by expressing each FAM83 protein with a GFP-tag at the N-terminus in 
HEK293 cells and testing their ability to pull down endogenous CK1α, δ and ε isoforms. 
As shown in Fig 4-15B, CK1α was co-immunoprecipitated with every FAM83 protein 
but not with the GFP-only control. FAM83B, FAM83E, FAM83G (PAWS1) and 
FAM83H interacted with CK1α with apparently higher affinities compared to FAM83A, 
FAM83C, FAM83D and FAM83F (Fig 4-15B). Furthermore, endogenous CK1δ and 
CK1ε were detected only in FAM83B, FAM83E, and FAM83H IPs, and to a lower extent 
in FAM83A IPs (Fig 4-15B). In line with previously reported data (Dunsch, Hammond 
et al. 2012, Vogt, Dingwell et al. 2014), endogenous SMAD1 co-precipitated with only 
PAWS1, while endogenous HMMR and DYNLL1 co-precipitated exclusively with 
FAM83D (Fig 4-15B). 
 Having validated that PAWS1F296A and PAWS1D262A mutants abolish the 
interaction with CK1α, the equivalent conserved Phe and Asp residues were mutated to 
Ala in FAM83E (F277 and D243), FAM83F (F284 and D250) and FAM83H (F270 and D236). 
Then, wild type GFP-FAM83E-H, GFP-FAM83E-HF/A, or GFP-FAM83E-HD/A mutants 
were expressed in U2OS cells and immunoprecipitated to assess their abilities to co-
precipitate endogenous CK1α or CK1ε isoforms (Fig 4-15C). In comparison to wild type 
FAM83E-H, both F/A and D/A mutations attenuated the interaction with CK1α and CK1ε 
(Fig 4-15C, by L. Fulcher). These observations suggest that the interaction between the 
DUF1669 domain and CK1 isoforms may be mediated through a conserved structural 
motif surrounding residues equivalent to PAWS1 D262 and F296. Consistent with previous 
observations (Fig 4-15B), while FAM83E and FAM83H bound both CK1α and CK1ε, 
FAM83F and PAWS1 bound only CK1α (Fig 4-15C). These observations, with other 
ongoing studies in the Sapkota lab, have consolidated the hypothesis that FAM83 proteins 
serve as anchors for different CK1 isoforms in order to regulate their subcellular 
distribution, and potentially their substrate accessibility, in response to different 
signalling cues. Therefore, a whole new avenue has opened up for investigating the 
regulation of CK1 biology and their substrates, through distinct FAM83 proteins. 
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Figure 4- 15 The FAM83 proteins interact with CK1 isoforms 
A. Sequence alignment of the FAM83 members around the CK1 binding sites. The 
blue arrows indicate the conserved residues (D262 and F296) required for the 
PAWS1-CK1α interaction. Alignment was performed with ClustalO in Jalview 
2.10.3 and colouring indicates the % of sequence identity as shown in the box.  
 
B. A single copy of FAM83A-H gene each tagged with GFP at the N-terminus was 
stably inserted downstream of a tetracycline-inducible promoter in Flp-In T-Rex 
HEK293 cells. Cells were treated with 20 ng/ml doxycycline for 24 h before lysis. 
Extracts (1 mg of protein) were subjected to GFP-IPs, followed by SDS-PAGE 
and immunoblotting with the indicated antibodies. (Performed by L. Fulcher). 
 
C. WT, conserved CK1-interaction residue (F/A and D/A) mutants of GFP-
FAM83E-H from (A) were transiently expressed in U2OS cells. Input extracts (20 
μg of protein) and GFP-IPs (from 1 mg protein extracts) were resolved by 
SDS-PAGE, followed by immunoblotting with the indicated antibodies 
(Performed by L. Fulcher). 
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4.2.5 Some FAM83 proteins can activate Wnt signaling 
 As discussed extensively in the Introduction, CK1 isoforms play critical roles in 
regulating Wnt signalling. After establishing all FAM83 members are capable of 
interacting with CK1α and half of them also interact with other CK1 isoforms, their ability 
to activate the canonical Wnt pathway was investigated. For this, the ability of FAM83 
members to activate Wnt transcriptional reporter activity in U2OS cells was tested (Fig 
4-16). Apart from PAWS1, overexpression of FAM83B, FAM83E and FAM83F 
significantly enhanced the Wnt transcriptional reporter activity upon treatment with 
Wnt3A-conditioned medium (Fig 4-16A). Notably, overexpression of FAM83F, which 
also selectively interacts with CK1α, activated the Wnt transcriptional reporter activity in 
cells substantially more than other FAM83 members and even in the absence of 
Wnt3A-conditioned medium (Fig 4-16A). Remarkably, FAM83F is the only other 
FAM83 member that induces axis duplication in Xenopus embryos (personal 
communication with K. Dingwell, The Francis Crick Institute, London). These findings 
suggest that there could be some synergistic or redundant action between FAM83F and 
PAWS1 in the regulation of CK1α action in the Wnt signalling cascade.  
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Figure 4- 16 Overexpression of FAM83B, FAM83E, FAM83F and FAM83G 
activates the Wnt-transcriptional luciferase reporter activity in U2OS cells 
A. Plasmids encoding (FAM83A-H)-GFP and GFP control were transiently 
expressed in U2OS cells together with those encoding TOPflash luciferase and 
Renilla luciferase. TOPflash luciferase activity was measured after treatment with 
either conditioned medium (L-CM) or Wnt3A conditioned medium (L3-CM) for 
12 h. Data are normalised to Renilla luciferase internal control. (n=4; Error bars 
represent ±SEM). 
 
B. Cell extracts from (A) were resolved by SDS-PAGE and immunoblotted with 
anti-GFP to monitor the levels of FAM83-GFP expression. 
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4.2.6 Generation of an endogenously driven transcriptional reporter for 
PAWS1 
 Given the robust nature of the PAWS1:CK1α interaction in cells, understanding 
how PAWS1 is regulated transcriptionally and post-transcriptionally could inform the 
regulation of CK1α function in cells. Because CK1α protein levels are regulated by 
PAWS1, manipulating the expression of PAWS1 mRNA and protein levels could regulate 
CK1α activity via regulating protein levels. While post-translational regulation of 
PAWS1 is a focus in the Sapkota lab (and is covered briefly in Chapter 6), very little is 
known about its transcriptional regulation. Therefore, in order to investigate the 
transcriptional regulation of PAWS1, an endogenous transcriptional reporter for the 
PAWS1 gene was generated using CRISPR/Cas9 genome editing. This technology 
allowed for an integration of a polycistronic cassette containing non-fused firefly 
luciferase and GFP genes at the start codon of the PAWS1 gene locus in U2OS cells (Fig 
4-16A). Directly downstream of the luciferase gene, an internal ribosome entry site 
(IRES) was incorporated to ensure separate expression of the GFP gene from the 
luciferase protein. A 2A self-cleaving peptide was also incorporated downstream of the 
GFP gene to ensure cleavage of the GFP protein from PAWS1, which was left in frame 
after 2A. A similar reporter system from the Sapkota lab, which introduced luciferase 
gene at the start codon of TGFβ-target gene PAI-1, has already verified the effectiveness 
of the system downstream of TGFβ signalling (Rojas-Fernandez, Herhaus et al. 2015).  
GFP protein expression was used to ensure the detection of transgene delivery and 
rapid isolation of positive single cell clones. Eighteen GFP-positive clones were subjected 
to luciferase assay and half of them were found to be positive for luciferase activity under 
basal conditions (Fig 4-16B). PAWS1 protein expression in luciferase- and GFP-positive 
clones was monitored by Western blotting (Fig 4-16C). It appeared that PAWS1 
expression was significantly reduced or lost in two GFP- and luciferase-positive cell 
clones. Loss of PAWS1 could be possibly attributed to mistakes during homologous 
recombination which resulted in incorporation of random mutations, base insertions or 
deletions that could lead to premature stop codon formation. To investigate if this was the 
case, genomic DNA from clones 3 and 4 was isolated and analysed by PCR and 
sequencing.  First, the genomic region of PAWS1 gene was amplified with primers 
located outside of the homologous recombination arms from DNA that was isolated from 
U2OS wild type and the PAWS1-reporter cells using genomic DNA isolated from clone 
3 and clone 4. Next, the PCR products were separated on an agarose gel (Fig 4-16D). The 
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DNA band at around 5000 bp indicated that both clones had integrated the reporter 
cassette in at least one allele. In clone 3 the second band that was visible close to the wild 
type length suggested that clone 3 was probably a heterozygote. To confirm this, the 
shorter fragments were amplified, cloned and sequenced. Two sets of primers were used; 
the first amplified the genomic region from the start codon of PAWS1 to the most 
upstream region of the luciferase gene and the second amplified the region from the last 
nucleotides of the GFP gene and the beginning of the PAWS1 coding region (Fig 4-18A, 
4-19A). Genomic sequencing confirmed that clone 4 had inserted the reporter cassette in 
both alleles, while clone 3 was a heterozygote (Fig 4-18B, 4-19B).  
Since this reporter system utilises intact endogenous chromatin architecture, it is 
ideal to identify signals and small molecules that regulate endogenous PAWS1 
transcription in a high throughput format. Once identified, positive and negative 
regulators of PAWS1 transcription will be verified by qPCR. A pilot experiment was 
performed to test the effect of different ligands and growth factors on PAWS1 
transcription. For this, the heterozygous clone 3 and the homozygous clone 4 were 
selected and treated with growth factors and ligands followed by measurement of their 
endogenous luciferase activity. As seen in Fig 4-20, EGF and FGF4 activated luciferase 
activity in clone 3 but not in clone 4. Significant decrease in the luciferase activity was 
observed in clone 3 cells that had been treated with BMP4, TGFβ and Wnt3A. A similar 
trend was obvious for clone 4 but the changes were not statistically significant. The 
incorporation of the luciferase cassette to just one of the two alleles might be a possible 
reason for the different degrees of sensitivity to the stimuli.  
Further work is required to validate the observed differences on PAWS1 transcript 
levels with qPCR and also to evaluate if there are changes at the protein levels of both 
PAWS1 and CK1α, too. Moreover, the screening of regulators of PAWS1 transcription 
can be expanded to panels of kinase inhibitors and small molecules that are available and 
can be easily administered to cell lines (Elkins, Fedele et al. 2016, Williams, Gray et al. 
2017). 
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Figure 4- 17 Generation of endogenous PAWS1-transcriptional reporter U2OS cells 
by CRISPR Cas9 genome editing 
A. Schematic representation of the strategy used to generate the 
PAWS1transcriptional reporter cells with CRISPR/Cas9. U2OS cells were co-
transfected with a pair of guide RNAS (gRNAs) targeting the start codon region 
of the PAWS1 gene, together with the PAWS1 reporter donor vector containing 
two homology arms of the PAWS1 gene, one upstream (L-arm) and one 
downstream (R-arm) from the gRNA targeting sites with the luciferase-IRES-
GFP-2A reporter cassette in the middle, to allow for homologous recombination.   
 
B. Measurement of basal luciferase activity of GFP-positive single cell clones.  
 
C. Cell extracts from clones from (B) that displayed luciferase activity were resolved 
by SDS-PAGE and immunoblotted with anti-PAWS1. Extracts from 
PAWS1GFP/GFP (KI), wild type (WT) and PAWS1-/- cells were used as controls. 
 
D. Schematic representation of the predicted genomic PCR products of the PAWS1 
gene and the reporter inserted allele. 
 
E. SYBR-safe-stained agarose gel showing PCR products of genomic samples of 
U2OS wild type controls and PAWS1-reporter clones 3 and 4. 
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Figure 4- 18 Genomic sequence of the PAW1-transcriptional reporter for the 
luciferase gene 
A. Schematic representation of the predicted genomic PCR products that were 
amplified with a pair of primers targeting the indicated regions. 
 
B. Sequence alignment of the PCR products from (A), showing that the luciferase 
gene (in yellow) was integrated in frame with PAWS1. Alignment was performed 
in Jalview 2.10.3 with ClustalO. 
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Figure 4- 19 Genomic sequence of the PAWS1-transcriptional reporter for the 
GFP gene 
A. Schematic representation of the predicted genomic PCR products that were 
amplified with a pair of primers targeting the indicated regions. 
 
B. Sequence alignment of the PCR products from (A), showing that the GFP gene 
(in green) and the 2A gene (in purple) were integrated in frame with PAWS1 in 
both alleles. In allele-1 of clone 3, an insertion of 7 nucleotides caused a 
frame-shift. Alignment was performed in Jalview 2.10.3 with ClustalO. 
 
C. A zoom into the PAWS1 coding region of allele-1 from (B) (top panel) and the 
corresponding amino-acid sequence (bottom panel) showing a premature stop 
codon that was formed due to the frame-shift mutations. Alignments were 
performed in Jalview 2.10.3. 
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Figure 4- 20 Luciferase activation in the PAWS1-reporter cells upon ligands 
stimulation 
PAWS1 reporter cells were stimulated with the indicated ligands and growth factors and 
luciferase activity was measured. Data were normalised to total protein concentration and 
to the basal activity of the untreated control cells for each clone. The red asterisks indicate 
statistically significant changes of p<0.05 (2way ANOVA with Bonferroni correction for 
multiple comparisons; n=3; Error bars represents ±SEM, dots represent technical 
replicates).  
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4.3 Discussion 
 In this Chapter, it has been demonstrated that PAWS1 and CK1α exist in a 
complex in cells and that they regulate each other’s protein levels reciprocally. The 
correlation between their protein levels was observed in a panel of mammalian cell lines 
that are commonly used for cancer research. This correlation was confirmed to be 
regulated at the protein level while no correlation on the PAWS1 and CK1α mRNA levels 
was observed. Loss of PAWS1 expression resulted in a decrease in the CK1α protein 
levels, whereas PAWS1 overexpression increased CK1α protein levels in cells, without 
affecting CK1α mRNA levels. These findings suggest that PAWS1 might enhance the 
protein stability of CK1α by preventing its degradation. However, inhibition of the 
proteasomal and lysosomal protein degradation pathways did not rescue the attenuated 
CK1α levels in PAWS1-/- cells. A possible explanation for the above findings would be 
that PAWS1 and CK1α are co-translationally regulated. Alternatively, the PAWS1:CK1α 
complex might regulate mRNAs to aid the translation of both proteins. Such 
protein:mRNA interactions can control the rate and efficiency of protein translation 
(Standart and Jackson, 1994). None of the above possibilities have yet been tested for 
PAWS1 and CK1α. 
PAWS1 was found to be phosphorylated at S614 by CK1α in vitro. The robust 
interaction between PAWS1 and CK1α is contrary to the notion that the association 
between a kinase and its substrate is transient and weak. However, the phosphorylation 
of PAWS1 by CK1α was only established in vitro. It was shown that CK1α 
phosphorylates PAWS1 at S614 independent of their interaction. CK1 isoforms have a 
preference towards acidic substrates and they usually phosphorylate S/T residues in a 
consensus motif D/E-x-x-S*/T* or pS/pT-x-x-S*/T*. S614 does not conform to either 
motif. Although it is not unusual for CK1 to phosphorylate a residue that does not fall 
into its consensus phosphorylation motif, it is still not known if PAWS1 is phosphorylated 
by CK1α at S614 in vivo. 
Nevertheless, the phosphorylation of PAWS1 at S614 was not found to be 
involved in its role in Wnt signalling. First, the minimum PAWS1 sequence that was 
required for the induction of axis duplication in Xenopus embryos did not include S614 
and second, the overexpression of the phospho-mutant PAWS1S614A still induced a 
secondary axis formation to the same extent as the wild type. However, the 
phosphorylation of PAWS1 at S614 may be required for other PAWS1 functions that 
have yet to be discovered. 
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Like PAWS1, wild type CK1α, but not the kinase dead mutant, also caused axis 
duplication in Xenopus embryos. An interesting observation here was that the co-
expression of PAWS1 with either wild type or catalytically inactive CK1α, which both 
interact with PAWS1, blocked the induction of a secondary axis caused by 
overexpression of PAWS1 or CK1αWT alone. These phenotypes are not surprising if we 
consider that the signaling pathways that control developmental processes must be tightly 
regulated. Therefore, perturbations that disturb the homeostatic balance of the 
components of a complex may have detrimental outcomes. Here, it has been shown that 
when the levels of PAWS1 or CK1α are over-expressed or depleted, the protein levels of 
the other partner are affected. In contrast, co-expression of both PAWS1 and CK1α, 
potentially, restores the balance that is required for their proper function. It is thus 
proposed that the biological outcome that is observed with the axis duplication assays is 
more due to the perturbation of the homeostatic PAWS1:CK1α complex, perhaps leading 
to the mislocalisation of the PAWS1:CK1α complex, thereby resulting in abnormal 
phosphorylation patterns of key CK1α substrates, thus affecting Wnt signalling 
responses.  
This proposal was further supported by the finding that the intrinsic kinase activity 
of CK1α was not inhibited by its interaction with PAWS1. Therefore, the axis duplication 
inhibition observed upon co-expression of PAWS1 and CK1α was not due to inhibition 
of intrinsic CK1α catalytic activity. Although PAWS1 was not found to influence the 
kinase activity of CK1α in cells, it regulates CK1α localisation (Fig 3-17) which could 
potentially affect its access to specific substrates in response to specific signals. 
Therefore, it is pertinent to understand the key PAWS1-dependent CK1α substrates in 
order to establish molecular mechanisms through which the PAWS1:CK1α complex 
regulates Wnt signalling. 
An initial foray into global phospho-proteomics analysis in U2OS wild type, 
PAWS1-/- and PAWS1WT-rescue cells, revealed hundreds of phospho-peptides that were 
differentially enriched or attenuated in the different cell lines under unstimulated or 
Wnt3A-stimulated conditions. The phospho-peptides that were enriched exclusively in 
the wild type cells, but were absent in the PAWS1-/- cells, might reveal CK1α substrates 
that are regulated by the PAWS1:CK1α interaction. Interestingly, one of phosphoproteins 
that was significantly altered between wild type and PAWS1-/- cells and was identified in 
both Wnt3A-stimulated and unstimulated wild type cells, was BICC1. BICC1 is an RNA-
binding protein that may act as a translational repressor (Park, Blaser et al. 2016). In 
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Xenopus embryos, the maternal bicc1 mRNA forms a gradient that regulates translational 
repression of signalling mRNAs, such as Wnt11 and ddx5 (Park, Blaser et al. 2016). Most 
of the BICC1 targets are modulators of Wnt signalling and it was suggested that it may 
act as a novel regulator of the Wnt signalling pathway (Maisonneuve, Guilleret et al. 
2009, Park, Blaser et al. 2016). Due to its potential relevance to Wnt signaling, BICC1 
should be considered in future studies focused on the role of the PAWS1:CK1α 
interaction in Wnt signalling. Additional phospho-proteins in the same category as BICC1 
could be evaluated on the basis of their known roles in the Wnt signalling, as well as their 
abilities to cause axis duplication in Xenopus embryos. 
Moreover, phospho-peptides that were enriched exclusively in the PAWS1-/- cells 
might shed light into the mechanisms that regulate the aberrant response of these cells to 
Wnt signaling. Under basal conditions most of the phospho-peptides enriched in 
PAWS1-/- cells were mapped to actin-binding proteins such as ADDA, XIRP1 and 
AHNK. Hence, it could be hypothesised that the phosphorylation of these proteins might 
regulate the actin cytoskeleton, which is known to be regulated by PAWS1 (Cummins, 
Wu et al. 2018) ;Chapter 5). 
To validate the phosphorylation of the identified proteins at the relevant sites in 
cells, a number of experimental strategies could be employed. First of all, in order to 
establish whether the phosphorylation of the endogenous substrates is due to CK1α, 
treatment of cells with pharmacological inhibitors of CK1α, such as D4476, should 
demonstrate reduced phosphorylation of the relevant residues. Alternatively, validation 
could be accomplished by the depletion of the CK1α protein in cells by RNAi. 
Furthermore, it should be demonstrated that PAWS1-/- cells, which have substantially 
lower levels of CK1α compared to wild type cells, display reduced phosphorylation of 
the relevant residues. An additional benefit of this approach would be the validation of 
CK1α substrates that are regulated by the PAWS1:CK1α interaction. In all cases, changes 
in the phosphorylation levels may be monitored in cell extracts with phospho-specific 
antibodies or by the Phos-tag method. Additionally, validation of the PAWS1-dependent 
CK1α substrates under Wnt3A- stimulated conditions, should include experiments that 
assess the impact of phospho-deficient and phospho-mimetic mutants of the relevant 
targets, in Wnt signalling activation assays in cells and in axis duplication studies in 
Xenopus embryos. 
 One of the most important findings presented in this Chapter, prompted by the 
initial observations of the PAWS1:CK1α association was the demonstration that each 
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member of the FAM83 family is able to interact with different CK1 isoforms via their 
DUF1669 domain. While all FAM83 members interacted with CK1α, FAM83A, 
FAM83B, FAM83E, and FAM83H also interacted with CK1δ and CK1ε. Key conserved 
residues within the DUF1669 domain were identified as critical mediators of the CK1 
interaction. The DUF1669 domain is evolutionarily conserved in vertebrates. The 
pleiotropic nature of CK1 isoforms probably necessitated additional regulatory 
mechanisms in the more evolutionary advanced organisms, which could have possibly 
resulted in, through an evolutionary pressure, the evolution of the DUF1669 domain as a 
CK1 interactor. In humans, the DUF1669 domain is present only in FAM83 proteins. 
Perhaps the DUF1669 domain of FAM83 proteins serves as an anchor for CK1 isoforms, 
tethering them to specific cellular organelles or membranes in proximity to their 
substrates, other enzymes or signalling molecules. This is not something new in the 
biology of cell signalling, as the A-Kinase Anchoring Proteins (AKAPs) regulate the local 
activation of Protein Kinase A by localising it to its substrates to streamline signal 
transduction (Esseltine and Scott 2013). However, it is yet to be defined whether FAM83 
proteins interact with CK1 isoforms in a synergistic or competitive manner, to regulate 
CK1 enzymatic function in cells. 
 The robust interactions between FAM83 proteins and the CK1 isoforms provide 
unique opportunities to target specific CK1 isoforms in cells. Misregulation of CK1 
isoforms has been linked with many human diseases, including cancer and 
neurodegeneration (see 1.6.5). However, poor understanding of CK1 functional 
regulation, together with the enzymatic pleiotropy, have limited the exploitation of CK1 
isoforms as targets in therapeutics. The data presented here have demonstrated that 
FAM83 proteins, and in particular PAWS1, can regulate CK1α and that perturbations of 
PAWS1 levels have a direct influence on CK1α levels, as well. Although further research 
is required to address if alterations in CK1α protein levels are accompanied by 
perturbations in its kinase activity, the ability to modulate PAWS1 levels will be a 
valuable tool in understanding and interfering in CK1 biology. In a similar vein, the 
generation of a PAWS1 transcription reporter system would be an ideal tool to screen for 
and identify small molecules, inhibitors or ligands, that could regulate PAWS1 
transcription in a sensitive and quantitative manner.  
 However, one limitation of modulating protein levels is that it can potentially 
affect other activities, related to the global enzymatic functions of CK1α in cells, resulting 
in non-specific or off-target effects. To overcome these limitations, the design of 
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molecules that specifically target and disrupt the interaction between PAWS1 and CK1α 
is recommended. Ongoing efforts (by A. Bullock lab, Oxford) aiming to solve the crystal 
structure of PAWS1 in complex with CK1α are underway and such a structure will 
facilitate drug design. Drugs generated in this manner could prove to be useful in treating 
pathological conditions associated with CK1α. Furthermore, solving the crystal structure 
of the PAWS1:CK1α complex could potentially reveal the basis of how different FAM83 
members interact with specific CK1 isoforms in cells.  
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5. PAWS1 interacts with the Calcium/Calmodulin-
dependent kinase 2  
 
5.1 Introduction 
 Phenotypic characterisation of the U2OS PAWS1-/- cell line, which was employed 
for studies in the previous Chapters, revealed morphological differences compared to the 
wild type controls (Cummins, Wu et al. 2018). Further characterisations of PAWS1-/- cells 
revealed that they displayed actin cytoskeletal defects, which severely inhibited their 
ability to migrate (Cummins, Wu et al. 2018). Examination of the proteins associated with 
PAWS1, which was presented in Chapter 3, revealed a number of proteins that are 
implicated in regulating cytoskeletal dynamics and cell migration. Among these, CD2AP 
was validated as an interactor of PAWS1 (Cummins, Wu et al. 2018). CD2AP is an 
adapter protein involved in the formation of cell junctions as well as the actin 
polymerisation during cell migration (Tang and Brieher 2013, Zhao, Bruck et al. 2013). 
In wild type U2OS cells, it was shown that a pool of PAWS1 interacts with CD2AP at 
the membrane ruffles at the cell periphery, where it appears to control actin dynamics for 
the initiation of lamellipodia formation and cellular migration (Cummins, Wu et al. 2018). 
In contrast, PAWS1-/- cells were shown to display defects in lamellipodia formation, 
which could be attributed to the absence of the CD2AP accumulation at the cell periphery 
(Cummins, Wu et al. 2018). Strikingly, CD2AP-/- U2OS cells phenocopy actin 
cytoskeletal and cell migration defects observed in PAWS1-/- cells (Cummins, Wu et al. 
2018). However, the precise mechanisms that control PAWS1 association with CD2AP 
to subsequently modulate actin cytoskeleton and cell migration remain elusive and are 
still under investigation in the Sapkota lab. 
 In addition to CD2AP, calcium and calmodulin-dependent kinases isoform D and 
G (CaMK2D and CaMK2G) were identified as PAWS1 interactors. This was quite 
exciting because Ca2+ influx and efflux play major role in controlling cytoskeletal 
dynamics (Tsai, Kuo et al. 2015). The two major Ca2+ sources for cells are the 
extracellular space and the endoplasmic reticulum (ER). A transient increase in the 
intracellular Ca2+ concentration leads to calcium binding by regulatory proteins which 
then activate biological responses. The major calcium-binding protein is the 
evolutionarily conserved protein Calmodulin (CaM) (Cheung 1980). CaM has no 
enzymatic activity per se but functions to sense Ca2+ signal and transduce it to 
158 
 
downstream enzymes (Hoeflich and Ikura 2002). One of the best characterised 
downstream targets is the group of CaM-dependent kinases (CaMKs), which in turn 
phosphorylate and modulate the activities of key components of the cytoskeletal 
machinery (Hoffman, Farley et al. 2013). 
 CaMK2s are Ser/Thr protein kinases whose activation is primarily dependent on 
Ca2+/CaM (Lee and Edelman 1994). Their kinase domain is followed by a regulatory 
domain which contains an autoinhibitory domain and a CaM-binding domain and an 
association domain (Fig 5-1A) (Swulius and Waxham 2008). Under basal Ca2+ levels, 
CaMK2s remain inactive via auto-inhibitory mechanisms that involve the regulatory 
domain, which blocks catalytic activity (Tokumitsu, Enslen et al. 1995). An increase in 
the intracellular Ca2+ concentration results in the saturation of CaM with four calcium 
ions followed by subsequent conformational change that allows its binding to CaMK2s, 
which then releases them from autoinhibition (Peersen, Madsen et al. 1997). Once 
activated, CaMK2s phosphorylate their substrates, which usually possess the consensus 
phosphorylation motif F/I/L/V/Y-x-R-x-x-S*/T* (White, Kwon et al. 1998).  
 CaMK2 enzymes are multifunctional, as they have many substrates in cells and 
they form multi-subunit complexes (Kolodziej, Hudmon et al. 2000). In mammals, there 
are four CaMK2 isoforms (A, B, D and G), that are encoded by four different genes (Fig 
5-1). CaMK2A and CaMK2B are brain specific, whereas CaMK2D and CaMK2G are 
ubiquitously expressed (Swulius and Waxham 2008). All isoforms are present in the 
cytosol as well as the nucleus, where they can regulate gene transcription (Tokumitsu, 
Enslen et al. 1995, Wu and McMurray 2001). Like all the CaMKs, CaMK2s remain 
inactive under basal Ca2+ levels, due to autoinhibition. A rise in the intracellular Ca2+ 
levels, followed by Ca2+-saturation of CaM results in the activation of each subunit of the 
CaMK2 holoenzyme. Adjacent subunits are then auto-phosphorylated at Thr287 (T286 
in A isoform) generating Ca2+-independent activity (Miller and Kennedy 1986, 
Bradshaw, Hudmon et al. 2002). This autonomous activity further increases the affinity 
of CaMK2 for Ca2+/CaM, an event known as “CaM-trapping” (Meyer, Hanson et al. 
1992). As a consequence, CaMK2 remains activated far beyond the duration of the Ca2+ 
signal that causes its initial activation. 
 CaMK2 isoforms regulate synaptic plasticity in the brain (Derkach, Barria et al. 
1999), cell proliferation (Skelding, Rostas et al. 2011), and cardiac contraction (Hudmon, 
Schulman et al. 2005) although the mechanisms of their activation as well as the 
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substrates they target remain unclear. More recently, several reports have linked the 
function of CaMK2 with cell migration and invasion of cancer cells (Easley, Brown et al. 
2008, Mercure, Ginnan et al. 2008, Chi, Evans et al. 2016). It has been shown that in the 
vascular smooth muscle cells, CaMK2D is activated in the leading edge of the 
lamellipodia of migrating cells and pharmacological inhibition or silencing of CaMK2D 
decreases migration (Mercure, Ginnan et al. 2008). In line with this, activation of CaMK2 
via autophosphorylation at T287 (or T286 for A isoform) was found to increase invasion 
and migration of breast cancer cells, osteosarcoma and gastric cancer cells (Daft, Yuan et 
al. 2013, Liu, Han et al. 2014, Chi, Evans et al. 2016). On the contrary, decreased 
expression of CaMK2D in osteosarcoma and prostate cancer cells was associated with 
decreased motility and invasion (Wang, Symes et al. 2010, Daft, Yuan et al. 2013). 
 Moreover, CaMK2 is a transducer of the Wnt/Ca2+ signalling pathway (Kuhl, 
Sheldahl et al. 2000). Wnt ligands, such as Wnt5A and Wnt11, cause an intracellular 
release of Ca2+, which in turn activates CaMK2 and PKC. In Xenopus embryos, CaMK2 
is active in the cells that promote the ventral cell fates and it was shown that inhibition of 
CaMK2 promotes dorsal cell fates (Kuhl, Sheldahl et al. 2000). Specifically, it was shown 
that overexpression of the constitutively active CaMK2 T286D mutant on the dorsal side 
of the embryo resulted in ventralisation, whereas overexpression of the kinase dead 
CaMK2 K42M mutant resulted in axis duplication (Kuhl, Sheldahl et al. 2000). In human 
cells, suppression of Wnt5A signalling was shown to inactivate CaMK2, monitored by 
its phosphorylation levels at T286 (Dissanayake, Wade et al. 2007). The output of 
Wnt/Ca2+ signalling is the dephosphorylation of the transcriptional regulator nuclear 
factor associated with T cells (NFAT) by calcineurin, followed its nuclear translocation 
for the activation of transcription of its target genes (Sheldahl, Slusarski et al. 2003). 
 The aim of this Chapter is to study the potential roles of the association between 
PAWS1 and CaMK2D and G isoforms. Due to time limitations, a thorough analysis has 
not been possible. However, this Chapter will present preliminary data and set the basis 
for further investigation into the possible roles of CaMK2s in regulating PAWS1 during 
cell migration, proliferation and calcium signalling. 
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Figure 5- 1 The mammalian CaMK2 isoforms 
A. Schematic illustration of the domain architecture of the CaMK2 isoforms. The 
catalytic domain, which is responsible for the phosphotransfer reaction to occur, 
is followed by the regulatory region that includes the autoinhibitory and the CaM-
binding domain, and by the association domain.  At basal Ca2+ levels, the 
autoinhibitory domain blocks substrate-binding or the catalytic activity of the 
catalytic domain. A rise in the intracellular Ca2+ levels, causes the binding of CaM 
to the CaM-binding domain, releasing autoinhibition. The association domain is 
present only in the CaMK2 enzymes and is required for their assembly into 
twelve-subunit holoenzymes (Adapted from Swulius and Waxham, 2008). 
 
B. Sequence alignment of the mammalian CaMK2 isoforms. Alignment was 
performed with ClustalO in Jalview 2.10.3 and colouring indicates the % of 
sequence identity as shown in the box.  
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5.2 Results 
5.2.1 PAWS1 interacts with CaMK2D and CaMK2G 
 As shown in Chapter 3, by mass spectrometry CK1α was identified as the major 
interactor of endogenous PAWS1 (Fig 3-12). CK1α was closely followed by CaMK2D 
and G isoforms as interactors of endogenous PAWS1, albeit the total spectral counts for 
CaMK2D/G were substantially lower than for CK1α (Fig. 3-12C). Similarly, CD2AP was 
also identified as an interactor of PAWS1 (Fig 3-12C). From these experiments, the 
peptide coverage of CaMK2D and CaMK2G isoforms identified in PAWS1 IPs but not 
in control IPs indicated a robust interaction (Figure 5-2A). 
To validate the interactions between PAWS1 and CaMK2 isoforms, GFP-tagged 
CaMK2D and CaMK2G were transiently expressed in U2OS cells. GFP-IPs co-
immunoprecipitated low levels of endogenous PAWS1 from both GFP-CaMK2D and 
GFP-CaMK2G expressing cells but not from GFP-control, indicating weak interaction 
(Fig 5-2B). Furthermore, FLAG-CaMK2D or FLAG-empty vector were transiently 
expressed in PAWS1GFP/GFP knock-in U2OS cells and the cell extracts were subjected to 
GFP- and FLAG-IPs (Fig 5-2C). FLAG-CaMK2D co-precipitated with GFP-PAWS1 and 
similarly GFP-PAWS1 was co-precipitated with FLAG-CaMK2D but not with FLAG-
control (Fig 5-2C). The results from the co-IPs show that the interaction between PAWS1 
and CaMK2 isoforms is rather weak and vastly weaker than the PAWS1:CK1α interaction 
that was described previously. There could be three possible explanations for this: first, 
the interaction is stimulus-dependent and so it is weak under unstimulated conditions; 
second, a limited pool of the PAWS1 and CaMK2 proteins contribute to the interaction; 
third, PAWS1 is a substrate for CaMK2D/G and so the interaction is only transient and 
so as soon as PAWS1 is phosphorylated, it dissociates from CaMK2D/G isoforms. Due 
to time constraints, focus was turned into investigating only the third possibility, that 
PAWS1 might be a substrate of CaMK2D/G. 
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Figure 5- 2 PAWS1 interacts with CaMK2D and CaMK2G isoforms 
A. The highlighted tryptic peptides on CaMK2D (top) and CaMK2G (bottom) 
indicate the overall protein coverage as identified by mass-spectrometry of 
PAWS1-GFP IPs from Fig 3-12A. The included images were obtained using 
Scaffold V4.3 analysis of the LC-MS/MS data. 
 
B. U2OS cells were transfected with GFP-CaMK2D, GFP-CaMK2G or GFP-control 
for 48 h prior to lysis. Cell extracts (500 μg of protein) were subjected to GFP-
IPs. Input extracts (10 μg of protein) and GFP-IPs (50% of the IP) were resolved 
by SDS-PAGE, followed by immunoblotting with the indicated antibodies. 
 
C. U2OS PAWS1GFP/GFP knock-in cells were transfected with FLAG-CaMK2D or 
FLAG-empty for 48 h prior to lysis. Cell extracts (200 μg of protein per IP) were 
subjected to GFP-IPs or FLAG-IPs. Input extracts (10 μg of protein) and GFP-IPs 
(100% of the IP) were resolved by SDS-PAGE, followed by immunoblotting with 
the indicated antibodies.  
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5.2.3 PAWS1 is phosphorylated at S356 by CaMK2D in vitro 
 To test if PAWS1 was phosphorylated by CaMK2, an in vitro kinase assay was 
set up using the recombinant GST-CaMK2D protein and the full-length 
GST-PAWS1-6xHis, both purified from E. coli. A reaction with GST-CK1α and PAWS1 
was employed as a positive control. As seen in Fig 5-3A, PAWS1 was phosphorylated 
robustly by CaMK2D while no signal was obtained in the absence of the kinase. The 
signal of the phosphorylated PAWS1 by CaMK2D was almost as robust as the signal 
from the CK1α-phosphorylated PAWS1 (Fig 5-3A). Additional bands at the molecular 
weight range from 75 to 37 kDa might represent CaMK2D autophosphorylation and/or 
degradation products of CaMK2D. In the absence of calcium and calmodulin from the 
reaction, PAWS1 was still phosphorylated, although the signal was substantially weaker 
compared to the reaction containing Ca2+/CaM (Fig 5-3B). The lower molecular weight 
bands were still detectable in the absence of Ca2+/CaM. Thus, if these products represent 
autophopshorylated CaMK2D, meaning that CaMK2D was still active then this could 
explain why PAWS1 phosphorylation was not completely abolished in the absence of 
Ca2+/CaM (Fig 5-3B). 
 To identify the CaMK2D phosphorylation site on PAWS1, an in vitro kinase assay 
reaction was set up using non-radioactive ATP. The reaction sample was resolved by 
SDS-PAGE and the phospho-PAWS1 band, as detected by Coomassie staining, was 
excised, trypsin-digested and subjected to analysis by Mass spectrometry. One peptide 
with a single phosphorylated residue was identified, with the molecular mass of 520.753 
Da. This was identical to the peptide expected for a tryptic phospho-peptide comprising 
residues 354-361 of PAWS1 (AKSVDEIAK), with the Ser356 being the phosphorylated 
residue. Indeed, analysis of PAWS1 that was transfected in U2OS and HEK93 cells by 
mass spectrometry, as well as global phosphoproteomics analysis in U2OS cells (Chapter 
4) had also identified this pSer356 as one of the most prominent phosphorylated residues 
in PAWS1 (unpublished observation in the Sapkota lab), suggesting that this site is 
phosphorylated in cells. Excitingly, Ser356 is conserved in vertebrates and conforms to 
the CaMK2D/G phosphorylation consensus F/I/L/V/Y-x-R-x-x-S*/T*-F/I/L/M/V/Y-D/E 
motif, except that R at -3 position is replaced by a K. (LVKAKSVD). 
 To study the CaMK2 phosphorylation on PAWS1, a phospho-specific antibody 
was generated in rabbits against a short PAWS1 peptide containing pSer356 (p-PAWS1 
S356) residue in the middle. In order to validate the specificity of the antibody, an in vitro 
kinase was set up where PAWS1 was phosphorylated in vitro by CaMK2D using non-
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radioactive ATP. Different amounts of unphosphorylated and CaMK2D-phosphorylated 
PAWS1 were then spotted onto nitrocellulose membranes, which were immunoblotted 
with anti-p-PAWS1 S356 and anti-GST antibodies. As shown in Fig 5-4B, the anti-p-
PAWS1 S356 antibody displayed a dose-dependent signal for PAWS1 phosphorylated 
by CaMK2D, whereas no signal was detected for the unphosphorylated PAWS1. Anti-
GST blots, employed as loading controls, displayed identical signals in both cases (Fig 
5-4B). 
 To test if the p-PAWS1 S356 antibody could recognize PAWS1 phosphorylated 
at Ser356 in cells, plasmids encoding wild type PAWS1, or phospho-deficient (S356A) 
and phospho-mimetic (S356E) mutants of PAWS1 were transiently expressed in 
PAWS1-/- cells and cell extracts were analysed by Western blotting using antibodies 
against total and p-PAWS1 S356. As seen in Fig 5-4C, the anti-p-PAWS1 S356 antibody 
recognized only PAWS1WT but not PAWS1S356A or PAWS1S356E indicating that the 
antibody selectively recognises PAWS1 phosphorylated by CaMK2D at S356 in cell 
extracts. Anti-PAWS1 antibody showed that the expression of wild type PAWS1 was 
slightly lower than the phospho-mutants Notably, when co-expressed with CaMK2D, the 
levels of PAWS1-pSer356 did not appear increase further (Fig 5-4C). 
 To determine whether PAWS1 phosphorylation at S356 in cells was indeed 
mediated by CaMK2D and/or CaMK2G, siRNAs were used to silence the expression of 
these two kinase isoforms, both individually and collectively. Upon increasing 
concentrations of siCaMK2D alone or in conjunction with siCaMK2G, the 
phosphorylation levels of PAWS1 at S356 were decreased by about 50% compared to the 
levels observed in untransfected cells and those that were transfected with non-targeting 
siRNAs (Fig5-5). Due to the lack of an antibody that recognizes endogenous CaMK2G, 
it was not possible to determine the efficiency of the siCaMK2G. Nevertheless, no 
difference in p-PAWS1 S356 levels were observed between the untransfected control and 
siCaMK2G transfected cells, suggesting that either the CaMK2G silencing was not 
efficient enough or PAWS1 phosphorylation at S356 is specifically mediated by 
CaMK2D isoform. 
 Following validation of the p-PAWS1 S356 antibody for detection of endogenous 
PAWS1 phosphorylated at S356, it was possible to test whether activating or inhibiting 
the kinase activity of CaMK2 in cells affected the phosphorylation of PAWS1 at S356. 
For this, the calcium ionophore A23187 (Reed and Lardy 1972) and the calcium chelator 
BAPTA-AM (Wie, Koh et al. 2001) were used. To monitor the activation of CaMK2 the 
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phospho-specific antibody recognizing the autophosphorylation site T286 (pCaMK2 
T286) was used. It should be noted that this antibody cannot distinguish between different 
CaMK2 isoforms. Elevated level of pPAWS1 S356 was observed upon Ca2+ ionophore 
treatment for 1 min, whereas no difference in pCaMK2 T286 was observed (Fig 5-6). 
BAPTA-AM treatment resulted in a slight decrease in the levels of pPAWS1 S356 levels 
(Fig 5-6). Rather surprisingly, the levels of pCaMK2 T286 were significantly increased 
upon treatment with BAPTA-AM (Fig 5-6) because the opposite outcome was expected, 
as chelating the calcium ions in cells should result in CaMK2 inhibition, which would 
mean decreased autophosphorylation at T286.  
 To investigate this peculiar result further, U2OS cells were subjected in a time 
course treatment of different calcium ionophores and inhibitors and CaMK2 activation 
was monitored by Western blotting (Fig 5-7). The levels of pCaMK2 T286 increased in 
a time-dependent manner after treatment with the calcium ionophores Ionomycin 
(Enyeart, Liu et al. 2011) and A23187, as well as with the calcium chelator BAPTA-AM, 
the calcium channel blocker SKF 96365 (Singh, Hildebrand et al. 2010) and the CaMK2 
inhibitor autocamtide-3 derived inhibitory peptide (AC3-I) (Chen, Otmakhov et al. 2001). 
However, the most striking observation to emerge from this experiment was the effect of 
DMSO on CaMK2 activation. An elevation in the levels of pCaMK2 T286 was detected 
after 30 and 60 min of treatment with DMSO control (Fig 5-7). Therefore, the above 
findings are somewhat affected by the fact that all the compounds used were dissolved in 
DMSO, in accordance with the manufacture’s guidelines. The effects of DMSO on 
calcium signalling have been underestimated in the existing literature despite some 
studies that have reported that 1% (v/v) DMSO in the culture medium could elevate 
intracellular Ca2+ levels (Brown and Rydqvist 1990, Morley and Whitfield 1993). Due to 
time limitations, the issues with the above compounds on calcium signalling have not 
been resolved. However, it would be recommended to dissolve these compounds either 
in water, or in other solvents that do not affect calcium signalling. 
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Figure 5- 3 PAWS is phosphorylated by CaMK2D in vitro 
A. In vitro kinase assay with GST-CaMK2D (200 ng) and GST-PAWS1-6xHis (2 
μg) in the presence of 32P-ATP (500 cpm/pmol). Phosphorylation of PAWS1 by 
CK1α was performed as a positive control. The reaction was stopped after 30 min 
at 30 °C and the samples were resolved by SDS-PAGE, the gel was Coomassie 
stained and radioactivity was analysed by autoradiography. 
 
B. Same as (A), except that the reactions were performed in the presence or absence 
of CaCl2 (200 mM) and Calmodulin (CaM) (40 μM) and gels were analysed by 
autoradiography. 
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Figure 5- 4 Validation of CaMK2D-phosphorylation of PAWS1 at S356 with a 
pPAWS1 S356 antibody 
A. Sequence alignment of PAWS1 from human, mouse and Xenopus laevis (XNLA) 
around the S356 phosphorylation residue, indicated by the blue arrow. Alignment 
was performed with ClustalO in Jalview 2.10.3 and colouring indicates the % of 
sequence identity as shown in the box.  
 
B. A phospho-specific antibody against 15 residues surrounding PAWS1 phosho-
S356 was generated by immunising rabbits and was purified by first passing sera 
through the dephospho-peptide dolumn and then affinity-purified on the phospho-
S356 peptide immunogen (by the DSTT antibody production team). A kinase 
assay was set up as in 5-3A but with non-radioactive ATP. Reaction mix was 
diluted as indicated and spotted on a nitrocellulose membrane, which was probed 
with the indicated antibodies. 
 
C. PAWS1-/- U2OS cells were transfected with plasmids encoding PAWS1WT, 
PAWS1S356A or PAWS1S356E with or without the plasmid encoding 
GFP-CaMK2D for 48 h prior to lysis. Cell extracts (20 μg of protein) were 
resolved by SDS-PAGE, followed by immunoblotting with the indicated 
antibodies. 
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Figure 5- 5 Validation of the PAWS1 S356 by CaMK2D in cells 
CaMK2D and CaMK2G expression was silenced in U2OS cells with indicated amounts 
of siRNA for 48 h prior to lysis. Cell extracts (20 μg of protein) were resolved by 
SDS-PAGE, followed by immunoblotting with the indicated antibodies. (UT: Untreated, 
NT: Non-targeting RNA). 
 
 
 
Figure 5- 6 PAWS1 does not appear to affect the calcium-induced activation of 
CaMK2D 
PAWS1-/- U2OS cells stably restored with PAWS1WT and PAWS1S356A were treated with 
the calcium ionophore A23187 for 1 min or the calcium chelator BAPTA-AM for 6 h 
prior to lysis. Cell extracts (20 μg of protein) were resolved by SDS-PAGE, followed by 
immunoblotting with the indicated antibodies. 
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Figure 5- 7 DMSO control induces calcium-responses in U2OS cells 
U2OS cells were treated with the indicated DMSO control, or calcium chelator 
BAPTA-AM, the ionophores Ionomycin and A23187, and the calcium channel blocker 
SKF 96365 or the CaMK2 inhibitor autocamtide-3 derived inhibitory peptide (AC3-I) for 
the indicated time points prior to lysis. Cell extracts (15 μg of protein) were resolved by 
SDS-PAGE, followed by immunoblotting with the indicated antibodies. 
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5.2.4 Biological role of PAWS1 S356 phosphorylation in cells 
 To study the potential physiological roles of PAWS1 phosphorylation at S356 in 
cells, PAWS1-/- cells were stably restored with PAWS1WT, PAWS1S356A or PAWS1S356E 
(Fig 5-8). Since PAWS1-/- cells were shown to display migratory defects (Cummins et al., 
2018), the first objective was to test if PAWS1 phospho-deficient (PAWS1S356A) and 
phosho-mimetic (PAWS1S356E) mutants could rescue the migration defects to the same 
degree as PAWS1WT. For this, cells were cultured to confluency in adjacent chambers 
separated by a spacer. Upon removal of the spacer, a uniform gap was formed and cell 
migration onto the gap was monitored by imaging for up to 12 h (Fig 5-9). PAWS1WT 
and PAWS1S356E cells completely closed the gap within 12 h, whereas PAWS1S356A 
migrated into the gap more slowly and failed to fill the gap even after 12 h (Fig 5-9). 
These results suggested that phosphorylation of PAWS1 at S356 is critical for cell 
migration, and could provide new insights into the CaMK2D function in regulating cell 
migration via phosphorylation of its novel substrate PAWS1. 
 Signaling cascades that regulate cell migration often regulate cell proliferation, 
(Collins, Ricketts et al. 1999, De Donatis, Comito et al. 2008) and CaMK2 isoforms have 
been implicated in cancer cell proliferation (Wang, Zhao et al. 2015). Thus, the next aim 
was to evaluate whether phosphorylation of PAWS1 at S356 could impact cell 
proliferation. A proliferation assay based on the reduction of MTS tetrazolium compound 
by metabolically active cells to generate a colored formazan product which is soluble in 
cell culture medium, was used to monitor cell proliferation in PAWS1-/- cells that were 
stably restored with PAWS1WT, PAWS1S356A or PAWS1S356E. Formazan production is 
proportional to the number of living cells, so the measurement of the absorbance of 
formazan gave an estimation of cell viability. Cells were seeded in a 96-well plate at 
different densities and left for 16 h before being subjected to the MTS assay. It was found 
that the intensity of the produced colour was proportional to the cell density (Fig 5-10). 
No significant differences were observed among PAWS1WT, PAWS1S356A and 
PAWS1S356E, in any of the cell densities tested, suggesting that phosphorylation of 
PAWS1 by CaMK2 at S356 is not involved in the regulation of cell proliferation in U2OS 
cells (Fig 5-10). 
 Next, the involvement of PAWS1 phosphorylation at S356 in Ca2+ signalling 
activation was investigated by monitoring the Ca2+-induced nuclear translocation of 
NFAT in U2OS wild type, PAWS1-/-, PAWS1WT, PAWS1S356A cells (Fig 5-11). Cells 
were transiently transfected with NFAT-mCherry for 24 h and cells were treated with or 
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without the calcium ionophore A23187 for 5 min. Cells were then fixed and analysed 
with fluorescence microscopy. In the untreated cells, NFAT-mCherry displayed cytosolic 
staining (Fig 5-11). Ca2+ stimulation resulted in the nuclear translocation of NFAT within 
5 min independent of PAWS1 expression in all cell lines. This result indicated that 
PAWS1 is not involved in sensing intracellular Ca2+ fluxes nor in inducing Ca2+-mediated 
nuclear localization of NFAT. Similarly, PAWS1 phosphorylation at S356 was not found 
to be required in the downstream responses of Ca2+ signalling (Fig 5-11). 
 
 
Figure 5- 8 Generation of PAWS1S356A and PAWS1S356E stable cell lines  
U2OS PAWS1-/- cells were stably integrated with a vector encoding PAWS1WT, 
PAWS1S356A, PAWS1S356E. Cell extracts (15 μg of protein) were resolved by SDS-PAGE, 
followed by immunoblotting with the indicated antibodies. Expression levels were 
compared to endogenous PAWS1 levels from wild type U2OS extracts. 
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Figure 5- 9 Mutation of PAWS1 S356 to A prevents rescue of migration defect in 
U2OS PAWS1-/- cells 
Representative images of wound healing migration assay of PAWS1WT, PAWS1S356A, 
PAWS1S356E cells at 0, 4, 8, and 12 h following removal of the insert separating wells of 
confluent cells. The percentage of wound (gap) closure was quantified and plotted as 
shown (n=3; Error bars represent ±SEM).  
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Figure 5- 10 Mutation of PAWS1 S356 to A or E does not affect cell proliferation 
PAWS1WT, PAWS1S356A, PAWS1S356E cells were ceded in different densities and cell 
viability was quantified using the MTS cell proliferation assay kit (Promega). (n=3; Error 
bars represent ±SEM). 
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Figure 5- 11 PAWS1 does not affect the calcium-induced nuclear localisation of 
NFAT 
U2OS wild type (WT), PAWS1WT, PAWS1S356A, PAWS1S356E cells were transfected with 
NFAT-mCherry for 24 h and treated with the calcium ionophore A23187 (Ca2+) or DMSO 
control (-) for 5 min. Cells were then fixed and analysed with fluorescence microscopy 
for NFAT-mCherry (red) and DAPI (blue). Scale bars represent 106 μm. 
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5.3 Discussion 
 The data presented in this Chapter has demonstrated that PAWS1 interacts with 
CaMK2D and CaMK2G isoforms, albeit with weak affinity.  The observation that 
PAWS1 is phosphorylated by CaMK2D in vitro and in cells at S356, suggests that 
PAWS1 is likely to be a substrate for CaMK2D isoforms. However, the exact signalling 
cues and mechanisms that govern the interaction between PAWS1 and CamK2D/G and 
the phosphorylation of PAWS1 at S356 remain to be defined. Considerably more work 
will be needed to determine whether the phosphorylation of PAWS1 at S356 occurs 
constitutively or is stimulus-dependent. 
 It has been shown that PAWS1 controls actin cytoskeleton dynamics and cell 
migration through its association with the SH3 adaptor CD2AP (Cummins, Wu et al. 
2018). Thus, PAWS1 deficiency in U2OS cells causes defects in actin cytoskeleton and 
cell migration. The precise signalling and molecular events that prompt PAWS1 to 
control cytoskeleton dynamics remain elusive. Interestingly, calcium signalling is thought 
to play crucial roles in cytoskeleton dynamics and cell migration (Prevarskaya, Skryma 
et al. 2011, Tsai, Kuo et al. 2015). The observations that both PAWS1WT and the phospho-
mimetic PAWS1S356E mutant can rescue the cell migration defects caused by PAWS1 
deficiency but that the phospho-deficient PAWS1S356A cannot, indicate an intriguing 
possibility that phosphorylation of PAWS1 at S356 by CaMK2 isoforms could be 
involved in mediating actin cytoskeleton organisation to facilitate cell migration.  
Dynamic association of PAWS1 with CD2AP in the leading edge of the migrating 
cell was shown to be involved in cell motility. Previous reports have shown that CaMK2 
isoforms also localise in the periphery of the cell and inhibition of their activity is linked 
to decreased migration (Mercure, Ginnan et al. 2008).  It would therefore be exciting to 
test if CaMK2 co-localises with PAWS1 and CD2AP at the cell periphery, phosphorylates 
the pool of PAWS1 that associated with CD2AP, or that phosphorylation at S356 
modulates PAWS1 association with CD2AP. If PAWS1:CD2AP complex is not affected 
by the phosphorylation of S356, a proteomic approach on p-PAWS1 S356 could reveal 
proteins that read and relay the pSer356 signal on PAWS1.  
 In addition to U2OS cells described above, a good alternative cell line to study 
the effect of PAWS1 in cell migration would be the prostate cancer PC3 cells, which 
naturally lack PAWS1 expression (Vogt, Dingwell et al. 2014). PC3 cells are derived 
from bone metastatic cancer and are widely used in wound healing assays as they are 
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highly aggressive and motile and they were shown to express high levels of CaMK2 
isoforms (Mamaeva, Kim et al. 2009). Re-introduction of PAWS1WT, PAWS1S356A and 
PAWS1S356E in PC3 cells would allow one to test if PAWS1 affects migration as well as 
the kinase activity of CaMK2D by immunoprecipitation followed by kinase assay 
towards a peptide substrate.  
Furthermore, despite the weak nature of the PAWS1:CaMK2D/G interaction, it 
would be recommended to identify the residues on PAWS1 that mediate its association 
with CaMK2D/G. CaMK2-interacting deficient PAWS1 mutants could then be tested for 
their ability to restore the phenotypes that are associated with PAWS1 deficiency in U2OS 
and PC3 cells, such as cell migration and actin cytoskeleton organisation.  
 In the previous Chapters, it was uncovered that PAWS1 functions in canonical 
Wnt signalling via its association with CK1α. The robust nature of PAWS1:CK1α 
interaction cannot be neglected, when considering any new functions of PAWS1. The fact 
that CaMK2 is a player of the non-canonical Wnt signalling cascade makes the possibility 
of PAWS1 being a potential link between canonical and non-canonical Wnt signalling an 
intriguing one, which should be explored. In Xenopus embryos, CaMK2 activity is 
required for induction of the ventral cell fates, whereas inhibition of CaMK2 promotes 
dorsal cell fates (Kuhl, Sheldahl et al. 2000). Thus, it could be hypothesised that PAWS1 
might exert some of its functions by inhibiting CaMK2 activity in the ventral side when 
overexpressed in Xenopus embryos. However, this hypothesis has not been tested yet. A 
second assumption would be that PAWS1 phosphorylation at S356 by CaMK2D might 
be involved in its interaction with CK1α and its ability to induce axis duplication. 
However, injection of PAWS1S356A mRNA in Xenopus embryos did not inhibit the 
formation of a complete secondary body axis (personal communication with K. Dingwell, 
The Francis Crick Institute, London). 
 To sum up, the preliminary results presented in this Chapter have thrown up many 
questions that need further investigation. The most important limitation of this study was 
the lack of optimised tools to study Ca2+ signalling in cells. Once this is transcended, 
several assays including live cell imaging in response to Ca2+ stimuli and Ca2+ channel 
blockers or CaMK2 inhibitors can be performed to explore the role of PAWS1 
phosphorylation by CaMK2 in more detail. 
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6. The pathogenic mutations on PAWS1 gene and their 
association with skin disorders 
 
6.1 Introduction 
While the majority of this thesis has focused on the biochemical analysis of 
PAWS1, several studies have highlighted more clinical roles for PAWS1 (Drogemuller, 
Jagannathan et al. 2014, Sayyab, Viluma et al. 2016, Maruthappu, McGinty et al. 2017). 
Indeed, with PAWS1 mutations being reported in pathological conditions of skin and 
hair, the potential clinical implications of PAWS1 research cannot be ignored. Therefore, 
a more thorough analysis of these disease-relevant PAWS1 mutations in this final Chapter 
was warranted.  
To begin with, a recessive missense mutation in the PAWS1 gene resulting in 
R52P substitution was identified in dogs suffering from hereditary footpad hyperkeratosis 
(HFH) (Drogemuller, Jagannathan et al. 2014). The same mutation has since been 
reported in more dogs with HFH (Sayyab, Viluma et al. 2016). More recently, a novel 
recessive missense mutation in the PAWS1 gene resulting in A34E substitution has been 
reported in patients with palmoplantar keratoderma (PPK) (Maruthappu, McGinty et al. 
2017) (Fig 6-1). Both sets of mutations in dogs and humans cause identical symptoms, 
characterised by thickening of footpads, abnormal hair growth and morphology, and 
epidermal hyperplasia (Drogemuller, Jagannathan et al. 2014, Sayyab, Viluma et al. 2016, 
Maruthappu, McGinty et al. 2017). Interestingly, mice displaying spontaneous “wooly” 
phenotype, which was characterised by rough or matted appearance of the hair, were 
found to harbour homozygous mutations in the PAWS1 gene leading to truncation of 
PAWS1 (Radden, Child et al. 2013). Furthermore, internal analysis of the exome 
sequencing data from patients with various skin diseases in collaboration with I. McLean 
(University of Dundee) identified an autosomal dominant mutation in the PAWS1 gene 
leading to G640R substitution in patients with hereditary benign trichilemmal cysts, 
which originate from hair follicles (unpublished data). Remarkably, all of the above 
pathogenic mutations in PAWS1 are linked to skin diseases. However, the molecular 
mechanisms that underpin the pathogenicity by PAWS1 mutations remain unelucidated. 
 As mentioned in the Introduction to the thesis, Wnt signalling plays pivotal role 
in skin and hair homeostasis and development. Hyperactivation of Wnt signalling is 
linked to the development of skin tumours (Malanchi, Peinado et al. 2008, Yang, Andl et 
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al. 2008). Wnt signalling is crucial in the maintenance of the skin stem cells in humans 
and mediates hair differentiation (Huelsken, Vogel et al. 2001). Interestingly, patients 
with mutations in the Wnt genes have also been reported to display palmoplantar 
hyperkeratosis and hair growth abnormalities (Adaimy, Chouery et al. 2007, Petrof, Fong 
et al. 2011).  Given the role of PAWS1 in Wnt signalling that has been described in 
Chapter 3, it is tempting to speculate that the pathogenic PAWS1 mutations interfere with 
Wnt signalling, by either influencing PAWS1 interaction with CK1α or the transcription 
of PAWS1-dependent genes. Remarkably, a recent study reported that deletion of CK1α 
from keratinocytes of mice resulted in epidermal thickening and skin hyperpigmentation 
(Chang, Kuo et al. 2017), symptoms that closely resemble those caused by PAWS1 
mutations R52P and A34E in dogs and humans respectively ((Drogemuller, Jagannathan 
et al. 2014, Sayyab, Viluma et al. 2016, Maruthappu, McGinty et al. 2017). 
 The key aim of this Chapter was to establish the effect of the pathogenic PAWS1 
mutations on its function and delineate the molecular mechanisms by which PAWS1 
mutations cause pathogenicity. In light of the knowledge accumulated on PAWS1 
function in this thesis, these aims are now feasible. However, at the time this project was 
started, limited functional assays were available for PAWS1. Furthermore, due to time 
constraints of the PhD, most of the data presented here is preliminary in nature and will 
provide a framework for further research on this area.  
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6.2 Results 
6.2.1 Pathogenic PAWS1 mutants are defective in mediating PAWS1-
dependent transcription in PC3 cells 
  Prior to establishing the role of PAWS1 in Wnt signalling and CK1α biology, 
PAWS1 was reported to influence the transcription of ~800 genes in PC3 cells (Vogt PhD 
thesis, http://discovery.dundee.ac.uk). In order to study the role of the pathogenic PAWS1 
mutants in gene transcription, prostate cancer PC3 cells, which lack PAWS1 expression, 
were restored with PAWS1WT or the pathogenic PAWS1R52P and PAWS1G640R mutants, 
by retroviral infection (Fig 6-2A), to limit expression to near-endogenous levels seen in 
other cells (Vogt, Dingwell et al. 2014). qPCR was performed for some of the top target 
genes that were previously (Vogt, Dingwell et al. 2014) identified to be regulated by 
PAWS1 (Figure 6-2B). Interestingly, while PAWS1WT led to significant increase in the 
transcription of the transforming growth factor beta induced (TGFBI) and matrix 
metalloproteinase 13 (MMP13) genes compared to control PC3 cells, the pathogenic 
PAWS1R52P and PAWS1G640R mutants did not (Fig 6-2B). These results that the 
pathogenic mutants of PAWS1 mirrored the transcriptional profiles in control PC3 cells, 
which are devoid of PAWS1, suggested a possible loss of PAWS1 function caused by the 
mutations. However, as PC3 cells are metastatic prostate cancer cells and do not resemble 
primary epidermal keratinocytes and hail follicular cells that these mutations affect, it is 
not possible to predict whether the pathogenesis involves the misregulated transcription 
of TGFBI and MMP13.  MMP13 is a matrix metalloproteinase that functions in the 
turnover of connective tissue components (Knauper, Will et al. 1996). TGFBI is a 
secreted protein that inhibits cell adhesion (Skonier, Bennett et al. 1994). The expression 
of other PAWS1-target genes, including LGR5, CCNA1 and Androgen Receptor (AR) 
were not significantly affected by the pathogenic mutants (Figure 6-2B).  
 The experiments in PC3 cells were repeated when the PAWS1A34E mutation was 
identified in human patients (through personal communication with D. Kelsell, Blizzard 
Intitute, London) PC3 cells were stably restored with PAWS1WT or the pathogenic 
PAWS1A34E mutant by retroviral infection and the transcription of PAWS1-dependent 
genes LGR5, MMP13 and AR assessed (Fig 6-3). As before, restoration of PAWS1WT in 
PC3 cells activated the transcription of LGR5 and MMP13 and inhibited the transcription 
of AR compared to control PC3 cells. However, restoration of PAWS1A34E in PC3 cells 
mirrored the transcription of  MMP13 and AR seen in control cells, while the transcription 
of LGR5 was enhanced even beyond that caused by PAWS1WT (Fig 6-3B). Interestingly, 
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PAWS1A34E protein displayed a difference in its electrophoretic mobility, as it appeared 
at a slightly lower apparent molecular weight than PAWS1WT (Fig 6-3A), suggesting that 
PAWS1A34E mutant might lack or harbour different post-translational modifications 
compared to PAWS1WT or display distinct structural features that could explain loss of 
possible functions. However, due to time limitations of the PhD, further characterisation 
of these mutants was not possible and this project has now been undertaken by another 
member of the Sapkota lab (Dr K. Wu). 
 
Figure 6- 1 Representative phenotypes of the pathogenic PAWS1 mutations 
A. The affected paw of a dog suffering from hereditary footpad hyperkeratosis 
carrying PAWS1R52P mutation (left) compared to a paw from a healthy dog (right) 
(adopted from Drogemuller et al., 2014). 
 
B. The affected soles and palms of two siblings carrying with palmoplantar 
keratoderma carrying PAWS1A34E mutation (adopted from Maruthappu et al., 
2017). 
181 
 
 
Figure 6- 2 Pathogenic PAWS1 mutants appear to affect the transcription of 
PAWS1-regulated genes in PC3 cells.  
A. Extracts (20 μg protein) from control PC3 cells or those stably expressing 
PAWS1WT, PAWS1R52P or PAWS1G640R were resolved by SDS-PAGE and 
analysed by immunoblotting using the indicated antibodies. 
B. RNA from control PC3 cells or those stably expressing PAWS1WT, PAWS1R52P 
or PAWS1G640R PC3 cells was isolated and the relative expression of the indicated 
genes was analysed by qPCR. The results show the fold change in gene expression 
relative to the controls. (n=3; Error bars represent ±SEM; ****:p<0.0001, 
***:p<0.0002 **:p<0.002).  
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Figure 6- 3 PAWS1A34E mutant affects the transcription of some PAWS1-regulated 
genes.  
A. Extracts (10 or 20 μg protein) from control PC3 cells or those stably expressing 
PAWS1WT or PAWS1A34E were resolved by SDS-PAGE and analysed by 
immunoblotting using the indicated antibodies. 
B. RNA from control control PC3 cells or those stably expressing PAWS1WT or 
PAWS1A34E was isolated and the relative expression of the indicated genes was 
analysed by qPCR. The results show the fold change in gene expression relative 
to the controls. (n=3; Error bars represent ±SEM; ****: p<0.0001, ***:p<0.0002, 
*:p<0.033). 
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Figure 6- 4 Generation of PAWS1-GFP knock-in HaCaT cells using CRISPR/Cas9 
genome editing 
A. Extracts (20 μg protein) from wild type HaCaT cells (WT) or PAWS1-GFP 
knock-in clones were resolved by SDS-PAGE, followed by immunoblotting with 
anti-PAWS1. Clone 4 was selected for further analysis. 
 
B. DNA was extracted from HaCaT wild type (PAWS1WT) and PAWS1-GFP 
knock-in cells (clone 4) and a pair of primers was used to amplify the genomic 
region by PCR, as described in Fig 3-11D, followed by PCR followed by agarose 
gel electrophoresis. 
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Figure 6- 5  Generation of endogenous PAWS1-transcriptional reporter HaCaT cells 
by CRISPR/Cas9 genome editing 
A. Extracts (20 μg protein) from wild type HaCaT cells (WT) or 10 GFP-positive 
single cell clones selected with FACS, were resolved by SDS-PAGE, followed by 
immunoblotting with anti-PAWS1.  
 
B. Measurement of luciferase activities under basal conditions of cell clones from 
(A).  
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6.3 Discussion 
  As described above, there is now an accumulating body of evidence suggesting 
that PAWS1 mutations cause skin diseases (Radden, Child et al. 2013, Drogemuller, 
Jagannathan et al. 2014, Sayyab, Viluma et al. 2016, Maruthappu, McGinty et al. 2017). 
How these mutations cause disease phenotypes remain to be defined and the lack of 
functional assays for PAWS1 has limited progress in this regard. The preliminary 
evidence presented here suggests that the three pathogenic mutations of PAWS1 
described to date, namely A34E, R52P and G640R, potentially confer context-dependent 
loss of PAWS1 function. 
 By exploiting PAWS1-dependent transcription in PC3 cells, it is evident that the 
transcription of some of these genes is affected by all pathogenic mutants. However, PC3 
prostate cancer cells do not represent the physiologically relevant epidermal keratinocytes 
(A34E and R52P) and hail follicular cells (G640R) that the PAWS1 mutations appear to 
impact in patients. Therefore, the physiological roles of these mutations should be 
addressed in physiologically relevant cell systems. With this in mind, HaCaT 
keratinocytes were chosen in the Sapkota lab to establish tools and assays to study the 
function of these mutations further. In this context, the endogenous PAWS1 gene was 
modified by an insertion of a GFP tag at the C-terminus, to allow proteomic approach to 
identify PAWS1-interacting proteins in keratinocytes (Fig 6-5). In similar vein, ongoing 
work by Dr. K. Wu in the Sapkota lab has established PAWS1-/- HaCaT cells by 
CRISPR/Cas9, and he has stably introduced the pathogenic mutants of PAWS1, similar 
to those done in PC3 cells. These cells will be useful in investigating the molecular 
mechanisms by which PAWS1 mutations might cause pathogenesis. 
In light of the fact that PAWS1 associates with CK1α to mediate Wnt signalling, 
the ability of the pathogenic mutants to impact CK1α binding and Wnt signalling should 
be tested. Two of the pathogenic mutants, A34E and R52P, lie at the DUF1669 domain, 
which has been shown in Chapter 3 to mediate CK1α binding.  Preliminary findings by 
K. Wu showed that R52P and A34E mutants block the interaction between PAWS1 and 
CK1α, suggesting that the pathological phenotypes might arise from defects in Wnt 
signalling. Moreover, recently it has been shown that deletion of CK1α from mouse 
keratinocytes results in skin disease (Chang, Kuo et al. 2017) with phenotypes resembling 
those described for these PAWS1 pathogenic mutants (Drogemuller, Jagannathan et al. 
2014, Sayyab, Viluma et al. 2016, Maruthappu, McGinty et al. 2017). These are exciting 
correlations that now put PAWS1 at the heart of regulation of CK1α biology and Wnt 
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signalling. Future experiments will establish whether PAWS1 mutants affect the CK1α 
kinase activity, localisation and protein abundance of CK1α in cells.  
Given the importance of PAWS1 in skin biology, understanding how PAWS1 is 
regulated transcriptionally or post-translationally could offer potential opportunities for 
therapeutic interventions. With this in mind, to facilitate studies on transcriptional 
regulation of PAWS1, HaCaT cells have been generated in which a transcriptional 
reporter cassette encompassing Luciferase-IRES-GFP-2A has been inserted at the start 
codon of the PAWS1 gene (Fig 6-4, 6-5). The benefits of using an endogenous PAWS1-
transcriptional reporter with intact chromatin architecture have already been discussed in 
Chapter 4. These reporter cells will be useful in identifying stimuli that regulate PAWS1 
transcription and can be used for high throughput chemical or genetic screens to identify 
novel regulators of PAWS1 gene transcription. In summary, the collection of tools that 
have been developed above, are going to be very useful in answering questions on how 
PAWS1 functions in keratinocyte biology and how mutations cause skin diseases. 
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7. Conclusion and future perspectives 
 
 In conclusion, one of the key discoveries of this thesis has been the identification 
of PAWS1 as a novel regulator of the Wnt signalling pathway. The thesis provides 
evidence that the association of PAWS1 with CK1α is critical for PAWS1 to modulate 
Wnt signalling. CK1α is a known regulator of Wnt signalling and phosphorylates many 
components of the pathway, however, how its activity and substrate specificity is 
regulated is poorly understood (Cruciat 2014). Although the precise molecular 
mechanisms by which the PAWS1:CK1α complex regulates Wnt signalling remain to be 
defined, the observations that PAWS1 interacts and co-localises with CK1α 
independently of Wnt stimulation and does not impact intrinsic CK1α kinase activity have 
led to the hypothesis that PAWS1 directs CK1α to or sequesters CK1α away from specific 
subcellular compartments and substrates to regulate Wnt signalling.  
PAWS1 is a member of the poorly characterised FAM83 family of proteins, which 
share the conserved DUF1669 domain of unknown function. Research on the protein 
function of PAWS1 in cells was initiated in the Sapkota lab following its discovery as an 
interactor of SMAD1 (Vogt, Dingwell et al. 2014). Focusing on the BMP signalling, it 
was shown that PAWS1 regulates the transcription of only a subset of non-canonical, 
SMAD4-independent BMP-target genes (Vogt, Dingwell et al. 2014). Additional data 
presented in this thesis in human cells and Xenopus embryos corroborates with these 
findings, and also shows that canonical BMP signalling is not affected by PAWS1. Given 
the role of the BMP pathway during embryonic development, the impact of PAWS1 on 
Xenopus embryogenesis was assessed, in collaboration with Jim Smith lab (The Francis 
Crick Institute, London). Remarkably, PAWS1, when injected at the 4-cell stage Xenopus 
embryos was shown to induce a complete secondary body axis at the tadpole stage. Such 
axis-duplication phenotypes are often the result of either canonical BMP signalling 
inhibition or canonical Wnt signalling activation (De Robertis and Kuroda 2004, 
Hashiguchi and Mullins 2013). With no apparent inhibition of the canonical BMP 
signalling pathway by PAWS1, the focus quickly turned to a possible role in Wnt 
signalling activation. 
Evidence obtained from Xenopus embryos and human cells established that 
overexpression of PAWS1 activates Wnt-transcriptional responses. In PAWS1-/- U2OS 
cells, Wnt-transcriptional responses were attenuated. Although the body of literature on 
Wnt signalling has grown exponentially over the years, there are still many unanswered 
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questions regarding the mechanisms that govern the key steps of Wnt signal transduction. 
Among the most tantalising questions are: (1) how is the β-catenin destruction complex 
regulated?; (2) how does the stabilised β-catenin translocate to the nucleus upon Wnt 
stimulation?; (3) how does Wnt signalling co-ordinate changes in cell fate, shape and 
polarity?;  (4) how does Wnt signalling modulate the behaviour of cancer cells?; (5) is it 
possible to interfere with Wnt signalling by specifically targeting the key individual 
components of the pathway? Although this thesis did not specifically deal with answering 
the above questions, the results presented in the first two chapters establish PAWS1 as a 
novel component of Wnt signalling in cells and development. Nevertheless, the 
identification of new players of the Wnt signalling not only provides new insights into 
dissecting the complex nature of the pathway, but also opens up potential therapeutic 
avenues for treatment of cancers caused by aberrant Wnt signalling. 
 In attempting to establish the mechanisms by which PAWS1 regulates Wnt 
signalling, one of the most striking findings made in the thesis, was the discovery that 
PAWS1 interacts with CK1α. After mapping the interaction sites between PAWS1 and 
CK1α, it was demonstrated that the association between PAWS1 with CK1α is necessary 
to modulate Wnt signalling. However, further research is required to address the precise 
mechanisms for the coordinated actions of PAWS1 and CK1α in Wnt signalling 
regulation. 
 CK1 isoforms have long been regarded as critical components of Wnt signalling, 
as they have been known to exert both positive and negative regulation on the pathway 
(Sakanaka, Leong et al. 1999, McKay, Peters et al. 2001, Amit, Hatzubai et al. 2002, Liu, 
Li et al. 2002, Elyada, Pribluda et al. 2011). There is still considerable disagreement in 
the field over which CK1 isoforms control the phosphorylation of specific components 
within the Wnt signalling cascade (Del Valle-Perez, Arques et al. 2011, Cruciat 2014). 
Part of this stems from the fact that very little is known about the regulation of CK1 
isoforms in cells (Knippschild, Kruger et al. 2014, Schittek and Sinnberg 2014). PAWS1 
interacts selectively with CK1α and CK1αL isoforms, but not CK1δ and CK1ε, to activate 
Wnt signalling in Xenopus embryos and in human cells. Like PAWS1, developmental 
studies in Xenopus have shown that overexpression of CK1α alone can also induce axis 
duplication (Peters, McKay et al. 1999, McKay, Peters et al. 2001); (Chapter 3), 
suggesting a positive regulation of this isoform in the Wnt pathway. However, contrasting 
evidence demonstrated that CK1α was also responsible for the phosphorylation of 
β-catenin at S45, which promotes its subsequent phosphorylation at S33/37/T41 by 
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GSK3, thereby inducing its ubiquitylation and degradation (Liu, Li et al. 2002). 
Nevertheless, other studies reported that both CK1δ and CK1ε could also phosphorylate 
β-catenin at S45 (Sakanaka, Leong et al. 1999, Amit, Hatzubai et al. 2002). The negative 
role of CK1α in Wnt signalling has been further supported by the observations that 
conditional knockout of CK1α from the intestinal epithelium of mice leads to activation 
of Wnt signalling, by blocking the phosphorylation of β-catenin at S45, resulting in the 
stabilisation of β-catenin (Elyada, Pribluda et al. 2011). Interestingly, the levels of 
pSer45-β-catenin in PAWS1-/- U2OS cells were comparable to those seen in wild type 
cells, suggesting CK1α bound to PAWS1 is unlikely to play a key role in the 
phosphorylation of β-catenin at S45. The data presented in this thesis suggests that 
PAWS1 and CK1α coordinate to regulate Wnt signalling but the influence of CK1δ and 
CK1ε on Wnt signalling remains unaffected by PAWS1. This corroborates with the 
hypothesis that different CK1 isoforms target specific sets of substrates in cells and are 
uniquely regulated in driving specific cellular processes, including Wnt signalling. 
 One of the major questions that this thesis attempted to address, was how the 
association of PAWS1 with CK1α activated Wnt signalling. Using Xenopus embryos, 
through the assessment of axis-duplication and Wnt-transcriptional responses in animal 
caps, it was found that the PAWS1:CK1α complex acts either on the β-catenin destruction 
complex or somewhere downstream of it. However, it is evident from the data included 
here that PAWS1 does not associate with any components of the destruction complex, 
and does not appear to impact the CK1α-mediated phosphorylation of β-catenin at S45. 
Although PAWS1 and Axin were shown to form robust complexes with CK1α and 
GSK3β respectively, neither of them appeared to bind β-catenin or the other Wnt pathway 
components robustly. This was slightly unexpected, as the generally accepted model 
suggests that CK1α and Axin are core components of the β-catenin destruction complex 
(Ikeda, Kishida et al. 1998, Liu, Li et al. 2002, Li, Ng et al. 2012). Further research is 
required to determine whether this data presented here are specific to U2OS cells, or 
applicable more globally. Consistent with observations made here, evidence from 
mechanistic studies on the β-catenin phosphorylation by CK1, also suggests that CK1 
isoforms do not form stable interactions with β-catenin in cells (Bustos, Ferrarese et al. 
2006). On the other hand, it should be noted that the majority of the existing studies on 
the involvement of CK1α in β-catenin phosphorylation lack definitive in vivo evidence 
and are mostly based on overexpression systems or in vitro studies (Ikeda, Kishida et al. 
1998, Amit, Hatzubai et al. 2002, Liu, Li et al. 2002, Marin, Bustos et al. 2003, Bustos, 
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Ferrarese et al. 2006). Interactions that are observed with overexpressed proteins might 
not reflect the true physiological conditions, as they may represent forced activation of 
signalling pathways caused by imbalances in the equilibrium of the signalling 
components. 
 The nuclear localisation of the active β-catenin is fundamental to the Wnt-
transcriptional response (Polakis 2012). Although the PAWS1:CK1α complex did not 
appear to affect the composition of the destruction complex or the phosphorylation of 
β-catenin at S45, the nuclear accumulation of the active β-catenin was promoted by 
PAWS1 overexpression in Xenopus embryos and attenuated in PAWS1-/- cells. Little is 
known about the nucleo-cytoplasmic shuttling of β-catenin in response to Wnt stimulation 
and it is not clear what factors mediate this process. Therefore, the identification of the 
PAWS1:CK1α complex as a regulator of the nuclear accumulation of β-catenin upon Wnt 
activation is a potential significant contribution to this field. 
A key question that still remains unanswered is how the PAWS1:CK1α complex 
regulates the nuclear accumulation of β-catenin and whether this sufficiently explains the 
role of the PAWS1:CK1α complex in Wnt signalling. Because of the robustness of the 
complex, independent of Wnt signalling, PAWS1 is likely to influence the activity of 
CK1α against key substrates. However, because PAWS1 immunoprecipitates CK1α 
kinase activity from extracts and does not influence kinase activity in vitro, it is unlikely 
that PAWS1 affects intrinsic catalytic activity of CK1α in cells. Another observation was 
that loss of PAWS1 from U2OS cells resulted in a decrease in CK1α protein levels. 
Reciprocal depletion of CK1α also resulted in reduction of PAWS1 protein levels, 
suggesting each protein regulates the integrity of the PAWS1:CK1α complex in cells. 
While precisely how the stability of the PAWS1:CK1α complex is regulated is currently 
not known, specific subcellular distribution of the PAWS1:CK1α complex in response to 
different signalling cues is likely to regulate specific CK1α substrates. A comprehensive 
landscape of PAWS1-dependent CK1α substrates in response to Wnt signalling is likely 
to reveal key mechanistic insights into how the PAWS1:CK1α complex regulates the 
nuclear accumulation of β-catenin and therefore, Wnt signalling responses. Recently 
generated phospho-proteomic data on U2OS wild type and PAWS1-/- cells has identified 
many candidates that could uncover the PAWS1-dependent CK1α substrates that may be 
essential for mediating Wnt signalling. In the same vein, non-Wnt targets of CK1α that 
are PAWS1-dependent could provide novel insights into PAWS1 function beyond Wnt 
signalling. As discussed extensively in Chapter 4 (section 4.3), validation of the PAWS1-
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dependent CK1α substrates may establish the molecular mechanisms through which the 
PAWS1:CK1α complex regulates Wnt signalling, or indeed other CK1α-dependent 
functions in cells. 
The interaction between PAWS1 and CK1α was mapped to two conserved 
residues within the DUF1669 domain, which are conserved in all FAM83 proteins. 
Excitingly, all members of the FAM83 family can associate with CK1α, while half of 
them also interact with CK1δ and CK1ε isoforms. Furthermore, it has been shown that 
different FAM83 members colocalise with the interacting CK1 isoforms in distinct 
subcellular compartments (Fulcher LJ, Bozatzi P et al. 2018); In Press). Remarkably, the 
conserved point mutations on the FAM83 protein sequence that abolish their association 
with CK1, disrupt not only the colocalization of FAM83 protein with specific CK1 
isoforms in cells, but also the subcellular distribution of the respective FAM83 proteins 
themselves. Thus, other FAM83:CK1 complexes might act redundantly or in a 
coordinated fashion to mediate cellular processes, including Wnt signalling. For example, 
a recent report demonstrated that FAM83H recruits CK1 to nuclear speckles in colorectal 
cancer cells, although the downstream biology of this event has not been elucidated yet 
(Kuga, Sasaki et al. 2016). 
To date, one of the main reasons that have hindered research on PAWS1, and on 
FAM83 proteins in general, is the lack of information on their biochemical properties. 
The DUF1669 domain that unites the family members, from the data presented here, has 
emerged as an anchor for CK1 isoforms, and in doing so, may act to potentially regulate 
both CK1 isoform subcellular localisation and substrate specificity in cells. Preliminary 
proteomics data have already indicated that each FAM83 members have unique sets of 
binding partners. Therefore, FAM83 proteins might prove to be elusive regulatory 
components of CK1 isoforms, thereby helping to explain how these constitutively active 
kinases can contribute to the regulation of the myriad of cellular processes that they are 
known to be implicated in. The hypothesis that different FAM83 members serve to recruit 
CK1 isoforms to specific subcellular locations and substrates in response to distinct 
signalling cues opens up many exciting new avenues for future research. 
The DUF1669 domain contains a pseudo-PLD-like catalytic motif, but it is still 
unclear whether it possesses any function in the PLD pathway, such as binding to 
phospho-lipids. Preliminary structural insights of this domain suggest that the predicted 
PLD-like pocket is located away from the surface that contains the two residues that 
mediate the interaction with CK1 isoforms. Furthermore, the only proteins that have been 
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identified as interactors of the DUF1669 domains from proteomic studies in the Sapkota 
lab are the different isoforms of CK1. These observations raise interesting possibilities 
for investigating whether the binding of certain phospho-lipids to the PLD-like pocket of 
the DUF1669 domains can influence the ability of FAM83 members to bind CK1 
isoforms or influence their catalytic activity or substrate specificity. Such possibilities 
could potentially explain the differences in the binding specificity and/or affinity of 
different FAM83 members for distinct CK1 isoforms.  
CK1 proteins have been associated with cancer and neurodegenerative diseases 
but the pleiotropic nature of CK1 isoforms, has limited the exploration of CK1 inhibition 
in therapeutics (Perez, Gil et al. 2011, Cozza and Pinna 2016). The current inhibitors, 
including CK1-7, IC261, D4476, suffer from selectivity issues and display off-target 
effects, related to other CK1 isoforms and protein kinases (Table 1-2). FAM83 proteins, 
as novel CK1 regulators in cells, provide us with novel therapeutic opportunities to target 
specific CK1 isoforms in diseases. One remaining challenge is to establish the molecular 
bases for the FAM83:CK1 interaction through structural biology studies. Then, the 
development of small molecules that potentially disrupt the FAM83:CK1 association will 
be more feasible and could prove useful in targeting specific CK1 isoforms in distinct 
subcellular compartments.  
Other than its role in Wnt signalling, this thesis has demonstrated that PAWS1 
associates with the calcium/calmodulin-dependent kinases CaMK2D and CaMK2G, 
implying a role of PAWS1 in calcium signalling. In parallel to this work, it was 
discovered that the loss of PAWS1 results in migratory defects in human cells. Calcium 
signalling is known to be implicated in cytoskeletal reorganisation which orchestrates cell 
movement (Tsai, Kuo et al. 2015). Migration of cancerous cells from the primary tumour 
to other tissues is the main cause of death in patients with tumours (Mehlen and Puisieux 
2006, Taketo 2011). The cancerous cells must therefore undergo changes, which allow 
them to migrate via the extracellular matrix into the bloodstream. This process partly 
depends on the intracellular concentration of Ca2+, which forms a gradient across the cells 
(Prevarskaya, Skryma et al. 2011, Tsai, Kuo et al. 2015). As the gradient increases, the 
focal adhesion proteins disassemble, and the cell retracts. (Prevarskaya, Skryma et al. 
2011).  Therefore, aberrant Ca2+ signalling plays a critical role in metastasis of cancerous 
cells.  
Phosphorylation of PAWS1 at S356, potentially by CaMK2 was found to be 
required for U2OS cells to migrate in a wound healing assay. However, the mechanisms 
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that control cell migration downstream of CaMK2-phosphorylation of PAWS1 are yet to 
be defined. An appealing hypothesis is that PAWS1 regulates the transcription of certain 
genes that are involved in cell movement. Unpublished data from the lab (J. Vogt) showed 
that introduction of the phospho-mutant PAWS1S356A in PC3 prostate cancer cells 
attenuates PAWS1-dependent gene transcription. One of those genes, NEDD9 has been 
implicated in cell migration, invasion and metastasis of cancer cells (Feng, Zhao et al. 
2015, Kozyulina, Loskutov et al. 2015). The emerging evidence that PAWS1 is involved 
in cell migration raises the intriguing question whether PAWS1 expression in certain 
cancer types correlates with proliferative and migratory advantage in cancer cells. 
Recent characterisation of the U2OS PAWS1-/- cells (Cummins, Wu et al. 2018), 
revealed that PAWS1 deficiency impacts cell morphology and cytoskeletal dynamics due 
to the loss of the PAWS1:CD2AP interaction. It remains to be shown whether CaMK2 
isoforms are part of the same PAWS1:CD2AP complex and if PAWS1 phosphorylation 
by CaMK2 affects its association and co-localisation with CD2AP in cells. 
PAWS1-/-  cells display disorganised actin distribution compared to U2OS wild type cells 
(Cummins, Wu et al. 2018). It would be therefore interesting to investigate whether 
rescuing the cells with CaMK2-phosphorylation-deficient mutant, PAWS1S356A, can 
restore actin organisation, as PAWS1WT rescue did (Cummins, Wu et al. 2018). Although 
no direct association between CaMK2 and CD2AP has been mentioned in the literature, 
they are both known to interact with actin in order to regulate actin polymerisation and 
cytoskeletal stabilisation (Bruck, Huber et al. 2006, Hoffman, Farley et al. 2013). Future 
experiments aiming to address if PAWS1 can associate with CaMK2 and CD2AP in cells 
in the presence or absence of Ca2+, through live cell imaging, could shed some light into 
the role of PAWS1 phosphorylation at S356 in actin dynamics. Furthermore, in light of 
the constitutive nature of the PAWS1:CK1α complex, the role of PAWS1 in actin 
cytoskeleton and cell migration should be investigated in this context.  
CaMK2 is a central component of the non-canonical Wnt signalling, which 
regulates tissue mobility during development and metastasis of cancerous cells (Gujral, 
Chan et al. 2014, Asem, Buechler et al. 2016, Sandsmark, Hansen et al. 2017). Given the 
critical role of PAWS1 in the canonical Wnt signalling pathway, it would be interesting 
to explore whether PAWS1 affects the non-canonical Wnt pathway, as well. Wnt5A has 
been widely used in literature as an activator of the non-canonical Wnt signalling, 
although it has been reported to activate or de-activate β-catenin signalling, depending on 
which membrane receptors it binds to (He, Saint-Jeannet et al. 1997, Nishita, Enomoto et 
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al. 2010). It is therefore very important to study the expression of Wnt receptors in the 
cell system of choice before proceeding with further investigations. Upon non-canonical 
Wnt activation, intracellular Ca2+ is released and CaMK2 is activated, which results in 
cell motility via reorganisation of the actin cytoskeleton and subsequent filopodia 
formation (Nishita, Yoo et al. 2006, O'Connell, Fiori et al. 2009). One intriguing 
experiment would be to monitor PAWS1 phosphorylation by CaMK2 at S356 upon 
Wnt5A stimulation and assess the impact on actin distribution and cell migration. In 
parallel, it would be interesting to perform live-cell imaging, to monitor Ca2+ release in 
response to Wnt ligands in PAWS1-/-, PAWS1WT and PAWS1S356A cells. Nevertheless, 
uncovering the intricate mechanisms of PAWS1 function with respect to its association 
with and phosphorylation by CaMK2, could open up therapeutic opportunities against 
aggressive metastatic tumours.  
During the course of this PhD research, it was exciting when first reports of 
PAWS1 mutations in hereditary footpad hyperkeratosis in dogs and humans emerged 
(Drogemuller, Jagannathan et al. 2014, Sayyab, Viluma et al. 2016, Maruthappu, 
McGinty et al. 2017). Interestingly, misregulation of Wnt signalling and CK1α are also 
associated with similar skin abnormalities (Adaimy, Chouery et al. 2007, Chang, Kuo et 
al. 2017). The findings that PAWS1 interacts with two protein kinases CK1α and CaMK2 
isoforms, which are involved in the canonical and non-canonical Wnt signalling 
respectively, raises the possibility that these diseases may arise from perturbations in the 
Wnt signalling pathway. Indeed, two of the hyperkeratosis mutants disrupt interaction of 
PAWS1 with CK1α (Unpublished data from K. Wu). It would be interesting to investigate 
whether rescuing the expression of PAWS1 and its pathogenic mutants in PAWS1-/- cells 
can restore Wnt signalling, actin organisation or cell migratory defects. This would 
provide important clues on the molecular aetiology of the observed phenotypes, and 
might open up potential therapeutic opportunities for patients with keratodermas. 
Moreover, a proteomic approach to identify potential differences in the binding partners 
of PAWS1 and its pathogenic mutants, would provide a better understanding of the 
impact that these mutations have at the molecular level. However, in order to achieve this, 
it is essential to generate cell lines expressing the PAWS1 mutants at the endogenous 
levels, by exploiting the CRISPR/Cas9 technology to knock-in these mutations on the 
PAWS1 locus Further studies could also assess the levels of expression of PAWS1 protein 
in the affected skin tissues from patients that carry the pathogenic mutations, to 
understand if the pathogenesis is due to PAWS1 loss- or gain-of function. Skin diseases, 
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including hyperkeratosis, are mainly characterised by defects of the epithelial keratin 
cytoskeleton (McLean and Moore 2011). Of note, another FAM83 member, FAM83H, 
has been reported to regulate the keratin cytoskeleton through its association with CK1 
(Kuga, Kume et al. 2013), although to date, no FAM83H mutations have been associated 
with skin diseases. 
In the beginning of this PhD, not much was known about the biological function 
of PAWS1. Overall, this thesis has identified PAWS1 as a novel component of the 
canonical Wnt signalling pathway. Through its interaction with CK1α, PAWS1 might 
present a new intersection in the Wnt pathway which could provide valuable insights into 
further delineating the details of regulation of Wnt signalling. Nevertheless, the findings 
presented here will aid further research aiming to understand how PAWS1 functions in 
cells and how it controls CK1 biology alone or together with other FAM83 members, in 
health and disease. 
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Appendix 
 
A- 1 Sequence alignment of the FAM83 proteins with disorder prediction 
Multiple sequence alignment was performed with ClustalO in Jalview. Disorder 
prediction was done using Globplot. The highlighted sequences in blue indicate the 
globular regions while the disordered regions are highlighted in pink. 
  
225 
 
 
A- 2 Identification of the CK1 phosphorylation consensus motif, D/E-x-x-S*/T* 
(highlighted in black) in the sequence of the phospho-peptides with a significant change 
higher than 2-fold in control unstimulated wild type U2OS cells from Fig 4-12A (left 
quadrant of the volcano plot).  
 
 
A- 3 Identification of the CK1 phosphorylation consensus motif, D/E-x-x-S*/T* 
(highlighted in black) in the sequence of the phospho-peptides with a significant change 
higher than 2-fold in unstimulated U2OS PAWS1-/- cells from Fig 4-12A (right quadrant 
of the volcano plot). 
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A- 4 Identification of the CK1 phosphorylation consensus motif, D/E-x-x-S*/T* 
(highlighted in black) in the sequence of the phospho-peptides with a significant change 
higher than 2-fold in Wnt3A-stimulated wild type U2OS cells from Fig 4-13A (left 
quadrant of the volcano plot). 
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A- 5 Identification of the CK1 phosphorylation consensus motif, D/E-x-x-S*/T* 
(highlighted in black) in the sequence of the phospho-peptides with a significant change 
higher than 2-fold in Wnt3A-stimulated U2OS PAWS1-/- cells from Fig 4-13A (right 
quadrant of the volcano plot). 
 
